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  Scope of the thesis 
Introduction 
 
Mycetoma is a chronic, granulomatous, progressive inflammatory disease, characterized by a 
subcutaneous mass, tumefaction and the formation of sinus tracts. The sinuses discharge 
seropurulent material and fungal or bacterial grains. This disease, which can be caused by 
both bacteria and fungi, is encountered all over the world but is endemic in the so-called 
“mycetoma-belt”, between 30 oN and 15 oS of the equator. Sudan is one of the countries in 
which mycetoma has a high incidence. In this country the most common causative agent is the 
fungus Madurella mycetomatis. 
 Although mycetoma was already described in 1842, still relatively little is known 
about this disease. Diagnostic assays and treatment are still suboptimal. Current diagnostic 
assays are time-consuming and not very reliable. Treatment, especially in eumycetoma, is 
difficult and usually involves both surgery and medical treatment. Adequate antifungal 
treatment may take years and is usually started without even knowing if the causative agent is 
actually susceptible to the chemotherapeutic agent applied.  
 
Scope of the thesis 
 
To understand the difficulties in diagnosing and treating mycetoma we first review this 
disease in chapter 2. The current knowledge about this disease, its prevelance, the diagnostic 
assays used, and the treatment given to the patients are highlighted. As will become clear in 
this chapter little is known about the disease. In the remaining of this thesis we will focus on 
three main themes:  
 
1. Genetic variation of M. mycetomatis and its human host 
 
In the chapters belonging to this theme it was assessed whether genetic variability of both 
pathogen and host could be related to the outcome of the disease. In chapter 3 the selective 
amplification of restriction fragments (AFLP®) is used to devide 37 Sudanese clinical isolates 
of M. mycetomatis into two main clusters (clusters I and II) and one minor cluster (cluster III). 
The strains in cluster I mostly derived from patients in Central Sudan and were generally 
obtained from larger lesions than the strains found in cluster II. In chapter 4 several human 
genes involved in neutrophil function were studied with PCR-restriction analysis. It appeared 
that patients usually had a genotype correlated with a higher CXCL8 expression and a lower 
nitric oxide expression. This was confirmed phenotypically.  
 
2. Antigenicity of M. mycetomatis 
 
In order to improve the diagnostic serology for mycetoma caused by M. mycetomatis the 
antigenicity of M. mycetomatis was assessed. In chapter 5 the first immunogenic antigen, a 
protein homologous to the translationally controlled tumour protein (TCTP) was discovered 
using a M. mycetomatis cDNA expression library. Both IgM and IgG responses could be 
measured for this protein, with the highest antibody levels found associated with the largest 
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lesions. Unfortunately, not all patients formed antibodies against this protein. In chapter 6 it 
was shown that although M. mycetomatis secreted significant amounts of galactomannan-like 
compounds into the culture medium, these compounds were not detected in the patient serum.  
 
3. Antifungal susceptibility of M. mycetomatis  
 
In order to improve the antifungal therapy in patients we tried to gain more insight in the in 
vitro susceptibility of M. mycetomatis against various antifungal agents. In chapter 7 a CLSI 
(formerly NCCLS) based assay was developed for M. mycetomatis. To facilitate endpoint 
reading a 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-
tetrazolium hydroxide (XTT) assay for fungal viability was used. In chapter 8 the assay 
described in chapter 7 was compared to a commercial Sensititre assay for the antifungal 
agents amphotericin B, ketoconazole, itraconazole, fluconazole and voriconazole. In chapter 
9 the in vitro susceptibilities for the less commonly used antifungal agents artemisinin and tea 
tree oil were determined. In chapter 10 it was assessed what the effect of melanin produced 
by M. mycetomatis was on the in vitro susceptibilities to amphotericin B, ketoconazole, 
itraconazole, fluconazole and voriconazole. 
 
Finally in chapters 11 and 12 the findings reported in this thesis are summarized and 
discussed.  
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Introduction 
 
Mycetoma is a chronic infectious disease, which remains localized, involves cutaneous and 
subcutaneous tissues, the fascia and bones (95). The disease is characterized by tumefaction, 
draining sinuses and the presence of grains (95).  
The oldest recorded case of possible mycetoma involves the skeleton found in Israel of 
an adult woman buried in the Byzantine period (300-600 AD) (95). This skeleton had 
morphologic changes in the bones of the distal portion of the lower extremities which are 
suggestive for mycetoma (95). The first written description of mycetoma was found in the 
Indian religious book Atharva Veda, where the disease was called “padavalmika”, meaning 
foot-anthill (95). In 1842 the first case was described in western literature by Dr. John Gill, a 
physician of the Madras Medical Service of the British Army in India (112). His colleague Dr. 
Colebrook proposed the name “Madura foot” in 1848 (95, 112). The term mycetoma was first 
used by Vandyke Carter in 1860 (112). He was the first to believe that mycetoma could be 
separated into two varieties depending on the colour of the grains associated with the disease. 
M. mycetomatis probably caused the black variety of mycetoma Carter described, whereas 
one of the aerobic actinomycetes caused the light-coloured variety (95).  
 
Epidemiology and causation 
 
As was already apparent from this short history lesson, mycetoma has a worldwide but 
uneven distribution. The disease is endemic in tropical and subtropical regions but the African 
continent has the highest prevalence (figure 1). Mycetoma prevails in the mycetoma belt that 
stretches between the latitudes of 15° south and 30° north (18, 86). The belt includes Sudan, 
Somalia, Senegal, India, Yemen, Mexico, Venezuela, Columbia, Argentina, and other 
countries (18, 86, 89, 93). In Africa, mycetoma is most frequently seen in Sudan, Senegal, 
Mauritania, Kenya, Niger, Nigeria, Ethiopia, Chad, Cameroon, Djibouti, and Somalia with 
increased morbidity in poor people lacking access to essential health care facilities (2, 3, 13, 
22, 37, 39, 85, 119).  
In Sudan, Abbot (2) noted the admission of 1231 mycetoma cases to outpatient clinics 
throughout the country within a period of 2.5 years. In 1964, Lynch (85) gave an estimation 
of 300–400 new cases per year in Sudan. The disease has also been extensively reported in 
India (17, 119). Reports on mycetoma have also come from the USA, Ceylon (now Sri 
Lanka), Germany, Egypt, Turkey, Philippines, Japan, Lebanon, Thailand, Iran, Netherlands, 
and Saudi Arabia (25, 31, 45, 47, 55, 77, 122). Most of these imported cases involved 
immigrants who probably contracted the infection in their home countries. This complicates 
the clinical diagnosis since it is frequently unexpected (31).  
  17  
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Figure 1: Mycetoma endemic areas. A: Dark grey coloured countries are countries with common and frequent 
incidence. Lighter coloured areas are countries with regular to moderately common incidence. B: 
Actinomycetoma (light grey) versus Eumycetoma (middle grey) in a selection of countries. To highlight the 
differences in etiological agents over the world M. mycetomatis is separately shown in dark grey (2, 15, 23, 36, 
37, 40, 75, 83, 101, 112).    
 
The geographical distribution of the mycetoma causative agents shows considerable variation 
that could be explained by environmental factors, especially lack of rainfall (18, 87, 93). 
Areas where mycetoma prevails are reasonably arid with a short rainy season of 4–6 months. 
Rainfall is 50–1000 mm per year, with a relative humidity of 60–80%, and fairly constant 
temperatures of 30–37°C throughout the day and night. The rainy season is followed by a dry 
season of 6–8 months with a relative humidity of 12–18%, and daytime temperatures rising to 
45–60°C. Temperatures might fall to 15–18°C during the night (87). This extreme alteration 
in weather conditions might be a prerequisite to the survival of the causative organism in its 
natural niche.  
Many micro-organisms are capable of causing mycetoma (table 1) and several of these 
organisms seem to have their natural habitat in soil or plant materials including thorns. The 
different micro-organisms form grains of different colours and morphology which may be of 
help in the taxonomic positioning and species identification of the causal organisms. The most 
prevalent causative agent of eumycetoma worldwide, and in Africa in particular, is Madurella 
mycetomatis (95). As is seen in figure 1 in some parts of central Africa, including Sudan, M. 
mycetomatis causes more than 70% of all mycetoma infections (18, 59). 
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Etiologic agents causing Mycetoma 
Eumycetoma  Actinomycetoma 
Agent Grain colour Occurrence Agent Grain colour Occurrence
Acremonium falciforme White E Actinomadura madureae White/ Yellow/Pink C 
Acremonium kiliense White R Actinomadura latina  E 
Acremonium recifei White R Actinomadura pellitieri Red O 
Aspergillus flavus Green E Actinomyces israelii White/Yellow O 
Aspergillus nidulans White E Gordona terrae - E 
Cladophialophora bantiana Black E Nocardia asteroides White R 
Corynespora casiicola Black E Nocardia brasiliensis White C 
Curvularia geniculata Black E Nocardia caviae White/Yellow R 
Curvularia lunata Black E Nocardia farcinica White/Yellow R 
Cylindrocarpon cyanescens White E Nocardia mexicana  E 
Cylindrocarpon destructans White E Nocardia transvalensis White E 
Exophiala jeanselmei Black E Nocardia veterana  E 
Exserohilum rostrata Black E Nocardiopsis dassonvillei Cream E 
Fusarium monoliforme White E Streptomyces somaliensis Yellow/Brown O 
Fusarium oxysoprum White E    
Fusarium solani White E    
Hormonema spp.  E    
Leptosphaeria senegalensis Black R    
Leptosphaeria thompkinsii Black E    
Madurella grisea Black R    
Madurella mycetomatis Black C    
Microsporum canis White E    
Neotestudina rosatii White E    
Phialophora verrucosa Black E    
Plenodomus avramii Black E    
Polycytella hominis White E    
Pseudallescheria boydii White C    
Pseudochaetosphaeronema 
larense Black E    
Pyrenochaeta mackinnonii Black E    
Pyrenochaeta romeroi Black R    
Rhinocladiella atrovirens  E    
Scedosporium apiospermum  E    
Scytalidium dimidiatum No grains E    
Trichophyton spp White E    
Table 1: Etiologic agents causing Mycetoma. Agents are divided into fungal and bacterial species. Next to the 
species, the grain colour and the occurrence are given. C = common, O = occasional, R = rare and E = 
exceptional (1, 2, 10, 15, 23, 29, 33, 34, 36, 37, 40, 45, 47, 55, 59, 75, 77, 82, 85, 101, 119, 122, 130). 
 
Clinical presentation 
 
Mycetoma initially presents as a slowly progressive and painless subcutaneous swelling, 
sometimes in combination with a history of preceding trauma (18, 95). However, the 
incubation time before classic signs develop is not well-defined: the first symptoms might 
need several months to years to become palpable. Investigations are complicated by the fact 
that most patients tend to present late, by an absence of clinical symptoms, by lack of 
accessible health care facilities, or because of patients' fear of amputation (18, 95, 112).  
The duration of the disease, the type of causative organism, the site of the infection 
and possibly the immune response of the host, can all affect the clinical presentation of 
Chapter 2 
mycetoma (52). However, patients with a short disease history might present with massive 
lesions and severe destruction of deep tissues and even of bones (figure 2). By contrast, others 
might present with minor localised lesions that had already existed for a long time without 
any evidence of major progressive tissue destruction (Ahmed Fahal, unpublished data). The 
subcutaneous swelling is usually firm and rounded but it can also be soft and lobular. It is 
rarely cystic (50), and is often movable. The subcutaneous nodule increases in size and 
secondary nodules might evolve as well (52). The nodules might suppurate and drain through 
multiple sinus tracts, and these sinuses can close transiently after discharge during the active 
phase of the disease. Fresh adjacent sinuses might open whereas some of the old ones might 
heal completely. The nodules are connected to each other through deep sterile abscesses, and 
to the skin surface (18, 52).  
Mycetoma can affect any part of the body, and lesions are not restricted to the limbs 
only (figure 2). Most cases are usually seen in the feet (70%), followed by hands (12%), then 
legs and knee joints (52, 95). In highly endemic areas, other parts of the body might become 
affected as well. These include the arm, head and neck, thighs, and the perineum. Rarely, the 
chest and abdominal walls, facial bones, mandible, paranasal sinuses, eyelid, vulva, orbit, 
scrotum, and old surgical incisions might also be affected (18, 52). Mycetoma spreads locally 
or through the lymphatic system, and, rarely, through the bloodstream. Secondary nodules can 
arise in the affected area, sometimes with more distant lymphatic metastases in some 
advanced cases. Secondary sites are seen more often in actinomycetoma than in eumycetoma, 
suggesting that bacteria might spread more easily. Mycetoma is usually painless, and the 
mycetoma lesion has been suggested to produce substances that have an anaesthetic effect 
(48). At a late stage of the disease, the absence of pain might be due to nerve damage by the 
tense fibrous tissue reaction or endarteritis obliterans, or alternatively, poor vascularisation of 
the nerves. In final stages of the disease, pain might be due to invasion of the bone or to 
secondary bacterial infections (6, 52). As the mycetoma granuloma increases in size, the skin 
may become smooth and shiny, and areas of hypopigmentation or hyperpigmentation can 
develop. Increased local hyperhydrosis has also been seen in some patients (18, 48). 
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A B
C 
D E
 
Figure 2: The clinical presentation of mycetoma. A: an early case of mycetoma of the foot; B and C: advanced 
cases of mycetoma of the foot; D: a X-ray showing bone destruction in mycetoma, E: advanced mycetoma of the 
hand, the second most common site for mycetoma. 
 
Susceptible population and risk factors 
 
Anyone living in an endemic area could become infected, but infection is more common in 
herdsmen, farmers, and other field laborers who are in frequent and direct contact with the 
field environment. Males are five times more often affected by mycetoma than females, even 
in areas where both sexes spend a lot of time outdoors (52, 95). Mycetoma is seen in all age 
groups, but it usually affects adults between 20 and 40 years old. The infection is not 
considered to be transmissible from person to person or from animal to human.  
There are some conflicting reports about the role of the immune status of the 
susceptible population. Some investigators reported partial impairment of the cell-mediated 
immune-response (CMI) in patients severely infected or not responding to medical treatment 
(92). But overall, mycetoma is commonly seen in immunocompetent individuals. However, 
dissemination from the primary site is a common feature among immunocompromised 
individuals (46). For example HIV-infected individuals show a tendency towards accelerated 
mycetoma progression (58). The small number of case studies available and HIV patients 
presenting with various forms of mycetoma does not yet allow for definite conclusions to be 
drawn on the relation between immune status and mycetoma susceptibility and progression 
(24, 103). In animals, some evidence supports the impaired CMI hypothesis. For example 
mycetoma is more successfully induced in athymic mice than in immunocompetent mice (88). 
  21  
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The more rapid progression of induced mycetoma in immunosuppressed goats compared with 
healthy goats provided another important piece of evidence (60). By contrast, Bendl and co-
workers (15) did not confirm this finding.  
The humoral immune response has been evaluated by Wethered and his colleagues 
(131) using an ELISA system. High IgM levels were seen in most patients with mycetoma 
due to M. mycetomatis, whereas low levels of IgA were detected in some of the patients. Sera 
from patients did better in the ELISA as compared to western blots, indicating possible 
involvement of polysaccharide or fatty acid antigens in M. mycetomatis infection. IgM and 
IgG and complement factors have been identified on the surface of the grains, and on the 
filaments inside the grains in case of actinomycetoma (42). 
 
Diagnosis 
 
In endemic areas, mycetoma must be considered in the differential diagnosis of all 
subcutaneous swellings. Clinical scores should be developed for a more thorough definition 
of the different disease presentations.  Presently, clinical evaluation is not very reliable. 
Therefore, it is advisable to send clinical specimens, preferably those containing grains, for 
adequate diagnostic microbiology laboratory testing. However, lack of experience, non-state 
of the art diagnostic facilities or improper clinical specimens complicate the identification of 
many of these relatively rare species (10, 31). Since different agents can cause mycetoma, 
identification of the causative agent is important to develop an appropriate plan of treatment 
(table 2). However, available strategies are few and have many limitations.  
At the level of the individual patient, modern imaging methodology is considered 
diagnostically valuable. Magnetic resonance imaging, for instance, has been shown to be 
informative in the detection and even identification of fungal grains and for the assessment of 
therapeutic success (28, 68, 118). Additionally, magnetic resonance imaging facilitates the 
detection of specific morphological features of the fungal grains (so-called dot-in-circle signs) 
which are suggested to be highly specific for mycetoma lesions (116). However, regions 
where these types of diagnostic facilities are most urgently needed, are usually the ones where 
such facilities are lacking because of financial difficulties.  
At the level of the fungus, direct examination of crushed grains might be useful in 
determining whether the mycetoma is caused by bacteria or fungi. Unlike fungal grains, 
crushed bacterial grains show fine filaments, which can be Gram-stained. Isolation of 
mycetoma agents can be difficult, especially in case of the obligate anaerobic actinomycetes. 
Culture needs deep surgical biopsies containing grains. Biopsies without grains are not 
suitable for diagnosis (44). The large numbers of causative organisms and the fact that many 
black-grain producing fungi do not produce conidia or do so only after long incubation 
periods, complicate the identification process (31, 105). 
Histopathological techniques are useful for confirming the clinical diagnosis of 
mycetoma and in the differentiation of several bacterial causes of mycetoma since the 
immunopathology of actinomycetoma is known (114, 115) (table 1). However, correct 
identification of fungi causing mycetoma by histology only is difficult, if not impossible, and 
culture confirmation should always be pursued (105). With histopathological examination of 
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fungal mycetoma it is only possible to categorize some of the pigmented fungi to a certain 
extent.  
 
Main clinical differences between eumycetoma and actinomycetoma 
 Eumycetoma Actinomycetoma 
Disease   
 Causative agents Fungi Bacteria 
 Lesion characteristics Well-encapsulated with a clear margin Diffuse with no clear margin 
 Sinuses Few Many 
 Colour of grains 
Different colours, but mostly white or 
black Different colours, but not black 
 Course of infection Slowly progressive Inflammatory and rapid progression 
 Bone invasion After a long time Rapid 
 
Cavities in radiograph Small in number, but large in size with clear margins 
Numerous, small in size (except in case 
of Actinomadura madurae with unclear 
margins) 
    
Management   
 
Drug of choice Ketoconazole Itraconazole 
Dapsone+Streptomycin  
Rifampicin or sulfadoxine-
pyrimethamine 
Amikacin+cotrimoxale  
 
Management of choice Both medical and surgical intervention required 
Only medical treatment is sufficient (in 
some advanced cases in combination 
with surgery) 
 Surgery only 
Might cure small, well-encapsulated 
lesions, up to 90% recurrence in most cases Not indicated 
 
Medical treatment only 
Partial cure or improvement 
Recommended before surgery to prevent 
local spread 
Needed after surgery to prevent recurrence
Useful in most cases 
 
Most successful 
outcome 
Early diagnosis followed by adequate 
antifungal treatment in combination with 
surgery 
Early diagnosis followed by medical 
treatment for a sufficiently long period 
Table 2: Main differences between eumycetoma and actinomycetoma in disease characteristics and 
management. 
 
Few studies have focused on serological methods for early detection and monitoring of 
patients under treatment (87, 98, 120). Immuno-electrophoresis, immunodiffusion and ELISA 
are developed for the extended diagnosis of mycetoma (61, 90, 120). The problem with such 
serological tests is the use of non-standardized and poorly prepared crude antigens, which are 
prone to cross reactivity, especially between actinomycetes, and false-positive and -negative 
results (10). Recently, the first genuine ELISA test for the detection of M. mycetomatis 
infection was presented (126). This test involved the detection of antibodies against the first 
protein antigen of M. mycetomatis that was serologically identified, cloned, sequenced and 
produced as a recombinant protein. The translationally controlled tumour protein (TCTP) was 
found to be a predictor for the size of the lesion and the duration of the infection. In cured 
patients the antibodies frequently became undetectable. The usefulness of this first assay 
should be evaluated in large serological screening tests in the endemic regions, preferably in a 
longitudinal study (126).  
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Fine-needle aspiration cytological methods for mycetoma have also been described, 
and are considered to be useful since they can be done with or without local anaesthesia (41).  
To improve the quality of diagnosis of mycetoma, molecular tests have recently been 
developed for several agents of black-grain eumycetoma (8, 35). The availability of these 
molecular detection and identification tests will help microbiologists in species definition, 
which is necessary for proper management of patients. Ahmed et al. developed M. 
mycetomatis-specific PCR-based tests based on the sequence of the internal transcribed spacer 
in the ribosomal gene complex, a region which has been successfully utilized by many 
investigators for the development of diagnostic DNA amplification assays (8). Post-
amplification restriction digestion facilitates correct species identification, and clearly 
differentiates M. mycetomatis from Madurella grisea (8). Similar results were recently 
reported from France, where large numbers of black-grain eumycetoma agents were studied 
(35). The test is not only useful for detection and identification of M. mycetomatis in patients 
(7), but can also be applied for the detection of fungal material in the environment. This 
approach led to successful amplification of M. mycetomatis DNA from soil samples, whereas 
attempts through culture efforts were negative for the same samples (4, 121).  
 
Disease management and treatment 
 
Mycetoma is difficult to treat and improper management is devastating, leading to poor social 
and economical perspectives. No cases of spontaneous cure have ever been reported. Proper 
management of mycetoma strongly depends on the identification of the causative organism. 
Knowing the mycetoma type (actinomycetoma or eumycetoma) is mandatory for the initiation 
of correct medical management. Actinomycetoma chemotherapy alone namely results in high 
cure rates (60% to 90%), and surgery is only required in advanced cases including those 
refractory to antimicrobial treatment (84). For eumycetoma surgery is still the most acceptable 
means of treatment (82, 84). The main aim of complementary surgery is complete excision of 
small, well-encapsulated lesions, or the reduction of the amount of infected tissue to be cured 
by chemotherapy. Surgery has major undesirable side-effects. Effective surgery needs 
aggressive excision or debridement under general anaesthesia, which usually cripples the limb 
or leads to permanent disability. Furthermore it’s success rate is usually dependent on the 
stadium of the disease. Early cases, in which the disease process is still limited and localized, 
with well-encapsulated lesions and without bone involvement can be treated efficiently with 
surgery. Advanced cases have a higher recurrence rate. In mycetoma surgery done without a 
combination of effective chemotherapeutic treatment is not feasible due to its high rate of 
recurrence (up to 90%). In overall combination of medical treatment before and after surgery 
results in the most successful outcome (49, 95). 
Chemotherapeutic treatment is dependent on the causative agent. If this agent is not 
known, patients are subjected to both empirical antifungal and antimicrobial treatment (63). In 
actinomycetoma the nature of the etiologic agent normally determines the choice of 
antimicrobial (combination) therapy (18). The choice of antimicrobial agent is usually based 
on personal, single-center experiences, since no double blind, placebo-controlled clinical 
studies into the efficacy of antimicrobial treatment are done (1, 21, 33, 46, 73, 74, 76, 79, 100, 
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102, 106, 107, 130). Consequently, there is no international consensus as to the nature of the 
optimal treatment regimen for mycetoma patients in general. 
Eumycetoma is deemed to be relatively non-responsive to antifungal treatment by 
many and radical surgical amputation is the intervention option preferred, especially in areas 
with limited medical resources and where not much else than surgery can be offered. Even 
when access to antifungal agents can be provided, eumycetoma still responds variably, 
ranging between complete clinical cure, limited improvement to no improvement whatsoever. 
Poor responses to different antifungal agents even occur when these are given in combination 
and at high doses. This is in contrary to in vitro  susceptibilities. Many reports showed that M. 
mycetomatis has a low MIC to the azoles, the polyene amphotericin B and the echinocandin 
anidulafungin (9, 127). Overall, early diagnosis followed by surgical excision of small lesions 
and antifungal treatment before and after surgery usually results in the most successful 
outcome (95). Local surgical excision alone is rarely successful and might in some cases even 
enhance the lymphatic spread (111).  
Chemotherapy of eumycetoma by treatment with the new azole-class antifungals was 
piloted in the late 1980s. The initial trials showed a clear progress in healing of the lesions 
(20). Itraconazole in particular showed great promise in these trials and in equivalent in vitro  
tests (124). Currently, although showing varying degrees of clinical efficacy, itraconazole and 
ketoconazole are still the best treatment options (38, 110, 129). Within the Mycetoma 
Research Center (Khartoum, Sudan; http://www.mycetoma.org), both ketoconazole (400–800 
mg daily) and itraconazole (400 mg daily) are recommended for first line use (48). The 
duration of treatment varies with the severity of the infection and the general health status of 
individual patients. Treatment may need to continue for 18-24 months or more and the liver 
function of the patients needs regular monitoring, especially in advanced mycetoma (49). 
However, long-term treatment may lead to antifungal resistance, which may in turn 
complicate patient management. Clinical follow-up has shown that itraconazole treatment has 
a better success and a lower recurrence rate than ketoconazole. In particular, lesions that 
eventually remain are well-encapsulated and distinctly localised. This renders final surgical 
treatment a likely option. But in advanced lesions, especially when bone tissue is involved, 
the response to chemotherapeutic treatment still remains very poor (111).  The disadvantage 
of the azole drugs is their expensiveness, which limits immediate availability to patients in 
poor regions.  
Hopes on effective medical treatment are increasing with the introduction of broad 
spectrum triazoles like voriconazole and posaconazole. However, lack of essential health care 
facilities, the absence of health insurance coverage, and high cost of these new azoles may 
limit their use in poor endemic regions in those developing countries where the agents are 
required most. In addition, solid antifungal efficacy data are desperately needed for the proper 
management of mycetoma. Only two recent papers are available for review. The first paper 
described a single-center open label efficacy and safety study of terbinafine in the treatment 
of eumycetoma. Twenty five percent of patients were cured and 55% showed clinical 
improvement. Although the study was limited by the small number of patients included 
(n=20), lack of randomization, missing control groups, lack of standardized cure or 
improvement criteria and the possible investigators bias, the study is still considered as one of 
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the unique ones done to evaluate the efficacy of antimycotic drugs used for treatment of 
mycetoma (100). In the second study, the effect of posaconazole was evaluated on 6 
eumycetoma cases caused by M. mycetomatis (n=2), M. grisea (n=3) and S. apiospermum 
(n=1). Five patients were successfully treated, whereas one did not show improvement (102).  
A difficult decision in case of mycetoma patients is when to stop treatment. The 
prevalence of the infection in poor patients living in remote areas renders continuation of 
treatment and regular follow-up rather difficult and usually even impossible. Some 
investigators tried to set some standards for clinical, serologic, or radiologic cure, but so far 
there is no consensus on these standards. Many patients in whom medical treatment was 
stopped without a well-validated clinical score suffered from recurrence after initial 
improvement.  There is no clear definition of cure in mycetoma and there is no test of cure 
that enables the differentiation between infected and non-infected patients (84). The TCTP 
ELISA that was recently described (126) revealed a correlation between serological response 
and the severity or stage of eumycetoma. This requires further elaboration, preferably also 
using additional fungal antigens in the test system. In the end such systems could be used for 
prospective detection of early stages of infection or relapse after therapy. 
 
The genus Madurella and its two species 
 
Usually, Madurella species are slow-growing fungi that produce dark colonies composed of a 
dense, melanised, and mostly sterile mycelium. Madurella species are well known agents of 
black-grain mycetoma. Two species are recognised, M. mycetomatis and M. grisea (32). In 
the past M. mycetomatis has been known under different names. In 1905, Brumpt placed an 
organism described by Laveran in 1902 as Streptothrix mycetomi in the genus Madurella. 
Later the fungus was renamed as Madurella mycetomi and this name was used for more than 
seven decades. In 1977, the British Medical Research Council published memorandum 
number 23 (Nomenclature of fungi pathogenic to humans and animals) in which the name 
was corrected to M. mycetomatis. The name was corrected because the specific epithet must 
be in the genitive case (the Madurella of mycetoma). Since mycetoma is a Greek neuter noun, 
the correct citation is mycetomatis (78).  
In different culture media, M. mycetomatis strains show various colony morphologies 
(figure 3). The growth rate is moderate, and the colonies are white and woolly at first, 
becoming olivaceous, yellow, or brown, generally producing a brownish, diffusing pigment. 
In poor media, sclerotia of 750 µm diameter can develop (105). Colonies are mostly sterile, 
composed of a dense melanised mycelium. No efficient sporulation has ever been seen. 
However, phialides with minute conidia in short chains and collarettes may be seen (32, 95, 
105). Some investigators reported that better sporulation was noted when M. mycetomatis was 
cultured in straw extract agar, wheat extract agar, soil extract agar, or water agar (78, 108). In 
most cases, the microscopic appearance of M. mycetomatis and M. grisea is quite similar. 
Some isolates of M. grisea were reported to form pycnidia. Such isolates are indistinguishable 
from Pyrenochaeta mackinnonii (105). Species-differentiation of M. mycetomatis and M. 
grisea can be made by differences in sugar assimilation and optimal growth temperature. M. 
mycetomatis assimilates lactose but not sucrose, whereas M. grisea assimilates sucrose but not 
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lactose. M. mycetomatis grows well at 37 oC, while M. grisea does not grow at 37 oC (growth 
is seen at 30 oC) (32, 105). This finding might also explain the observed difference in 
virulence.  
  M. mycetomatis and M. grisea are both placed in the genus Madurella but recently 
molecular techniques showed that these fungi in fact do not have the same phylogenetic 
ancestors. Based on the ribosomal sequences, M. mycetomatis has been repositioned in the 
order of the ascomycetes, whereas M. grisea is now an acknowledged member of the order of 
the pleosporales (30). In the same study it appeared that a wide range of closely related agents 
can actually cause eumycetoma. These data might be essential to make a complete inventory 
of potential eumycetoma agents (30).  
When different isolates of M. mycetomatis deriving from patients originating from 
endemic areas were genetically compared by large scale random amplification of polymorphic 
DNA (RAPD) they did not show major differences, despite the sometimes strongly differing 
phenotypes seen when cultured (5). Later this same set of strains was compared with a more 
differentiating technique, called amplified fragment length polymorphism (AFLP) analysis. 
From this study it appeared that the strains were indeed genetically diverse and that the 
isolates obtained from larger lesions were genetically closely related and clustered separately 
(125). Interestingly, a molecular marker segregating isolates originating from similar 
geographical focus was also associated with a higher MIC for amphotericin B (125).  
 
Pathology of M. mycetomatis infection and ultrastructure of the lesion 
 
In tissues, M. mycetomatis forms numerous black sclerotia (grains). Grains are vegetative 
aggregates of the fungal mycelia embedded in a hard brown matrix (figure 4) (44). This 
matrix consists of extra-cellular cement that seems to be 1,8-dihydroxynaphthalene melanin in 
combination with host tissue debris. This rigid matrix might act as a barrier protecting the 
fungus from the natural immunity of the host and from antifungal agents (95). Melanin-like 
pigments in Cryptococcus neoformans or the dimorphic fungal pathogen Paracoccidioides 
brasiliensis are detectable in vitro  and in vivo  and have an important role in the pathogenesis 
of various mycoses (56, 57). Melanins are thought to be protective in circumstances of host-
induced oxidative stress (64, 69, 80).  
The grains have different shapes and sizes. In stained sections, the grain is mostly 
rounded, oval, or trilobed. Two types of grains have been identified: filamentous and, less 
commonly, vesicular. The filamentous type of grain consists of brown, septate and branched 
hyphae that might be slightly more swollen and thick towards the periphery of the colony (44, 
51, 95). The vesicular type of grain, which is less common, has a cement-like matrix in the 
cortex and a central area filled with numerous vesicles (6–14 µm in diameter) and light-
coloured hyphae (105).  
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Figure 3: Various colony morphologies of M. mycetomatis. A: isolate mm44 on sabouraud agar, B: isolate 
mm55 on sabouraud agar, C: isolate mm55 melanised, on minimal medium agar 
 
Triple layered tissue reaction zones have been described around the grains (51). An 
inner neutrophil zone immediately around the grain, an intermediate zone containing mainly 
macrophages, and an outer zone consisting of lymphocytes and plasma cells mainly can be 
seen under the microscope (figure 4) (42, 44, 51). 
 
Figure 4: Triple layered tissue reaction around a M .mycetomatis grain 40x enlarged (left) and 400x enlarged 
(right). In both pictures the grain (G) is surrounded by the neutrophil layer (N) and the macrophage zone (M).  
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Studies on the ultrastructure of M. mycetomatis showed an elaborate development of 
mesosomes as the most striking ultrastructural feature (54). In tissue sections, the hyphae 
show a thick cell wall, which becomes thicker in the periphery of the grain (44, 48, 67). It 
seems that excessive production of polysaccharides in the fungal cell wall renders the fungus 
less susceptible to the action of antifungal agents and more resistant to the host immune 
system, owing to possible interference with leucocyte interaction with specifically recognised 
cell–wall antigens (66, 67, 132).  
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Fungal viability and antifungal susceptibility 
 
The vegetative cells of M. mycetomatis die rapidly in conditions of moist heat (e.g., 60°C for 
30 min) and are easily killed by 70% ethanol. Homogenised mycelia from fresh agar cultures 
survive well at 4°C, −20°, and −80°C for several weeks (unpublished data, A.O.A. Ahmed). 
Little is known about the in vitro  and in vivo  susceptibility of the fungus to different 
antifungal agents, especially to the new generation azoles and the echinocandins. In the past, 
some reports described the effectiveness of ketoconazole in treating mycetoma patients. 
Ketoconazole treatment usually leads to some degree of improvement (27, 91). Few 
investigators have described in vitro  susceptibility testing results. Preliminary data have 
shown that azoles were capable of inhibiting the growth of at least 50% of all M. mycetomatis 
strains included in the studies. Unfortunately, the in vivo  activity of azoles is often poor (14, 
128). Still, long-term treatment with itraconazole seems to be the best therapeutic regimen at 
present. However, variable responses to itraconazole have also been described (14, 95). 
Eumycetoma due to M. mycetomatis responds poorly to medical treatment with ketoconazole, 
especially in late, advanced cases, but lesions of patients under ketoconazole treatment remain 
localised and well encapsulated (48).  
Until recently, no rigorous study using a standard protocol had been done to assess the 
susceptibility of large numbers of M. mycetomatis clinical isolates. In general, most 
investigators agree that early diagnosis followed by both surgery and chemotherapy with 
appropriate antifungal agents results in the most successful outcome (12, 18, 49, 95). Mendez-
Tovar and colleagues (96) have shown that progesteron can inhibit the growth of M. 
mycetomatis and Pyrenochaeta romeroi, which might contribute to the sex bias in the 
incidence of mycetoma (48, 95). Addition of hormone therapy to the standard 
chemotherapeutic regimen has not yet been assessed in clinical trials. Recently two antifungal 
susceptibility testing protocols were published (9). One was based on guidelines approved by 
CLSI (previously the National Committee for Clinical Laboratory Standards) for assessing 
culture base viability, whereas the other was based on XTT (2,3-Bis[2-methoxy-4-nitro-5-
sulfophenyl]-2H-tetrazolium-5-carboxanilide) chemistry (65). Susceptibility data for a large 
number of clinical isolates were obtained for the antifungals amphotericin B and itraconazole 
(9). Most isolates were more susceptible to itraconazole, which might be the most obvious 
current choice for therapy of mycetoma. The notion is confirmed by recent clinical results 
(unpublished data, A.O.A. Ahmed).  
 
Mycetoma in animals 
 
In addition to humans, natural mycetoma has also been reported in dogs, cats, horses, cows, 
goats, and even dolphins (19, 43, 60, 62, 70, 71, 81, 94, 97, 104, 109, 113, 117, 123). Many 
investigators have reported reproducible animal models for bacterial mycetoma, but few have 
been successful in developing M. mycetomatis infection in small animals in the laboratory. 
Occasionally, the characteristic black grains due to M. mycetomatis have been reproduced in 
an animal. This was done either by inoculation of M. mycetomatis mixed with killed tubercle 
bacilli or by use of congenitally athymic nude mice. In immunocompetent mice such lesions 
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were sometimes seen after repeated intraperitoneal inoculation (26, 88, 99). The most 
reproducible current infection model for M. mycetomatis eumycetoma is the one described for 
BALB/c mice (11). Different routes of inoculation, various adjuvants, host immune status, 
and gender of mice were evaluated for effect on the infection rate. The infection was found to 
be inoculum-dependent with increasing infection rates for larger inocula. Adjuvants were 
essential for induction of infection and both autoclaved soil from an endemic region or 
Freund's incomplete adjuvant seemed to be very effective adjuvants. Small black grains were 
produced in the peritoneal cavity of infected mice, once more corroborating the validity of the 
mouse model. Establishment of infection in immunocompetent mice suggests that in human 
too, an intact immune system is unable to eliminate the infectious agent (11). The role of 
adjuvant in establishing the infection is not clear, but it might be favoring the infection by 
modifying the host immune response. Scedosporium apiospermum (teleomorph 
Pseudallescheria boydii) and Scedosporium prolificans can infect immunocompetent 
individuals causing eumycetoma or disseminated invasive infections in immunocompromised 
hosts. S. prolificans is resistant to virtually all commonly used antifungal agents, and 
therefore their infections are difficult if not impossible to treat. In an experimental murine 
model of S. prolificans scedosporiosis, the combination of amphotericin B and caspofungin 
increased mice survival when treatment started one day post inoculation. However, 
combination therapy of amphotericin B and caspofungin did not show synergy (16). In 
contrast, infections due to S. apiospermum have been treated successfully with different 
azoles including ketoconazole and itraconazole. Voriconazole chemotherapy together with 
surgical debridement was used to successfully treat nodular skin lesions due to S. 
apiospermum in kidney transplant patients (53). 
 
Conclusions 
 
The morbidity caused by eumycetoma is large, and local health-care facilities are usually 
insufficient. The clinical impact of mycetoma has essentially remained unchanged over the 
last decades. Clinicians can still offer limited help, which is mostly restricted to amputation 
and supporting chemotherapy for which the efficacy has not yet been unequivocally proven.  
Developing curative and preventive measures should be the prime focus of ongoing and future 
research activities in eumycetoma. Whether the simple distribution of shoes to prevent people 
being infected through direct contact with soil, or the use of a successful vaccine will fill this 
current vacuum remains to be seen.  
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Abstract 
 
One of the causative organisms of mycetoma is the fungus Madurella mycetomatis. 
Previously, extensive molecular typing studies identified Sudanese isolates of this fungus as 
clonal, and polymorphic genetic markers have not yet been identified. Here, we report on the 
selective amplification of restriction fragments (AFLP®) analysis of 37 Sudanese clinical 
isolates of M. mycetomatis. Out of 93 AFLP® fragments generated, 25 were polymorphic of 
which 12 were found in a large fraction of the strains. Comparative analysis resulted into a 
tree, composed of two main (clusters I and II) and one minor cluster (cluster III). Seventy-five 
percent of the strains found in cluster I originated from Central Sudan while in cluster II the 
origin of the strains was more heterogeneous. Furthermore, strains found in cluster I were 
generally obtained from larger lesions than the strains found in cluster II (Chi-Squared Test 
for Trend, p=0.03). From the 12 more commonly found polymorphisms four showed 
sequence homology with known genes. Marker A7 was homologous to an endo-1,4-beta-
glucanase from Aspergillus oryzae, 97% identical markers A12 and B3 matched a 
hypothetical protein from Gibberella zeae and marker B4 was homologous to casein kinase I 
from Danio rerio. This latter marker seemed to be associated with strains originating from 
Central Sudan (p=0.001).  This is the first report on a genotypic study where genetic markers 
were obtained which may be used to study pathogenicity in M. mycetomatis. 
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Introduction 
 
In the 1840s, physicians of the Royal Army stationed in the Madura region in India reported 
an invasive disease which severely affected the foot. The foot degenerated into “one mass of 
disease of a fibrocartilaginous nature, with entire destruction of the joints, cartilages and 
ligaments”. This disease is now known as mycetoma and can be differentiated into advanced 
cases and moderate to minor cases, with 80% of cases affecting the dorsal part of the foot (9, 
17). However, it is also possible for other areas to become infected, including the hand, knee, 
arm, legs, head and neck (9). Since the first reports on mycetoma it appeared that mycetoma is 
not restricted to India but has a world-wide distribution (9). It is endemic around the Tropic of 
Cancer, between latitudes 15° South and 30° North (4). In these regions the climate is 
relatively arid and hot with alternating short rainy seasons and longer dry seasons (15). 
Countries where mycetoma has been reported include Argentina, Colombia, Venezuela, 
Yemen, Tunesia, Senegal, Somalia and Sudan (7-9). Sudan appears to have the highest 
number of cases per capita per year, which amounts to about 300-400 actual infections (17).  
Mycetoma can be caused by a great variety of micro-organisms but these are not 
evenly distributed throughout the ‘mycetoma belt’ (17). In Sudan the most frequently 
encountered causative organism is Madurella mycetomatis. M. mycetomatis is a slow-growing 
fungus which forms a dark, sterile mycelium (4). Only two reports on genetic variability or 
lack thereof in M. mycetomatis isolates have appeared. In a report published by Lopes et al. it 
was shown that random amplification of polymorphic DNA (RAPD) and restriction 
endonuclease assays (REA) differentiated M. mycetomatis strains from different countries 
(14). In contrast, a large set of clinical M. mycetomatis isolates obtained from Sudan showed 
little genetic variation based upon classical high-throughput RAPD tests and PCR-RFLP tests 
and the species was identified as a clonal organism (2). Neither of these studies presented 
genetic markers, which could be used to generate epidemiologically relevant information or 
taxonomic frameworks. Another microbial DNA-based typing method is the AFLP® 
technique, a selective restriction fragment amplification method, which detects the absence or 
presence of DNA restriction sites by means of selective PCR (20, 21). Genomic DNA is 
completely digested with two restriction enzymes after which double-stranded adaptors are 
ligated to the resulting DNA fragments. The resulting fragments are then amplified using 
primers complementary to the adapter and restriction site sequences. To limit the number of 
amplified fragments, selective nucleotides can be added at the 3’ ends of the primers (20, 21).  
AFLP® is a useful technique to differentiate strains within a species, even when clonal (20).  
The aim of the current study was to test whether the AFLP® technique could differentiate 
clinical M. mycetomatis isolates obtained from mycetoma patients in various regions of 
Sudan. Another important question addressed was whether genetic differences among M. 
mycetomatis isolates could be used to link isolates with demographic and clinical 
characteristics.  
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Materials and methods 
 
Strains and patients 
A total of 39 fungal isolates of black-grain eumycetoma patients were included. Thirty-eight 
of these strains were obtained from patients seen in the Mycetoma Research Centre, 
University of Khartoum, Sudan. One additional strain was obtained from a patient from Mali. 
The strains were isolated from biopsies and maintained on Sabouraud Dextrose Agar  (Difco 
Laboratories, Paris, France). The strains were previously identified to the species level on the 
basis of morphology, PCR-based restriction fragment length polymorphisms (RFLP) and 
sequencing (1, 3). Thirty-seven of the isolates were identified as M. mycetomatis, one as a 
fungal species belonging to the M. mycetomatis cluster without appropriate species definition 
(strain mm27) and one as Leptosphaeria senegalensis (strain mm3) (6). For the patients the 
following characteristics were recorded: geographical origin, their lesion size, sex, age and 
duration of the disease. Assessment of the lesion size was by visual interpretation. Small 
lesions were those without sinuses and the volume of which was less than average. Large 
lesions clearly exceeded the average size and had multiple sinuses. No objective size 
parameters were developed. 
 
Antifungal susceptibility 
MICs were determined after 7 days using the colorimetric Sensititre® YeastOne® method 
(Trek Diagnostic Systems, Ltd, East Grinstead, England) as reported elsewhere (19). 
 
DNA isolation 
DNA was isolated as described before (2).  
 
AFLP® analysis 
AFLP® analysis was performed as described before (21). In short, DNA was restricted using 
endonucleases EcoRI and MseI. After restriction, adaptors were ligated to the resulting 
fragments. The resulting fragments were pre-amplified with primers E: 5’-
GACTGCGTACCAATTC-3’ and M: 5’-GACGATGAGTCCTGAGTAA-3’ after which a 
selective PCR was performed. The selective primers were identical to primers E or M but 
were extended with selective dinucleotides at the 3’ terminus. Two primer combinations were 
used: E12/M12 and E20/M12.  Primers E12 and M12 were extended with AC and primer E20 
with GC. Primers E12 and E20 were radioactively labelled and the amplified material was 
analysed on 4.5% polyacrylamide slabgels. The presence or absence of markers is scored in a 
table, which could be transformed into a dendrogram with the program NTsys (Exeter 
Software, Sekautet, New York, USA).  
 
Sequencing and primer design 
 Selected markers were excised from gel and reamplified with the following primers: 5’- 
AGCGGATAACAATTTCACACAGGACACACTGGTATAGACTGCGTACCAAT-3’ and 
5’-GACGATGAGTCCTGAGTAA-3’. These PCR fragments were sequenced, aligned and 
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compared to each other and to other sequences in the NCBI databank by BLASTN 2.2.8 and 
BLASTX 2.2.8 (5). Internal primers were designed for screening purposes (table 1). 
 
 
Frag. Accession number Seq. Length (bp) Present  (%) Homology Primer Sequentie (5’ Æ 3’) 
Ann. 
temp. 
(OC) 
- - A3 - - 46.1 - - - - 
A4 fw CCT TCA TCG TGC CAC AGG CG A4 AY918173 65  61.5 No homology A4 rv CGC TGA GTA AAC GAG TTT TC 52 
A5fw TCA CAC TTA TCG AGG CAG AT A5 AY918174 223  53.9 No homology A5rv GTA TGT CCA CGC AGG GCA TG 55 
- - A6 - - 51,3 - - - - 
A7fw ATG AGC TGG CTT GAT GGC GG A7 AY918175 161  15.4 endo-1,4-beta-glucanase A7rv TCC TGA GTA AAC GTC GAT CC 55 
- - 
A8 - - 35.9 - - - - 
- - A9 - - 51.3 - - - - 
A10 fw GAG GAT GCG ACT TCG CCG CT A10 AY918172 180  69.2 No homology A10 rv CGC GAC GAG GGA CGT GAA TC 60 
A11 fw GTA TAG TAC TAC GAC CAC CA A11 AY918176 168  80.6 No homology A11 rv CTT AGG ACT AGT ATA ACT AG 50 
A12 fw CAG CGA AGC ACT AAT GAG GTA12 AY918177 235  71.8 Hypothetical protein* A12 rv CCA TGT TAG TAT CCT ACA AG 52 
B3 fw AAG CAT CTA TGA GGT GAC CA B3 AY918178 233  28.2 Hypothetical protein* B3 rv CCA TGT TAG TAT CCT ACA AG 52 
B4 fw TTC GCC ACA TAC ATT GAC TA 
B4 AY918179 387  33.3 casein kinase 1, delta B4 rv TTC TAA ATC GGC TGT AAG TC 50 
Table 1: Madurella mycetomatis polymorphisms detected by AFLP® and the PCR primers at condititions 
designed for detecting each individual polymorphism. * The sequences obtained for these two fragments are 
97% homologous. - no sequences determined 
 
 
PCR analysis of the selected polymorphisms 
The PCRs were performed in 50 µl reaction volumes containing 50 ng DNA, 1x Supertaq 
PCR buffer 1 (HT Biothechnology Ltd., United Kingdom), 0.2 mM PCR nucleotidemix 
(Amersham Life Sciences, Roosendaal, The Netherlands), 25 pmol forward primer, 25 pmol 
reverse primer and 1.2 U Supertaq (HT Biothernology Ltd., United Kingdom). The PCR 
consisted of a pre-denaturation step of 4 minutes at 94oC and 40 cycles each of 1 minute 
denaturation at 94oC, 1 minute annealing at variable temperatures and 1 minute elongation at 
72oC each. This was followed by a post-elongation step of 7 minutes at 72oC.  The annealing 
temperatures differ for each fragment and are stated in table 1. PCR products were visualised 
by electrophoresis on 3% agarose gels (Hispanagar, Sphaero Q, Leiden, The Netherlands).  
 
Statistical analysis 
Associations between fungal DNA polymorphisms, demographics and disease characteristics 
were tested for significance with the Fisher’s Exact test (two-sided). The association of 
genetic features with geographic origin of the strain was studied by comparing each region 
with all others. The association with size of the lesion (small, medium, large) was tested with 
the Chi-Squared test for Trend. Correlations with age, disease duration, and MIC’s to 
antifungals were tested with the Mann-Whitney test (two-tailed). All statistical calculations 
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were performed with GraphPad InStat version 3.00 (GraphPad InStat Software, Inc., San 
Diego, USA) except for the adjustment of the lesion size for disease duration. This latter was 
done by linear regression analysis with SPSS release 10.1.0 (SPSS, Inc., Chicago, USA). 
 
Results 
 
AFLP® fragment analysis 
With the two primer combinations used for the 39 clinical black grain mycetoma isolates, 93 
AFLP®  markers were generated. Comparative analysis of the markers resulted into a score 
table and the phylogenetic tree shown in figure 1.  
From the tree it can be concluded that strains mm3 and mm27 differ considerably from 
the other strains. Strain mm3 appeared to be the fungus Leptosphaeria senegalensis and strain 
mm27 is an as yet ill defined species but still a close relative of M. mycetomatis  (see 
Materials and Methods and reference (6)) Consequently, mm27 is more closely related to the 
M. mycetomatis isolates than mm3. This was verified by comparisons of ITS sequences. In 
table 2 it can be seen that the ITS sequences obtained for strains mm39 and mm55 only differ 
in 0.6% from the already published ITS sequence for M. mycetomatis (GenBank accession 
number AF162133). The ITS sequence for mm27 (7.3% difference) and L. senegalensis 
(30.8% difference) differs considerably more. 
 
 
Name ITS difference (%) Difference in bp Identification at the species level 
Reference 0 0 Madurella mycetomatis 
Mm55 0.6 3 Madurella mycetomatis 
Mm39 0.6 3 Madurella mycetomatis 
Mm27 7.3 39 Madurella species 
Mm3 30.8 164 Leptosphaeria senegalensis 
Table 2: ITS sequence comparison of mm27 and mm3 with true Madurella mycetomatis isolates. ITS 
differences are stated as the percentage of base pair differences with the previously published sequence 
AF162133. Variability within the genus M. mycetomatis was noted at 8 positions (14). 
 
 
In the M. mycetomatis cluster twenty-five markers were polymorphic. Thirteen of 
these markers were only incidentally seen in one to three strains while the rest of the markers 
were seen in at least 15% of the strains. This means that out of the M. mycetomatis markers, 
26.9% were polymorphic, which is a relatively large fraction as compared to our previous 
RAPD data (2).    
Two of the strains used in this study, strains mm72 and mm73 were isolated from a 
female patient with two independent large lesions, one on the sole of the foot and one in the 
knee. The lesion on the sole of the foot had been there for over 13 years while the lesion on 
the knee joint was just 4 years old. Figure 1 shows that both isolates are found in cluster I and 
are closely related but not identical. Strains mm33 and mm44 appeared to be 100% “AFLP® 
identical”. Those strains originated from two different Central Sudanese patients (a 24-year-
old male with a moderate lesion and a 28-year-old female with a large lesion) belonging to the 
same tribe. They were infected for two years, which could imply that they were infected with 
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the same strain originating from somewhere in that area. In cluster II strains mm46 and mm50 
had exactly the same AFLP® banding pattern. Those two strains derived from Central 
Sudanese patients (a 28-year-old male and a 35-year-old male). Those two patients had both 
been infected for 1 year and had only small lesions.  
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Figure 1: A: Sudanese sampling areas for clinical Madurella mycetomatis isolates, Sudan is divided into Central 
Sudan (C), Western Sudan (W), Northern Sudan (N) and Khartoum (K). B: Phylogenetic tree based on the 
AFLP® data obtained for 39 clinical black grain mycetoma fungal isolates. Thirty-seven of these isolates are 
Madurella mycetomatis isolates. Strain mm3 represents the fungus Leptosphaeria senegalensis and strain mm27 
represents a fungal species belonging to the M. mycetomatis cluster without precise species definition. The M. 
mycetomatis strains are divided into clusters I, II and III. For each isolate the geographic origin and the size of 
the lesion are presented. Strains originated from Central Sudan (C), Western Sudan (W), Northern Sudan (N), 
Khartoum (K) and Mali (M). The lesion size is designated as small (1), moderate (2) and large (3). (U = 
unknown). 
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The M. mycetomatis strains were divided in two main clusters: I and II (figure 1). 
Minor cluster III consists of only one strain (mm83) which originated from Western Sudan 
and caused a large lesion. Cluster I and cluster II have several distinctive features but the most 
striking one is that in cluster I fragment A12 is largely absent and fragment B3 is largely 
present while in cluster II this is the other way around. Seventy-five percent of the strains 
found in cluster I originated from Central Sudan, while in cluster II only 45.8% of the strains 
originated from Central Sudan. The other 54.2% from the strains encountered in this cluster 
are divided as follows: 16.7% of the strains originated from Khartoum, 12.5% from North-
Sudan, 8.3% from West-Sudan and 4.2% (n=1) from Mali.  Data on lesion size are displayed 
next to the phylogenetic tree in figure 1 and it appeared that in cluster I only one strain caused 
a small lesion. All other strains in cluster I caused moderate (41.7%) or massive (41.7%) 
lesions. In cluster II, half of the strains caused small lesions while 12.5% and 33.3% caused 
moderate and large lesions, respectively. This may point to differences in virulence between 
the strains from the two main clusters.  
 
DNA sequencing of polymorphic markers 
 Out of 93 amplimers, a total of 25 markers were polymorphic in the M. mycetomatis strains. 
Thirteen of these markers were only seen in one to three strains while the rest of the markers 
were seen in at least 15% of the strains. Eleven of these more common polymorphic markers 
were reamplified and sequenced. From four of these fragments no useful sequence could be 
obtained, probably due to the fact that mixtures of DNA fragments were excised from the gel. 
After BLASTN and BLASTX analysis, it appeared that the sequences obtained for fragments 
A12 and B3 were 97% identical. A tri-base substitution and two deletions were the only 
differences obtained, suggestive of gene duplication or heterozygostiy. Fragment A7 showed 
the highest homology (66% identity) with an endo-1,4-beta-glucanse gene from Aspergillus 
oryzae. Fragment B4 showed similarity with a casein kinase 1 isoform delta gene. The highest 
homologies for this gene were obtained with the species Danio rerio, namely 55%. The 
closely related fragments A12 and B3 matched a gene for a non-characterized hypothetical 
protein from Gibberella zeae. The other four fragments showed no significant homology with 
any other known sequence. 
 
Development of PCR tests 
Because no genome data are available for M. mycetomatis, internal PCR primer pairs were 
designed for all of the sequences obtained. PCR with the novel primers for fragments A4, A5, 
A7, A12 and B3 resulted in equally sized amplicons for all strains, except for mm3 and 
mm27. For fragments A10, A11 and B4 size-variable amplicons were obtained. As is stated in 
table 3, PCR for fragments A11 and B4 resulted only in positive PCR signals for those strains 
in which the original AFLP® fragment was present. For fragment A10, all strains gave a 
positive PCR signal but in the strains where the original AFLP® fragment was not present the 
PCR products were smaller in size. This size difference still allowed the discrimination of 
different types. 
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Strain  
10 13 14 16 18 22 25 26 28 29 30 31 33 35 36 39 41 43 44 45 46 49 50 52 54 55 56 58 63 64 68 71 72 73 78 83 p1
A 0 1 1 1 1 1 1 2 1 1 0 0 1 0 1 1 1 1 1 0 1 0 1 1 0 0 1 1 1 1 1 1 1 1 1 0 0 
A
10
 
P 1’ 1 1 1 1 1 1 1’ 1 1 1’ 1’ 1 1’ 1 1 1 1 1 1’ 1 1’ 1 1 1’ 1’ 1 1 1 1 1 1 1 1 1 1’ 1’ 
A 1 1 1 0 0 0 1 1 1 0 1 1 1 1 0 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 0 0 1 
A
11
 
P 1 1 1 0 0 0 1 1 1 0 1 1 1 1 0 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 0 0 1 
A 0 0 1 1 0 1 0 1 0 1 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 0 1 0 1 0 1 0 0 0 
B
4 
P 0 0 1 1 0 1 0 1 0 1 0 1 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 0 1 0 1 0 1 0 0 0 
Table 3: Presence of AFLP® amplimers versus PCR amplicons A = AFLP, P = PCR, 0 = no amplicon present, 1 
= amplicon present, 1’ = amplicon present but slightly smaller, 2 = very faint amplicon present  
 
Analysis of correlations 
Strains from Central Sudan significantly more often belonged to cluster I (p = 0.049; table 4).  
With respect to the AFLP® markers tested we found the B4 fragment (a casein kinase delta 
homologue) in half of the strains originating from Central Sudan, but in none of the strains 
from the other regions (p = 0.001). Lesions caused by cluster I strains tended to be larger than 
those caused by other strains (p = 0.03). The size of the lesion appeared strongly associated 
with duration of disease (p=0.001, Pearsons’s correlation coefficient). However, the 
association between lesion size and cluster did not decrease after adjustment for disease 
duration. No linkage with either cluster was found between genetic strain features and sex or 
age of the patients, or with duration of disease.  
 
Trait Clusters  Marker 
   I II P-value marker p-value absent present
Geographic origin       
 Central Sudan versus the rest of Sudan 9/1 10/10 0.049 B4 0.001 8/12 11/0 
 West Sudan versus the rest of Sudan 1/9 3/17 NS  NS  
 North Sudan versus the rest of Sudan 0/10 3/17 NS  NS  
 Kharthoum versus the rest of Sudan 0/10 4/16 NS  NS  
Lesion Size       
 Small versus Moderate versus Large 1/5/5 12/3/5 0.03  NS  
Sex       
 Male verus Female 6/6 17/6 NS  NS  
Age of the patients in years (median) 19 21.5 NS  NS  
Duration of the disease in years (median) 3 3 NS  NS  
Antifungal Susceptibility (median MIC)       
 Amphotericin B 1 0.5 NS A4 0.02 1 0.5 
  0.5 1  B4 0.02 0.5 1 
 Fluconazole 2 8 NS  NS  
 Itraconazole 0.032 0.032 NS  NS  
 Ketoconazole 0.032 0.064 NS  NS  
 Voriconazole 0.125 0.125 NS  NS  
Table 4: Correlations of Madurella mycetomatis strains genetic clusters and polymorphic markers and various 
demographics, disease characteristics and antifungal susceptibility. P-values were obtained by Fisher’s Exact 
test, Chi-Squared Test for Trend (size of the lesion), and Mann Whitney test (age, duration, and comparison of 
MICs). 
 
Additionally, associations between genetics of the strains and antifungal susceptibility 
were studied. In figure 2A the distribution of the antifungal susceptibilities of cluster I and II 
are shown. MICs were obtained for the azoles itraconazole, ketoconazole, fluconazole and 
voriconazole as well for the polyenic amphotericin B, but not for 5-flucytosine.  
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As was already seen in the MIC distribution in figure 2A there is no obvious correlation 
between the antifungal susceptibility and strain clustering. This was confirmed with the Mann-
Whitney test. For the individual markers the same analyses were performed. After statistical analysis 
of two of the polymorphic markers, namely A4 and B4, a correlation was found with susceptibility to 
amphotericin B.  These data are shown in figure 2B. As is seen in this figure strains positive with A4 
had lower MICs for amphotericin B (median MIC 0.5) than strains in which this fragment was not 
present (median MIC 1) (Mann-Whitney, p = 0.02). Strains for which fragment B4 could be amplified 
had higher MICs for amphotericin B (Median MIC of 1.0) than strains without B4 (Median MIC of 
0.5) (p = 0.02). This difference is very small. However, all four strains with a MIC for amphotericin B 
of 2 or higher (usually implicated in therapy failure) were found in the group without fragment A4. 
Absolutely no association between the other markers and susceptibility for any of the antifungals 
tested was found.  
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Figure 2: A: The antifungal distributions for both clusters I and II are shown for the following antifungal agents: 
amphotericn B (AMB), fluconazole (FLZ), itraconazole (ITZ), ketoconazole (KTZ), voriconazole (VCZ) and 5-flucytosine 
(FC). Each bar represents the number of strains (as shown on the top of the bar) with a MIC at the concentration listed on the 
x-axis for the antifungal shown on the y-axis. For example in cluster I there are three strains with an MIC of 1 mg/l for 
amphotericin B. B: the MIC distribution for amphotericin B for fragments A4 and B4. The number of strains for a certain 
MIC are shown for the two fragments. The strains for which a fragment is present are indicated with black bars (), the 
strains for which this fragment is absent are indicated with white bars (). 
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Discussion 
 
Not much is known about genetic diversity in M. mycetomatis. Until now only two reports 
appeared in which genetic heterogeneity was investigated (2, 14). Lopes et al. collected 17 
isolates from countries all over the world, ranging from the Netherlands Antilles to Argentina 
and from Djibouti to Morocco (14). By using both REA and RAPD it appeared that the 17 
strains could be divided into 10 different groups (14). In contrast, the 38 strains from Sudan 
and 2 from Mali used in high throughput RAPD analysis by Ahmed et al. appeared to be 
highly clonal and all attempts to identify genetic markers failed (2). In the study performed by 
Lopes et al. the isolates obtained from Sudan could not be discriminated from each other as 
well, confirming regional clonality (14).  
In the past AFLP® was demonstrated to be a valuable technique to type various fungal 
species such as Aspergillus fumigatus and Cryptococcus neoformans (12, 22). For M. 
mycetomatis we showed that AFLP® is as valuable for the to differentiation of this species as 
well. Despite the remarkable clonality found before with RAPD (2) AFLP® was able to 
discriminate these same strains into three clusters. This suggest that AFLP® is a much 
stronger technique than RAPD to discriminate M. mycetomatis.  With AFLP® the M. 
mycetomatis isolates could be divided into two main and one minor clusters. Cluster I 
consisted mainly of strains originating from Central Sudan which caused moderate or large 
lesions while cluster II was more heterogeneous. Although there was an association with the 
lesion size and the duration of the disease the association found between cluster I and larger 
lesions still remained intact after adjustment for disease duration. As a matter of fact, the 
lesion size is probably defined on the basis of individual host-pathogen interactions. With the 
AFLP® conditions used it was also possible to discriminate between two M. mycetomatis 
isolates obtained from the same patient but from different lesions.  
At least four of the 12 polymorphic markers were actually part of coding regions, two 
of which were not yet identified (A12/B3). Marker A7 was homologous to the gene for endo-
1,4-beta-glucanase, an important enzyme involved in cellulose degradation (11, 18). 
Polymorphic marker B4, homologous to casein kinase 1 (CK1) delta, was primarily detected 
in strains isolated from Central Sudanese patients. CK1 is thought to play a physiological role 
in activating transcription of various DNA repair genes, in intracellular trafficking and in 
normal cell cycle progression (10, 13, 16, 23).   
In the present study, MICs were determined by using the Sensititre system instead of 
using the modified NCCLS method for M. mycetomatis. It has been demonstrated that this 
system is in good agreement with the modified NCCLS method. Percentages agreement 
ranged between 91.2-100.0 %, depending on the antifungal tested (19). The reproducibility of 
this test system was also satisfactory ranging between 88.2 to 97.1 % (19). We found an 
association between susceptibility for amphotericin B and both markers B4 and A4. The 
distribution of MIC’s of strains with and without the B4 and A4 marker differed significantly 
(p=0.02), but the difference was very small. The median of the groups differed only a single 
two-fold dilution, which is allowed as background variation in antifungal susceptibility 
testing. Furthermore, the median MICs for each group were in the treatable range and are 
therefore probably not clinically relevant. The association found in this study could be a 
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chance finding and not reproducible in other strain collections. Further study to the relevance 
of this finding is needed.   
In conclusion, the AFLP® method differentiates clinical isolates of M. mycetomatis. 
AFLP® groups I and II are associated with different clinical presentation, with the group I 
strains apparently causing larger lesions. An AFLP® marker sequence with CK1 homology 
seemed to be associated with the geographical origin of the fungal isolate. We present the first 
pathogenicity markers for a fungal species that still has a devastating socio-economic effect 
on small communities in rural Sudan. 
  
Nucleotide sequence accession numbers 
 
The sequences reported here are deposited in the GenBank database under accession numbers 
AY918172 (fragment A10), AY918173 (fragment A4), AY918174 (fragment A5), AY918175 
(fragment A7), AY918176 (fragment A11), AY918177 (fragment A12), AY918178 (fragment 
B3) and AY918179 (fragment B4). 
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Abstract 
 
Madurella mycetomatis is the main causative agent of mycetoma, a tumourous fungal 
infection characterized by infiltration of large numbers of neutrophils at the site of infection. 
In endemic areas the majority of inhabitants have antibodies to M. mycetomatis, though only a 
small proportion of individuals actually develop mycetomal disease. It, therefore, appears that 
neutrophils are unable to clear the infection in some individuals. To test this hypothesis, 
eleven single nucleotide polymorphisms (SNPs) involved in neutrophil function were studied 
in a population of Sudanese mycetoma patients versus geographically and ethnically matched 
controls. Significant differences in allele distribution for interleukin 8 (CXCL8), its receptor 
CXCR2, thrombospondin-4 (TSP-4),  nitric oxide synthase 2 (NOS2) and complement 
receptor 1 (CR1) were found. Further, the NOS2Lambaréné polymorphism was clearly associated 
with lesion size. The genotypes obtained for CXCL8, its receptor CXCR2 and TSP-4 all 
predisposed to a higher CXCL8 expression in patients, which was supported by the detection 
of significantly elevated levels of CXCL8 in patient serum. The NOS2 genotype observed in 
healthy controls was correlated with  an increase in NOS2 expression and higher 
concentrations of nitrate and nitrite in control serum. We present the first evidence of human 
genetic predisposition towards susceptibility to mycetoma, a neglected infection of the poor. 
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Introduction 
 
Madurella mycetomatis is the most common fungal causative agent of eumycetoma in Sudan 
(2). This agent is abundantly present in the soil and on the vegetation in the endemic region 
(1). Chances for coming into contact with this fungus are, therefore, high for inhabitants of 
these areas. When using an ELISA system based on crude fungal extracts all individuals in 
the Sudanese endemic regions seemed to posses IgG antibodies against this fungus (2). With 
an ELISA based on a specific antigen of M. mycetomatis, the translationally controlled 
tumour protein (TCTP), antibody levels were found to be elevated in endemic control 
populations as well, although these levels were lower than for the patient population. No 
antibodies were found in Caucasian controls from Europe (38). This implies that most of the 
individuals living in endemic regions are regularly exposed to this pathogen, but that only a 
small percentage of these individuals actually develops the disease. A predisposing factor 
could be that the immune status of mycetoma patients is impaired (27). Using the tuberculin 
test, 2,4-dinitrochlorobenzene sensitization and lymphocyte proliferation induced by 
phytohaemagglutinin, deficiencies in cell-mediated immunity were previously documented 
among patients (27). Also, differences in blood group antigens between mycetoma patients 
and a matching healthy control population were investigated, but no correlation with blood 
group type and development of mycetoma was reported (12). Investigators did not note 
defects in HLA mediated presentation of pathogen-derived peptides to T-cells (12). It is 
currently not known if mycetoma patients suffer from substantial immune defects. 
In previous reports it was shown that large numbers of neutrophils are present in the 
mycetoma lesion (10, 11, 17). Apparently, neutrophils are important in the early defence 
against mycetoma. Since the neutrophils are unable to clear the infection it was hypothesized 
that there might be genetic impairment in neutrophil function in mycetoma patients.  
Neutrophils and monocytes are attracted to the site of infection by either antigens secreted by 
the invading micro-organism or by locally produced host-chemokines such as interleukin 8 
(CXCL8), monocyte chemoattractant protein-1 (MCP-1) and tumour necrosis factor α 
(TNFα). In mycetoma it has previously been shown that neutrophils are actively attracted by 
antigens secreted by M. mycetomatis in a complement dependent manner (40). Normally, 
when neutrophils arrive at the site of infection they will eliminate the pathogen through 
phagocytosis. In order to ingest pathogens, neutrophils are equipped to directly recognize 
either molecules on the surface of invading microbes or their opsonisation with serum host 
proteins including complement factors, mannose binding lectin (MBL) or antibodies. An 
example of such a receptor is complement receptor 1 (CR1), which is also the determinant for 
the Swain-Langley (Sl) blood group antigen and the McCoy (McC) blood group antigen (31, 
36). After pathogen recognition, reactive oxygen species (ROS) including hydrogen peroxide, 
superoxide and nitric oxide are formed, which effectively kill ingested micro-organisms (21). 
This process is summarised in Figure 1.  
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Figure 1: A simplified scheme of the innate immune response against fungi. When a fungus enters the body the innate 
immune system will be activated. Complement is activated via the alternative and lectin binding pathways by binding of C3 
and MBL, respectively, to the fungal surface. Both pathways lead to the formation of the opsonin C3b on the fungal surface, 
which is recognized by complement receptor 1 (CR1) expressed by macrophages and neutrophils. MBL is also recognized by 
this receptor. Macrophages are already present in healthy tissue and will release a number of cytokines in order to kill the 
invading pathogen and attract more monocytes and neutrophils from the bloodstream to the site of infection. Monocytes are 
attracted by macrophage chemoattractant protein-1 (MCP-1) which will mature to macrophages into the tissue. Neutrophils 
are attracted by interleukin 8 (CXCL8). CXCL8 is recognized by neutrophils via receptors CXCR1 and CXCR2. Both 
chemokines also activate their target cells; in particular, CXCL8 and TNFα , which activate neutrophils to generate among 
others nitric oxide via nitric oxide synthase 2 (NOS2). Thrombospondin 4 (TSP4) is secreted by endothelial cells to stimulate 
the production of oxygen radicals and excretion of CXCL8. 
 
Many genetic polymorphisms that influence phagocytosis and killing by neutrophils 
have been described.  For instance, a point mutation in the nitric oxide synthase type 2 
promotor, namely NOS2Lambaréné, has been shown to be associated with a 7-fold higher NOS 
activity (24). This genotype, and subsequently its higher nitric oxide levels, were shown to 
offer protection against severe malaria to a level similar to that of the sickle cell trait (24). 
Since neutrophils attracted to the mycetoma lesion apparently are unable to clear the 
infection, we investigated whether selected single nucleotide polymorphisms (SNPs) in genes 
involved in neutrophil function were more commonly found in the patient population than in 
an endemic reference population or vice versa. 
 
Materials and methods 
 
Study cohort 
Blood samples were taken from patients and a matched control population in the Sudan 
endemic area between 2001 and 2004. Furthermore, from some of the patients biopsies were 
taken as well.  No co-infections were recorded. Serum was stored at –20 oC until further use. 
For patients, the duration of disease, the size of the lesion and the site of infection were 
recorded. The mean age of the patients was 27.4 years (7-80 years), 72.8 % of the patients 
was male, which were figures comparable to those of the matched endemic control population 
(mean age 28.6, 73.8% male). For the patients, the mean duration of the disease was 6.98 
years (<1 year-27 year). 89.6% of the patients had eumycetoma, 8% actinomycetoma and for 
2.4% the type of mycetoma was not known. 78.4% of the patients had a lesion on the foot, 
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9.6% on the hand, 11.2% on the lower leg and 0.8% (1 patient) had a lesion on both foot and 
hand. 51.2% of the patients had a small lesion, 48.8% had a moderate to large lesion. Lesion 
size was measured in a comparable and standardized manner among mycetoma patients. A 
more clear definition of size was not possible since mycetoma lesions are diffuse, have a 
mass,  and have ill-defined margins.  
 
DNA isolation and genotyping 
Genomic DNA was isolated from 265 blood samples (125 patients and 140 controls) with the 
large volume kit for the MagnaPure (Roche, Almere, The Netherlands) according to the 
manufacturer’s descriptions. DNA was stored at –20 oC until further use. All PCR primers 
and amplification conditions are stated in Table 1. Genotyping of CXCR2, CXCL8 and TNFα 
was performed using a PCR tetra-primer amplification refractory mutation system (ARMS) 
(31). Genotyping of the other genes was performed with classical PCR-RFLP methods. 
Restriction enzymes used are also shown in Table 1 and were either obtained from New 
England Biolabs (Leusden, The Netherlands) or Fermentas (St. Leon-rot, Germany). All 
restriction endonucleases were used as described by the manufacturer. 
 
Polymorphism primer sequence  (5'-->3') PCR program  5’94oC Æ …. Æ 7’72oC 
Restr. 
Enzyme allele 
length  
(bp) Ref. 
CR1 
 Sl 24KnNde 
 
25Rb 
ACCAGTGCCACACTGGACCAGATGGAGAAC- 
     AGCTGTTTGAGCAT 
GGAGGAGTGTGGCAGCTTG 
44x(1’ 94oC+1’ 58oC+1’ 72oC) MfeI 1 
2 
305 
261+44 
36 
 McC 24KnNde 
 
25Rb 
ACCAGTGCCACACTGGACCAGATGGAGAAC- 
     AGCTGTTTGAGCAT 
GGAGGAGTGTGGCAGCTTG 
44x(1’ 94oC+1’ 58oC+1’ 72oC) BsmI a 
b 
305 
166+139 
36 
CXCL8 
 -251TÆA CXCL8-infw(T) 
CXCL8-inrv(A) 
CXCL8-outfw 
CXCL8-outrv 
GTTATCTAGAAATAAAAAAGCATACAA 
CTCATCTTTTCATTATGTCAGAG 
CATGATAGCATCTGTAATTAACTG 
CACAATTTGGTGAATTATCAAA 
5x(1’ 94oC+1’ 52oC+1’ 72oC)Æ 
       30x(1’ 94oC+1’ 47oC+1’ 72oC)
None T 
A* 
349+169 
349+228 
31 
CXCR2 
 +785CÆT CXCR2-infw(C) 
CXCR2-inrv(T) 
CXCR2-outfw 
CXCR2-outrv 
TCTTTGCTGTCGTCCTCATCTTCCTGAT 
AGGACCAGGTTGTAGGGCAGCCAGAAA 
CTGCTTGTCTTACTTTTCCGAAGGACCG 
TCTTGAGGAGTCCATGGCGAAACTTCTG 
5x(1’ 94oC+1’ 67oC+1’ 72oC)Æ 
      30x(1’ 94oC+1’ 62oC+1’ 72oC)
None C 
T 
451+226 
441+281 
31 
MBL 
 54 MBLfw 
MBLrv 
GTAGGACAGAGGGCATGCTC 
CAGGCAGTTTCCTCTGGAAGG  
35x(30s 94oC+ 1’ 58oC+ 1’ 72oC)  BanI w* 
m 
245+84 
329 
39 
 57 MBLfw 
MBLrv 
GTAGGACAGAGGGCATGCTC  
CAGGCAGTTTCCTCTGGAAGG  
35x(30s 94oC+ 1’ 58oC+ 1’ 72oC)  MboII w* 
m 
329 
248+81 
39 
 XY MBLpromfw 
MBLpromrv 
GTTTCCACTCATTCTCATTCCCTAAG 
GAAAACTCAGGGAAGGTTAATCTCAG 
35x(30s 94oC+30s 60oC+45s 72oC) BsaJI X 
Y* 
242+108 
166+108+76
34 
MCP-1 
 -2518 MCP-1fw 
MCP-1rv 
GCTCCGGGCCCAGTATCT 
ACAGGGAAGGTGAAGGGTATGA 
5x(1’ 94oC+1’ 52oC+1’ 72oC)Æ 
      30x(1’ 94oC+1’ 47oC+1’ 72oC)
PvuII A 
G* 
236 
182+54 
14 
NOS2 
 Lambaréné NOS-F 
NOS-4 
CATATGTATGGGAATACTGTATTTCAG 
TCTGAACTAGTCACTTGAGG 
40x(30sec 94oC+1’ 60oC+1’ 72oC) BsaI G 
C* 
680 
490 
25 
TNFα 
 -308GÆA TNF-308fwin 
TNF-308rvin 
TNF-308fwout 
TNF-308rvout 
TGGAGGCAATAGGTTTTGAGGGGCAGGA 
TAGGACCCTGGAGGCTGAACCCCGTACC 
ACCCAAACACACGCCTCAGGACTCAAC 
AGTTGGGGACACGCAAGCATGAAGGATA 
5x(1’ 94oC+1’ 67oC+1’ 72oC)Æ 
      30x(1’ 94oC+1’ 62oC+1’ 72oC)
none G* 
A 
323 + 224 
323 + 154 
31 
TSP 
 29926 
GÆC 
TSP4fw 
TSP4rv 
AATTCCGCATCTTCACTTCAC 
AACCGGTTCTGCTTTGATAAC 
32x(40s 94oC+30s 59oC+40s 72oC) AvaII C* 
G 
143 + 78 
221 
42 
Table 1: Primer sequences and PCR conditions for the different polymorphisms. All polymorphisms described 
here resulted not only in a nucleotide change but also in a functional amino-acid change, expect for CXCR2. For 
most genes difference of amino-acid resulted in differences in expression of the protein encoded. The allele 
which was indicated with higher expression of the corresponding protein is indicated with*. 
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CXCL8 expression  
CXCL8 expression was measured in serum from 43 patients and 37 healthy controls with a 
CXCL8 ELISA (Diaclone, Amsterdam, The Netherlands) according to the manufacturer’s 
instructions. 
 
NOS production 
The concentrations of nitrite and nitrate in serum from 43 patients and 37 healthy controls 
were determined as a reflection of NOS activity. Serum was diluted 4-fold in a solution 
containing 50 µM NAPDH (Sigma-Aldrich, Zwijndrecht, The Netherlands), 5 µM flavin 
adenine dinucleotide (FAD) (Sigma-Aldrich) and 200 U/l nitrate reductase (Sigma-Aldrich). 
To convert nitrate into nitrite the sample was incubated for 20 min at 37 oC. Excess NADPH 
was oxidised by adding 7760 U/l lactate dehydrogenase (Fluka Biochemicals, Buchs, 
Switzerland) and 10 mM sodiumpyruvate (Sigma-Aldrich) during a further incubation of 5 
min at 37 oC. Finally, the sample was deproteinised by adding 10 µl of 300 g/l zinc sulphate. 
The sample was centrifuged for 10 min at 10,000 rpm and 100 µl of the supernatant was used 
to determine the nitrite concentration colorimetrically using the Griess Reagent System 
(Promega, Madison, WI). Concentrations of nitrite were estimated by comparing absorbance 
readings at 540 nm against those of standard solutions of sodium nitrite.    
 
In situ analysis 
Five mycetoma biopsies and one biopsy from the uninfected part of the foot of a mycetoma 
patient were embedded in paraffin. The mean age of the patients was 25.4 years (22-30 years), 
two of the patients were male. The mean duration of the disease was 5.3 years (2.5 year-9 
year). All patients were infected with M. mycetomatis and had a lesion on the foot. One of the 
patients had a small lesion, the others had large lesions. Biopsies taken from the infected parts 
of the foot were chosen on the basis of the visible presence of grains to ascertain that grains 
were present in stained slides. 
Slides were deparaffinized in xylene, dehydrated through a graded ethanol series and 
washed in distilled water. In order to retrieve the antigen epitopes, slides were heated for 10 
min at 650 W in a microwave oven in 10 mM citrate buffer pH 6.4. Endogenous peroxidase 
was blocked by immersing the slides in 0.3% H2O2 in methanol for 30 min at room 
temperature. Non-specific bindingsites were blocked with 1:50 diluted normal goat serum  
(Vector Laboratory, Burlingame, CA) for 1 h at room temperature.  Then the sections were 
incubated with the primary antibody at 4oC overnight. Anti-CXCL8 (H-60, sc-7922, Santa 
Cruz Biotechnology Inc., Santa Cruz, CA) was used in a concentration of 4 µg/ml, anti-NOS2 
(N-20, sc-651, Santa Cruz Biotechnology Inc.) in a concentration of 2 µg/ml. Both primary 
antibodies were rabbit polyclonal antibodies. Sections were further incubated with 
biotinylated goat anti-rabbit IgG (Vector) for 1 h at room temperature and another 30 min in 
ABC reagent (Vector). Peroxidase was developed with 3-amino-9-ethylcarbazole (Sigma-
Aldrich) for 12 min. Development was stopped by washing 15 min in PBS-0.05% Tween. 
Sections were counterstained with haematoxylin (Sigma-Aldrich).  For reference purposes 
some of the slides were also stained with haematoxylin and eosin or Grocott stain. As a 
control 2 M. mycetomatis isolates, in vitro cultured on Sabouraud agarose, and 1 Candida 
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albicans isolate were stained for endogenous CXCL8 like molecules, following the same 
procedure. 
  
Statistical analysis 
Verification of Hardy-Weinberg equilibrium was performed with Pearson’s chi-square test . 
The effect of human polymorphisms in susceptibility to mycetoma was assessed with the 
logistic regression model (SPSS 11.0). Differences in allele frequency were analysed with the 
Fisher’s exact test (GraphPad Instat software). The significance of differences in CXCL8 and 
nitrite/nitrate concentrations in serum were calculated with the Mann Whitney Test 
(GraphPad Instat software).  P values lower than 0.05 were considered significant. 
 
Results 
 
Neutrophils are attracted to the site of infection 
As is seen in figure 2 neutrophils are attracted to the site of infection. Around the fungal grain 
two main types of inflammatory reaction can be observed (11). The first was the type I 
reaction, where M. mycetomatis grains were surrounded by a large zone of neutrophils (Figure 
2A) (11). The second reaction was characterized by the presence of histiocytes and 
multinucleated giant cells and a small number of neutrophils (Figure 2B).  
 
Figure 2: Two different inflammation reaction types in mycetoma (HE stained). A: type I inflammation reaction, 
characterized by an inner zone of neutrophils (N) surrounding the grain embedded in cementmaterial (G) and an outer 
vascular zone (V) (100x enlarged). B: type II inflammation reaction, in which the neutrophil zone is absent and is replaced by 
histiocytes and multinucleated giant cells (100x enlarged). C: type I inflammation reaction, 400 x enlarged. D: type II 
inflammation reaction, 400x enlarged.  
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CXCR2, CXCL8, TSP-4, NOS2 and CR1 polymorphisms are differentially distributed among 
mycetoma patients versus healthy endemic matched controls 
To elucidate the possible deficiencies in neutrophil function among mycetoma patients, 
genotype and allele frequencies for the genes encoding for CXCR2, CXCL8, MCP-1, TNFα, 
MBL, MBL promoter, CR1, NOS2, and TSP-4 were determined. As shown in Table 2, 
genotype distributions for all SNPs reached Hardy Weinberg equilibrium except for CXCL8. 
Genotype distribution for CXCL8 in the control population was in disequilibrium (HWE, p = 
0.003), but was in equilibrium in the patient population (HWE, p = 0.81). Differences in 
genotype distributions were found for CR1, CXCR2 and NOS2 (Table 2). Significant 
differences in allele frequencies were found for CR1, CXCR2, CXCL8, TSP-4,  and NOS2 
(Table 3). Obviously, the statistical significances of the CR1, CXCL8 and NOS2 
polymorphisms are the most important ones, given the low p-values. No significant 
differences were found for MCP-1, TNFα, MBL, and MBL promoter SNPs.  
 
Gene Mycetoma genotype 
   Patients 
N=125 (%) 
Controls 
N=140 (%) 
Hardy-Weinberg 
Equilibrium 
Binary logistic regression  
OR (95% CI) 
CR1 
 Sl 11 46 (36.8) 63 (45.0) 0.83 1 
  12 53 (42.4) 61 (37.9)   2.23 (1.1-4.6) 
  22 26 (20.8) 16 (11.4)  1.19 (0.7-2.0) 
 McC aa 105 (84.0) 93 (66.4) 0.40 aa versus ab and bb 
  ab 19 (15.2) 44 (31.4)   0.38 (0.21-0.68) 
  bb 1 (0.8) 3 (2.1)   
CXCL8 
 -251 AA 82 (65.6) 78 (55.7) 0.003 AA versus AT and TT 
  AT 39 (31.2) 43 (30.7)  0.66 (0.4-1.0) 
  TT 4 (3.2) 19 (13.6)   
CXCR2 
 +785 TT 8 (6.4) 13 (9.3) 0.78 TT versus TC and CC 
  TC 38 (30.4) 57 (40.7)  0.38 (0.21-0.68) 
  CC 79 (63.2) 70 (50.0)   
MBL 
 54 ww 113 (90.4) 132 (94.3) 0.73 Ww versus wm  
  wm 12 (9.6) 8 (5.7)  1.76 (0.7-4.4) 
  mm 0 (0) 0 (0)   
 57 ww 95 (76.0) 104 (74.3) 0.06 Ww versus wm  
  wm 28 (22.4) 30 (21.4)  0.91 (0.5-1.6) 
  mm 2 (1.6) 6 (4.3)   
 XY XX 19 (15.2) 21 (15.0) 0.05 1  
  XY 48 (38.4) 52 (37.1)  1.05 (0.5-2.1) 
  YY 58 (46.4) 67 (47.9)  1.07 (0.6-1.8) 
MCP1 
 2518 AA 79 (63.2) 91 (65.0) 0.46 AA versus AG and GG 
  AG 36 (28.8) 42 (30.0)  1.08 (0.7-1.8) 
  GG 10 (8.0) 7 (5.0)   
NOS2 
 L GG 107 (85.6) 94 (67.1) 0.21 GG versus GC and CC 
  GC 18 (14.4) 44 (32.9)  0.34 (0.2-0.6) 
  CC 0 (0) 2 (0)   
TNFα 
 -308 AA 106 (84.8) 117 (83.6) 0.29 AA versus AT and TT 
  AT 17 (13.6) 23 (16.4)  0.91 (0.5-1.8) 
  TT 2 (1.6) 0 (0)   
TSP4 
 29926 GG 83 (66.4) 108 (77.1) 0.96 GG versus GC and CC 
  GC 36 (14.4) 30 (21.4)  1.71 (1.0-2.9) 
  CC 6 (2.4) 2 (1.4)   
Table 2: Genotype distributions of mycetoma patients in comparison to a matching healthy control population.  
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Mycetoma Allele frequency 
Gene  Allele Patients 
N=125 (%) 
Controls 
N=140 (%) 
P value OR (95% CI) 
CR1 
 Sl 1 145 (58.0) 187 (66.8) 0.0390 0.68 (0.48-0.98) 
  2 105 (42.0) 93 (33.2)   
 McC a 229 (91.6) 230 (82.1) 0.0014 2.37 (1.38-4.08) 
  b 21 (8.4) 50 (17.9)   
CXCL8 
 -251 A 203 (81.2) 199 (71.1) 0.0081 1.76 (1.17-2.65) 
  T 47  (18.8) 81 (28.9)   
CXCR2 
 +785 T 54 (21.6) 83 (29.6) 0.0372 0.65 (0.44-0.97) 
  C 196 (78.4) 197 (70.4)   
MBL 
 54 w 238 (95.2) 272 (97.1) 0.2618 0.58 (0.23-1.45) 
  m 12 (4.8) 8 (2.9)   
 57 w 218 (87.2) 238 (85.0) 0.5306 1.20 (0.73-1.97) 
  m 32 (12.8) 42 (15.0)   
 XY X 86 (34.4) 94 (33.6) 0.3988 1.04 (0.72-1.49) 
  Y 164 (65.6) 186 (66.4)   
MCP1 
 2518 A 194 (77.6) 224 (80.0) 0.5236 0.87 (0.57-1.32) 
  G 56 (22.4) 56 (20.0)   
NOS2 
 L G 232 (92.8) 232 (83.6) 0.0006 2.67 (1.51-4.72) 
  C 18 (7.2) 48 (16.4)   
TNFα 
 -308 A 229 (91.6) 257 (91.8) 1.0000  
  T 21 (8.4) 23 (8.2)   
TSP4 
 29926 G 202 (80.8) 246 (87.9) 0.0301 0.58 (0.36-0.94) 
  C 48 (19.2) 34 (12.1)   
Table 3: Allele frequencies of mycetoma patients in comparison to a matching healthy as assessed with the Fisher’s exact 
test. P-values and Odds ratio’s are given. Significant p-values are highlighted in the bold lettertype. 
 
 
Lesion Size Lesion Size 
Genotype Massive 
N=41 (%) 
Moderate 
N=20 (%)  
Small 
N=64 (%) 
Allele Massive 
N=41 (%) 
Moderate 
N=20 (%) 
Small 
N=64 (%) 
p-value 
(massive 
compared to 
small) 
OR (95% CI) 
CR1 SI 
11 14 (34.1) 8 (40.0) 24 (37.5) 1 44 (53.7) 25 (62.3) 76 (59.4) 0.4753 0.79 (0.45-1.39) 
12 16 (39.0) 9 (45.0) 28 (43.8) 2 38 (46.3) 15 (37.5) 52 (40.6)   
22 11 (26.8) 3 (15.0) 12 (18.8)       
CR1 McC 
aa 36 (87.8) 17 (85.0) 52 (81.3) a 77 (93.9) 36 (90.0) 116 (90.6) 0.4487 1.59 (0.54-4.70) 
ab 5 (12.2) 2 (10.0) 12 (18.8) b 5 (6.1) 4 (10.0) 12 (9.4)   
bb 0 (0.0) 1 (5.0) 0 (0.0)       
CXCL8 
AA 31 (75.6) 11 (55.0) 40 (62.5) A 72 (87.8) 30 (75.0) 101 (78.9) 0.1368 1.93 (0.88-4.23) 
AT 10 (24.3) 8 (40.0) 21 (32.8) T 10 (12.2) 10 (25.0) 27 (21.1)   
TT 0 (0.0) 1 (5.0) 3 (4.7)       
CXCR2 
CC 2 (4.9) 1 (5.0) 5 (7.8) C 64 (78.0) 30 (75.0) 102 (79.7) 0.8623 0.91 (0.46-1.79) 
TC 14 (34.1) 8 (40.0) 16 (25.0) T 18 (22.0) 10 (25.0) 26 (20.3)   
TT 25 (60.9) 11 (55.0) 43 (67.2)       
NOS2 
GG 31(75.6) 15 (75.0) 61 (95.3) G 72 (87.8) 35 (87.5) 125 (97.7) 0.0063 0.17 (0.05-0.65) 
GC 10 (24.3) 5 (25.0) 3 (4.7) C 10 (12.2) 5 (12.5) 3 (2.3)   
CC 0 (0.0) 0 (0.0) 0 (0.0)       
TSP-4 
GG 28 (68.3) 12 (60.0) 43 (67.2) G 67 (81.7) 30 (75.0) 105 (82.0) 1.0000 0.98 (0.48-2.01) 
GC 11 (26.8) 6 (30.0) 19 (29.7) C 15 (18.3) 10 (25.0) 23 (18.0)   
CC 2 (4.9) 2 (10.0) 2 (3.1)       
Table 4: Allele frequencies of mycetoma patients with massive, moderate and small lesions. Differences in 
allele frequencies in patients with large lesions compared to patients with small lesions were assessed with the 
Fisher Exact test. 
 
Mycetoma patients do more often posses the Sl2 and McCa genotypes of CR1  
In the gene encoding for CR1 two different polymorphisms were determined, namely the Sl 
polymorphism and the McC polymorphism. These polymorphisms were previously shown to 
be associated with resistance to severe malaria (36). In the patient population the allele Sl2 
was more often found than in the control population (Tables 2 and 3). The McCb allele was 
more dominant in the control population. To assess if one of these polymorphisms in the gene 
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encoding CR1 were also associated with disease progression, the allele frequencies obtained 
for the patients were divided into three groups according to lesion size. Allele frequencies for 
the Sl allele and the McC allele were compared between the group with the largest lesions and 
the group with the smallest lesions. It appeared that in both groups no differences in allele 
frequencies for the Sl allele (p=0.47, Table 4) and the McC allele (p=0.45, Table 4) were 
found.  
 
Mycetoma patients express high levels of CXCL8 during infection 
Different allele frequencies were also found in the genes encoding for the neutrophil attractant 
CXCL8, its receptor CXCR2 and TSP-4. The genotypes for these genes that were more often 
encountered in the patient population were all correlated to phenotypes expressing high 
CXCL8 levels. When comparing the allele frequencies of the patients with large lesions with 
the allele frequencies of the patients with the small lesions, no correlation was found between 
these allele frequencies and the size of the lesion (Table 4).  
To analyse whether the neutrophils present at the site of infection did indeed express 
CXCL8, lesion tissue was stained for CXCL8. CXCL8 producing cells were found in all 
samples. Grains surrounded by a so-called type I tissue-reaction (Figure 1) had only a few 
CXCL8 positive cells, neutrophils generally produced no CXCL8. More CXCL8 positive 
cells were noticed during a type II tissue reaction. Cells expressing CXCL8 were mainly 
macrophages, especially macrophages with hemosiderin deposits or cells surrounding them 
(Figure 3).  Interestingly on about 50% of the hyphae within the grain CXCL8 was found 
(Figure 3A). This was not found when cultured M. mycetomatis was stained with antibody 
CXCL8. In contrast cultured C. albicans did stain with antibody CXCL8 which agrees with 
previously published data (3). CXCL8 only appeared to be present at the site of infection 
(n=5), since in control tissue from a non-infected part of the foot no CXCL8 expression was 
noted (n=1). 
Because of the presence of CXCL8 at the site of infection it was presumed that it was 
also secreted in serum. Therefore, a CXCL8-specific ELISA was performed to measure the 
amount of CXCL8 present in serum. As is seen in Figure 4 serum CXCL8 levels were 
significantly elevated in mycetoma patients (mean=431.2 pg/ml). This increase was 
statistically highly significant when compared to the matched endemic population (Mann-
Whitney, p<0.0001). To assess if the CXCL8 concentration was also an indication of the 
severity of the disease, it was analysed whether the CXCL8 serum concentrations found in 
patients with large lesions were higher than the concentrations found in patients with small 
lesions. No significant correlation with the size of the lesion and the amount of CXCL8 
present in serum was found (Mann-Whitney, p=0.0973).  
 
 
  
 
62   
Mycetoma patients have high  CXCL8 and low NO levels 
Figure 3: CXCL8 and NOS2 in M. mycetomatis mycetoma infected skin (400x enlarged). A: no CXCL8 is
found in the epidermis. B: NOS2 expression in the epidermis. C: no expression is found in the control. D:
CXCL8 expression on individual hyphae in the grain. E: No expression of NOS2 on hyphae, but some
expression found in cells surrounding the grain. F: Control slide of the grain. G: high CXCL expression in
activated macrophages and cells surrounding them in the vascular zone. H: NOS2 expression in the vascular
zone. I: activated macrophages in the vascular zone of the non-stained control .
Figure 4: CXCL8 and nitrite/nitrate levels in serum. A: CXCL8 levels (pg/ml) determined in the serum of
patients and a healthy Sudanese control population. B: nitrite/nitrate levels (�M) determined in the serum of
patients and a healthy Sudanese control population. Significance was calculated with the Mann-Whitney test 
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NOS2 is expressed at the site of infection 
The last polymorphism which was not equally distributed between patients and endemic 
control populations was in the gene encoding NOS2. The NOS2Lambaréné polymorphism 
appeared to be more common in the control population as compared to the patient population. 
With immunohistochemistry it was shown that NOS2 was present at the site of infection 
(Figure 3). NOS2 was expressed throughout the entire dermis and epidermis. NOS2 
production was found in the stratum corneum and stratum spinosum in both infected and 
uninfected parts of the foot and was therefore probably not specific for mycetoma (Figure 
3B). NOS2 expression was also found in phagocytic cells. The number of NOS2 positive cells 
differed per patient and per grain but were clearly present in all 5 patients. The closer the 
grain was to the dermis, the more NOS2 positive cells were detected.  
The frequency of the NOS2Lambaréné polymorphism differed among sub-groups. Not 
only was the polymorphism more often found in the control population, but it was also more 
frequent among patients with the largest lesions. Only 3 out of 64 patients with small lesions 
displayed this polymorphism, whereas the frequency of this polymorphism was much higher 
in the patient group with the largest lesions (in 15 out of 61 patients (p=0.0027, Table 4)). 
Since the NOS2Lambaréné polymorphism was more frequent in the control population we 
expected to find a higher NOS activity in the control sera. Therefore, the nitrite and nitrate 
concentrations in serum were determined. As is seen in Figure 3 the serum nitrite and nitrate 
concentrations were significantly lower among patients (mean=2.83 µM) than in the matched 
endemic control population (mean=9.28 µM). Since the NOS2Lambaréné polymorphism was 
also found more often in  patients with larger lesions it was determined whether the 
nitrite/nitrate concentration in serum of these patients were higher than in serum of patients 
with smaller lesions. Although the patients with the larger lesions did indeed have a higher 
nitrite/nitrate concentration in their serum (mean=4.36 µM versus mean=2.55 µM), the 
difference was not statistically significant (Mann-Whitney, p=0.6028).   
 
Discussion 
 
In this study it was shown that neutrophils are attracted to the mycetoma grains in situ. Two 
main types of inflammatory reaction were observed. Both reactions could be seen in the same 
lesion and are not unique to M. mycetomatis. They are also observed in mycetoma caused by 
Petriellidium boydii, Neotestudina rosatii, Fusarium spp. and Acremonium spp. (17). It has 
been suggested that the type I reaction is an early response to grain formation which is 
succeeded by the type II reaction (10). Apparently, neutrophils are important in the early 
defence against mycetoma. Some differences in genotype distributions between patients and a 
matched endemic population for some genes involved in neutrophil function were observed. 
The control individuals who were sampled were living in the same region as the patients and 
had a similar tribal and ethnic background. Unfortunately, at the time of collection of the 
samples we were not in a position to collect extensive amounts of demographic and health 
related data and we therefore cannot be totally sure that the control group was a complete 
match to the patient population. When the mycetoma patients were compared to the control 
population, differences were found for CR1, CXCL8, CXCR2, TSP4 and NOS2. No 
differences in distribution of SNPs in MCP-1, TNFα, MBL and MBL promoter were found. 
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In mycetoma patients the Sl2 and McCa genotypes of CR1 were more common than in the 
endemic control population. The CXCL8, CXCR2 and TSP-4 genotypes correlated with a 
higher CXCL8 production, the NOS2 SNP correlated with lower NOS2 secretion. The latter 
were confirmed by physiological measurements of higher CXCL8 levels and lower 
nitrate/nitrite levels in patient serum.  
 
Sl2 and McCa genotypes of CR1 in mycetoma patients 
From the data presented in the present paper it appeared that having a deviating complement 
receptor 1 could enhance the chance of developing a mycetoma infection. This observation 
was in agreement with our hypothesis that mycetoma patients have a genetic impairment in 
neutrophil function. Although CR1 is expressed on neutrophils, it is not unique for this cell 
type. In fact, CR1 is a receptor expressed by a whole range of other cells including follicular 
dendritic cells, macrophages, T- and B- lymphocytes, and erythrocytes. Two of the 
polymorhisms in the CR1 gene are responsible for the Swain-Langley (Sl) blood group 
antigen and the McCoy (McC) blood group antigen, both members of the Knops blood group 
typing system (32). Here we showed that the Sl2 and the McCa  alleles were more often found 
in mycetoma patients than in the matched endemic control population. This was unique since 
with other blood group typing systems such as the ABO blood groups and Rhesus factors no 
association was found with a predisposition to develop mycetoma (12). The McCa allele 
associated with mycetoma was already described to be associated with severe cerebral malaria 
caused by Plasmodium falciparum (36). In contrast, the Sl2 allele offered some protection 
against this type of malaria (36).   
 
 
Figure 5: A schematic figure of complement receptor 1 (CR1). Complement receptor 1 is composed of 20 complement 
control protein repeats (CCPs), which are arranged in four long homologous regions (LHRs). CCP1-3 represent a C4b 
binding site, CCP8-10 and CCP15-17 represent two identical copies of a C3b/C4b binding site. In LHR D an additional 
bindingsite exists for C1q and MBL. The Knops blood group type polymorphisms are found in CCP25, on aminoacid 
positions 1590 and 1601 
 
As is seen in Figure 5, the Sl and McC polymorphisms are present in the long, 
homologous repetitive D region of the CR1 gene. This is the region which codes for the 
binding structure of the protein in which MBL- and C1q binding occurs and could therefore 
cause conformational changes which could influence the function of the molecule, not only as 
executed on erythrocytes but also on other cell types (22, 36). On neutrophil surfaces, CR1 
binds pathogens such as Escherichia coli and Staphylococcus aureus and presents them to 
phagocytic cells (15, 23). It is, therefore, conceivable that conformational changes in the 
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receptor also influence the efficacy of M. mycetomatis phagocytosis (15, 23).  However, this 
remains to be determined since the effects of these polymorphisms on the function of the 
receptors has not yet been defined in full detail.  
 
Mycetoma patients express high levels of CXCL8 during infection 
Additional differences in allelic distributions were found for the genes encoding CXCL8, its 
receptor CXCR2 and TSP4, which implied that alterations in neutrophil attraction are 
associated with the development of mycetoma. In mycetoma patients the CXCL8 -251A 
allele, the CXCR2 +785C allele and the TSP4 29929C allele (also known as the 387P variant) 
were found more often than in the control population. These alleles are all associated with an 
increased production of CXCL8 (31). CXCL8 is produced by many cell types, including 
macrophages, as a chemokine to attract neutrophils to the site of infection. TSPs are also 
secreted at the site of injury and stimulate the chemotactic response of neutrophils (29). 
CXCR2 is activated by CXCL8 and this activation enhances the generation of ROS and the 
phagocytosis of pathogens (33). CXCL8 is usually barely detectable in the normal skin, but 
strong CXCL8 production can be observed in psoriasis, atopic dermatitis and in acute 
generalized exanthematous pustulosis (19). Here we show that in the mycetoma lesions 
CXCL8 is also abundantly present. The extent of CXCL8 expression appeared to be 
dependent on the inflammation type with more CXCL8 positive cells present during the type 
II reaction, a reaction characterized by a higher amount of histiocytes and giant cells. 
Macrophages with hemosiderin deposits and with high CXCL8 expression were found in the 
vascular zone (see Figure 3G). CXCL8 was also found on hyphae within the grain, suggesting 
that CXCL8 is bound to the M. mycetomatis hyphae in order to prevent either neutrophil 
attraction or activation. Another explanation could be that CXCL8 simply becomes trapped 
when the cement material is formed. Cement material is composed of remnants of fungal and 
host cells. It is not expected that M. mycetomatis forms CXCL8 analogs such as C. albicans 
does, since cultured M. mycetomatis did not react with anti-CXCL8 antibody (3).  
CXCL8 was not only expressed in the skin, high amounts of CXCL8 were also 
detected in the serum of the mycetoma patients. CXCL8 concentrations normally found in 
infectious diseases are 5-10 times lower as reported here (18, 26, 37) except for very severe 
infections such as gram-negative bacteremia (20). The concentrations of CXCL8 found in the 
serum of the mycetoma patients were even 10 times higher as concentrations found in skin 
diseases like psoriasis (6). However, such elevated concentrations of CXCL8 are not 
exceptional since in skin diseases such as dermatitis herpetiformis, a skin condition 
characterized by the accumulation of neutrophils,   comparable concentrations CXCL8 were 
found (16). Apparently, neutrophil accumulations are accompanied by high CXCL8 
concentrations in serum, which supports the data suggesting that CXCL8 production is indeed 
important during the innate immune response to mycetoma.  
 
NOS2 is expressed in lower amounts in patients than in controls 
The fifth gene with SNP frequency differences between patient and controls was NOS2. This 
gene encodes a synthase involved in generating nitric oxide, a radical toxin to most micro-
organisms (41). However, nitric oxide can play a dual role in infections. Nitric oxide defends 
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the host against various microbial agents, but sometimes the nitric oxide-mediated 
inflammation causes too much damage to host cells and thereby conversely supports 
microbial invasion (41). Comparing allelic distribution of the NOS2 gene variants, it appeared 
that the NOS2 G954C mutation was more common among Sudanese healthy controls than in 
mycetoma patients. This genotype was considered beneficial since the substitution from G to 
C results in a phenotype with a 7-fold higher baseline NOS activity (24). Indeed, a higher 
NOS activity in the control population was confirmed by an elevated nitrate/nitrite 
concentration measured in the sera as compared to the patients. Although for most infections 
nitrite and nitrate levels are increased, especially in active infections, reduced nitrite and 
nitrate levels were also found in patients with chronic hepatitis, tuberculosis or malaria (4, 5, 
13). Apparently, a high concentration of nitric oxide in serum offers protection against 
mycetoma.  
 
High CXCL8 production and low NOS2 expression delay wound healing 
Both CXCL8 and NOS2 levels influence acute inflammation and repair of damaged tissues in 
the skin (27). By attracting neutrophils to the site of infection, CXCL8 co-determines efficient 
killing of invading microbes either by phagocytosis or by secreting oxygen- or nitrogen- 
radicals (30). This is confirmed by the high NOS2 expression during wound repair (28). If for 
some reason NOS2 expression is suppressed, wound repair is much slower (28). Too much 
nitrogen and especially oxygen radicals can also cause serious tissue damage (8, 9). This will 
hamper wound healing as was shown by improved wound-healing in neutrophil-depleted 
mice as compared to control mice (8).  Mycetoma is thought to develop after traumatic 
inoculation of the causative agent by for instance a thorn prick. If too much CXCL8 is 
produced after this thorn prick at the site of entry, too many neutrophils are attracted which 
could result in additional tissue damage. Patients tend to have low levels of nitric oxide which 
could result in less efficient killing. NOS2 has shown to be of importance in another 
cutaneous infection, namely leishmania. For this infection it has been shown that inhibition of 
NOS2 results in non-healing cutaneous leishmanial lesions and even in reactivation of latent 
leishmania (7, 35).  
 
In conclusion, functional expression differences in genes involved in neutrophil function were 
documented for mycetoma patients. The Sl2 and McCa blood group antigens were more often 
found in the patient population than in the endemic Sudanese reference population. Deviations 
in genes encoding for CXCL8, CXCR2 and TSP-4 were found which resulted in a higher 
CXCL8 production in mycetoma patients. Altered allele frequencies in the NOS2 gene 
resulted in a lower nitric oxide production in mycetoma patients. Higher CXCL8 production 
and lower nitric oxide production are both implicated in less efficient wound healing, which 
could be a significant risk factor for developing mycetoma.  
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Abstract 
 
About forty years ago antibodies against the fungus Madurella mycetomatis were first 
demonstrated to be present in eumycetoma patients, a disease characterized by tumourous 
swellings. To date nothing is known about the individual immunoreactive antigens present in 
this fungus. We here identify its first immunogenic antigen, a protein homologous to the 
translationally controlled tumour protein (TCTP), a well-conserved histamine release factor in 
a range of eukaryotes. The gene for this antigen was demonstrated to be present in two 
variants in M. mycetomatis, with 13% amino acid difference between the two proteins 
encoded. In vitro, TCTP was secreted into the culture medium. In vivo, it was found to be 
expressed on hyphae present in developing stages of the eumycetoma-characteristic black 
grain. Significant IgG and IgM immune responses, against the whole protein and selected M. 
mycetomatis-specific peptides, were determined. The antibody levels correlated with lesion 
size and disease duration. Overall, the patients with the largest lesions had the highest 
antibody level, which lowered with decreasing size of the lesion. After 6-15 years of disease 
duration the antibody levels were the highest. TCTP is the first well-characterized 
immunogenic antigen, simultaneously the first monomolecular vaccine candidate, identified 
for the fungus M. mycetomatis. 
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Introduction 
 
Madurella mycetomatis is a fungus 
capable of inducing eumycetoma in 
humans (figure 1) (5). Eumycetoma 
is a major mycological health 
problem of severe morbidity in 
tropical and subtropical areas (20). 
The disease is characterized by 
extensive tumour-like subcutaneous 
masses and discharge of fungal 
grains, blood and pus and primarily 
affects the earning members of the 
society (5, 18, 20). Treatment of 
advanced cases usually implies 
amputation of the infected limb (17, 
26).   
Figure 1: An advanced case of eumycetoma caused by 
Madurella mycetomatis of the foot. 
Almost nothing is known about the pathogenic routes used by this fungus. Both host 
and fungal factors involved in disease progression are essentially unknown. Identification of 
such factors is important for the development of prophylactic and therapeutic measures 
against eumycetoma. In addition, the diagnosis of M. mycetomatis as the primary cause of 
eumycetoma is troublesome. Recently developed PCR tests are useful but do not provide a 
simple tool for bedside use (3). There is an urgent need for the development of simple high 
speed and high throughput tests for use in the endemic tropical regions. The usefulness of 
serological tests is under-explored and ELISA tests need to be developed.  
As early as in 1964 Mahgoub was able to demonstrate that eumycetoma patients 
developed antibodies against M. mycetomatis (27, 30). Counter immuno-electrophoresis 
(CIE), immunodiffusion and ELISA, were developed to detect antibodies raised against 
different mycetoma causative agents, using crude culture extracts as antigen (23, 29). This did 
not identify the type of antibodies produced or the nature of the antigens involved. It was not 
until the second half of the 1980s that it was experimentally demonstrated that the cytoplasm, 
organelles and, predominantly, the cell wall of M. mycetomatis were antigenic (40). About the 
same time it was also determined that IgM and IgG were the dominant immunoglobulins 
resulting from mycetoma (39). In 1991, the first attempts were made to characterize the nature 
of the epitopes present in the crude extracts used for the initial experiments (42). Cytoplasmic 
proteins were extracted from several eumycetoma agents and, although the different M. 
mycetomatis isolates had very heterogeneous protein profiles by SDS-PAGE, the antigenic 
make-up was quite similar within the species (42). The precise nature of the immunodominant 
proteins was not determined in this study. 
Molecular biology techniques were previously used for the identification of antigens 
and allergens from various fungal species such as Aspergillus fumigatus and Fusarium 
culmorum  (24, 33). In analogy to these studies, we now searched a newly developed M. 
mycetomatis cDNA expression library for immunodominant antigens. Our aim was to identify 
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antigens present on M. mycetomatis, which might be used in serodiagnostic tools or as 
vaccines, both therapeutic and prophylactic. We present the full characterisation of the 
translationally controlled tumour protein (TCTP), the first immunoreactive protein of M. 
mycetomatis, its histopathological features, and its use in immunological monitoring of 
disease progression.  
 
 
Materials and Methods 
 
M. mycetomatis strains 
M. mycetomatis strain mm55, isolated from the lesion of a 22-year-old patient seen in the 
Mycetoma Research Centre, University of Khartoum, Sudan, was used in this study. This 
strain was isolated by direct culture of the black grains obtained by a deep biopsy and 
identified by morphology, PCR-RFLP and sequencing of the ITS region (3). This strain is part 
of a well-defined strain collection deriving from Sudanese patients and is considered the type 
strain in phylogenetic and antifungal susceptibility testing as well (2, 4, 6, 37). The strain was 
maintained on Sabouraud Dextrose Agar (Difco Laboratories, Paris, France) at 37 oC. Passage 
to fresh medium was done on a monthly basis. Of this same collection four strains, strains 
mm30, mm45, mm46 and mm83, were used for comparative sequencing studies. 
 
Sera and tissues 
48 human sera were obtained from patients in various stages of mycetoma development 
(Mycetoma Research Centre, University of Khartoum, Sudan). For each patient age, sex, 
disease duration, relative size of the lesion and site of infection were recorded. The definition 
of small, moderate and large lesions were based on comparisons among mycetoma patient 
lesion. More accurate measurements were not possible, since some mycetoma lesions are 
diffuse, have a mass, and have ill-defined margins. As a control population, random sera from 
39 healthy Sudanese individuals from the same region were collected. As a true negative 
control, sera from 6 healthy Dutch individuals were taken. Mice sera were obtained by 
infecting female BALB/c mice intraperitoneally with 140 mg sonicated wet weight mycelia of 
the strain mentioned above according to the previously published protocol (6). The sera from 
10 infected mice were pooled and used in the experiments described here. Furthermore, grains 
and surrounding tissue derived from infected mice were obtained and preserved in buffered 
formalin. Permission for animal experiments was granted by the Animal Ethics Committee of 
Erasmus MC. Polyclonal anti-Translationally controlled tumour protein (TCTP)-antibodies 
were raised commercially in rabbits by Eurogentec (Eurogentec, Liège, Belgium). In short, 
rabbits were immunised by injecting 100 µg recombinant TCTP, and after 2, 4 and 8 weeks 
the immunisation was boosted using 100 µg per boost. Serum was taken before immunisation, 
one month after immunisation and three months after immunisation.  
 
Construction of the cDNA library 
The M. mycetomatis mm55 strain was cultured for 4 weeks on Sabouraud Dextrose Agar  
(Difco Laboratories) at 37 oC. The colony was excised from the agar, frozen in liquid nitrogen 
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and ground in a porcelain mortar. The resulting pulp was kept frozen in liquid nitrogen until 
the RLT buffer from the RNeasy® Maxi system (Qiagen GmbH, Hilden, Germany) was 
added. The sample was incubated for 3 min at 56 oC to fully disrupt the cell walls. Total RNA 
was isolated using the bacterial protocol from the RNeasy® Maxi system (Qiagen). After total 
RNA isolation, traces of DNA were removed with DNAse I (Ambion Ltd., Huntingdon, 
United Kingdom) according to the manufacturers’ indications. Poly(A)+ mRNA was purified 
by binding it to Oligotex® particles using the Oligotex® mRNA spin protocol (Qiagen). The 
purified poly(A)+ mRNA was used to synthesise double-stranded cDNA with the Universal 
RiboClone® cDNA Synthesis System (Promega Benelux BV, Leiden, The Netherlands). 
Finally, the double-stranded cDNA was ligated into the λgt11/EcoRI/CIAP-treated vector 
(Stratagene Europe, Amsterdam, The Netherlands). The quality of the library was established 
by adding X-gal  (Promega) in a final concentration of 2 mg/ml in topagar and blue-white 
screening for recombinant phages. The percentage of phages containing M. mycetomatis 
cDNA was 20%. 
 
Immunological screening of the cDNA library 
E. coli Y1090 cells (Stratagene Europe) were grown overnight in LB-broth supplemented 
with 0.2% (w/v) maltose, 10 mM MgSO4 and 50 µg/ml ampicillin.  The bacteria were pelleted 
for 10 min at 500 g and resuspended in 10 mM MgSO4 to an OD600 of 0.5. Two hundred 
thousand recombinant phages were absorbed to the cells for 20 min at room temperature. Top-
Agar medium (26 ml) was added to 2.4 ml of cells and poured on a pre-warmed 500 cm2 LB 
agar plate. The plate was incubated at 37oC until the plaques were clearly visible. 
Subsequently they were overlaid with a Protran® nitrocellulose membrane (Schleicher & 
Schuell GmbH, Dassel, Germany) for 10 min at room temperature. The membrane was 
washed three times with Tris-Buffered Saline Tween-20 (TBST) (10 mM Tris-HCL, 150 mM 
NaCl, 0.05% Tween-20, pH 8.0) and blocked for 30 min with 1% BSA (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) in TBST. Mouse serum obtained from M. mycetomatis 
infected mice was diluted 1:130 in TBST and pre-incubated with E. coli Y1090 extract to 
absorb non-specific antibodies. This extract was prepared by pelleting an overnight E. coli 
Y1090 culture, resuspending the pellet in a third of the original volume in EDTA buffer (50 
mM Tris-HCl pH8, 10mM EDTA), freezing it 1 h at –80oC and sonicating it 6 times for 15 s 
at 10 micron. Cell remnants were pelleted at 500 g and the supernatant was used as the E. coli 
Y1090 extract. The blot was incubated for 45 min with the treated mouse serum. After 
washing, the membrane was incubated for 30 min with anti-IgG alkaline phosphatase 
conjugate. Colour development was started by adding Nitro Blue Tetrazolium/5-Bromo-4-
Chloro-3-Indolyl Phosphate (NBT/BCIP) (Roche Diagnostics Gmbh, Mannheim, Germany). 
Positive phages were selected and purified by repeated screening.  
 
Sequence analysis 
To determine the nature of the insert present in antigenic phages, purified phages were boiled 
for 10 min. Five µl of this crude extract was amplified in 50 µl PCR-mixture consisting of 1x 
Supertaq PCR buffer 1 (HT Biotechnology Ltd., United Kingdom), 0,2 mM PCR nucleotide 
mix (Amersham Life Sciences, Roosendaal, The Netherlands), 25 pmol primer gt11fw (5’-
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GGTGGCGACGACTCCTGGAGCCCG-3’), 25 pmol primer gt11rv (5’-
TTGACACCAGACCAACTGGTAATG-3’) and 1.2 U Supertaq (HT Biotechnology Ltd.). 
The PCR was composed of a pre-denaturation step of 4 min at 94 oC and 35 cycles consisting 
of a 1 min denaturation at 94 oC, 1 min annealing at 50 oC and 2 min elongation at 72 oC. This 
was followed by a post-elongation step of 7 min at 72 oC. The PCR products were sequenced 
(BaseClear, Leiden, the Netherlands) and their insert sequences were compared with other 
sequences in the NCBI database (http://www.ncbi.nlm.nih.gov/BLAST).  
 
Population analysis 
We used the primers TCTPfw (5’-GCCGAGGAGGCTCTCGAGGA-3’) and TCTPrv (5’-
ATCGGGATCCTTAGACCTTCTCCTCCTTCAG-3’) to determine presence of the TCTP 
sequence in the other 37 M. mycetomatis strains in our collection. The PCR program was 
identical to the one described in the next section for constructing the expression vector. The 
resulting PCR products were digested with the endonuclease AluI to determine the variability 
within TCTP found in various strains.    
 
Construction of a TCTP expression vector 
The purified phages containing the complete TCTP coding region were boiled for 10 min and 
5 µl of these extracts were amplified in 50 µl PCR-mixture consisting of 1x Supertaq PCR 
buffer 1 (HT Biothechnology Ltd., United Kingdom), 0.2 mM PCR nucleotidemix 
(Amersham Life Sciences, Roosendaal, The Netherlands), 25 pmol forward primer (5’-
ACGTGCTAGCCATCACCATCACCATCACATTATCTACAAGGATATTAT-3’), 25 pmol 
reverse primer (5’-ATCGGGATCCTTAGACCTTCTCCTCCTTCAG-3’) and 1.2 U Supertaq 
(HT Biotechnology Ltd., United Kingdom). The PCR was composed of a pre-denaturation 
step of 5 min at 92 oC and 10 cycles consisting each of 10 s denaturation at 92 oC, 30 s 
annealing at 45 oC and 1 min elongation at 68 oC followed by 15 cycles consisting each of 10 
s 92 oC, 30 s 45 oC  and 1 min at 68 oC which extended with 10 s per cycle. The PCR ended 
with a post-elongation step of 4 min at 68 oC. In a 2:1 molar ratio the PCR product and vector 
pET11c (New England Biolabs Inc, Ipswich, USA) were restricted for 2 h at 37 oC with 10 U 
Nhe I and 10 U Bam HI in buffer M (All Roche Diagnostics). After removal of excess 
restriction enzyme (Zymo Research, Orange, USA) the PCR product was ligated into the 
pET11c vector with 3U T4 ligase (Promega Benelux BV, Leiden, The Netherlands). The 
resulting plasmid was electroporated into electrocompetent E. coli  BL21. To determine the 
absence of point mutations generated during the cloning process, the sequence of the insert 
was verified (BaseClear) by alignment with the sequence obtained from the original 
recombinant phages.  
 
Expression and purification of the recombinant fusion protein 
To express the His-tagged TCTP fusion protein, a culture containing the E. coli BL21 strain 
with the recombinant plasmid was grown to an OD600 of 0.6. To induce expression, IPTG 
(Promega Benelux BV) was added to a final concentration of 1 mM and the culture was 
grown for another 2 h. The culture was pelleted and resuspended in 20 mM phosphate, 0.5 M 
NaCl and 10 mM imidazole. The cell suspension was sonicated at 4 oC and cell remnants 
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were pelleted. The histidine-tagged recombinant proteins were purified using a HiTrap™ 
column (Amersham Life Sciences) and eluted (300 mM imidazole, 10 mM Na2HPO4⋅H2O, 10 
mM Na2HPO4⋅H2O, 0.5 M NaCl). The eluate was dialysed against distilled water for 6 h. The 
size and purity of the recombinant protein were determined on a 12% SDS-PAGE gel stained 
with Coomassie® G250 (Bio-Rad). 
 
Immunohistochemistry 
Grains obtained from experimentally infected mice were embedded in paraffin and 
histological slides were prepared. The slides were rehydrated in PBS and incubated for 30 min 
in a blocking solution (1% BSA,  5% sucrose in PBS). The primary antibody was diluted 
1:100 in blocking solution and incubated for 30 min. As primary antibody, rabbit serum raised 
against recombinant M. mycetomatis TCTP was used. This serum was obtained 6 weeks after 
immunisation. As negative control, pre-immune serum from the same animal was used under 
the same conditions. After washing, the slides were incubated with diluted goat anti-rabbit 
IgG horseradisch peroxidase conjugated antibody (1:50, Sigma-Aldrich). The substrate 
NovaRedTM (Vector, Burlingame, CA, USA) was as the primary stain, haematoxyline was 
used as counterstain. 
 
Recombinant protein ELISA: The purified recombinant protein (12.5 µg per well) was coated 
onto Maxisorp plates (Nunc A/S, Roskilde, Denmark) overnight at 4 oC. After blocking for 
two h with 1% BSA (Sigma-Aldrich) and 5% sucrose (Mallinckrodt Baker, Deventer, The 
Netherlands) plates were washed and incubated for 1 h with 1:50 diluted patient serum. After 
washing, 1:5000 diluted goat anti-human IgM (Sigma-Aldrich) or 1:10000 diluted goat anti-
human IgG (Sigma-Aldrich) was applied and incubated for 1 h.  The reaction was developed 
for 15 min in 3,3’, 5,5’ tetramethyl benzidine (TMB) (Meddens Diagnostics) which was 
stopped with 2M H2SO4. Absorption was measured at 450 nm in a model 550 microplate 
reader (Bio-Rad). 
 
Peptide ELISA 
In order to bind the peptides shown in table I to Covalink ELISA-plates (Nunc), these plates 
were pre-incubated for 30 min at 37oC with 10 mM SPDP (3-(2-pyridyldithio)propionic acid 
N-hydroxysuccinimide ester) (Sigma). Each peptide (10 µM in 0,1 M Tris-HCl, pH 8.0), was 
coupled to the bivalent linker via the N-terminal cysteine residue for 60 min at 37oC. Empty 
binding sites were blocked for 2 h at 37oC with 6% low-fat milk (Similac 2, Abbott) before 
1:50 diluted patient serum was allowed to bind (45 min at 37oC). After 30 min of incubation 
with the secondary antibody (1:10000, goat anti-human IgG (Sigma-Aldrich)) the reaction 
was developed as described above.    
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Name Variant I Variant II 
Peptide 1 VDCAMVVEDAVNA Not determined 
Peptide 2 EAEEALEDAAVKV EAEEALEDQAIKV 
Peptide 3 DAAVKVNNVVNSF DQAIKVNDVIHYF 
Peptide 4 SVKKALQDAGKSE SVKKALQDAGKSE 
Peptide 5 KSEDEVKEFETKA KSEDEVKEFETKA 
Peptide 6 TKAQAYVKDTVLP TKAQAYVKDTILP 
Table 1: Peptide sequences constructed on the M. mycetomatis specific TCTP domains. These sequences were 
based upon non-conserved sequences of variant I of the TCTP sequence when compared to other TCTPs. In this 
table the homologues for variant II are also shown. Differences between this variant and variant I are highlighted 
in the bold font in the sequence for variant II. The peptide 1 homologue in variant II could not be determined 
because no sequence data was available for this area. Peptides developed for variant I are the ones constructed 
and used in the peptide ELISAs. 
 
Statistical analysis 
IgG and IgM levels raised against the TCTP antigen or the various TCTP peptides were 
compared between study populations by the Mann-Whitney test (GraphPad Instat 3.00). A 
p<0.05 was considered significant. The Mantel-Haenszel Chi square test for trends was used 
to test if there was a significant trend of higher levels in bigger lesions, by including size 
(small, moderate, massive) as independent variables, and the log transformed antibody level 
as dependent variable.  
 
Nucleotide sequence accession numbers 
The sequences of the M. mycetomatis homologues of  TCTP were deposited in the GenBank. 
GenBank accession numbers of the cDNA sequences for variants I of this gene are DQ218143 
(strain mm55), DQ218146,  (strain mm46) and DQ218147 (strain mm83).  GenBank 
accession numbers for variants II of this gene are DQ218144 (strain mm30) and DQ218145 
(strain mm45). The DNA sequences for the two variants in these strains are deposited under 
numbers DQ218148-DQ218152. 
 
Results 
 
Antigenic phages contain a M. mycetomatis translationally controlled tumour protein (TCTP) 
homologue 
In our search for antigens of M. mycetomatis, an expression library in phage λgt11 was 
constructed. This library consisted of 6.0 x 104 independent clones with an average insert 
length of 1500 bp. A total of approximately 6 x 108 recombinant phages were screened with 
sera obtained from mice experimentally infected with M. mycetomatis. Twelve phage clones 
were found to significally bind antibodies and these were rescreened to purity. PCR 
amplification, restriction analysis and subsequent sequencing demonstrated that all 12 
immunoreactive plaques harboured the same 692 base pair insert, encoding a single open 
reading frame (ORF) of 516 nucleotides. The ORF defined a 171 amino acid polypeptide 
sequence, which was followed by an untranslated sequence of approximately 156 bp 
including a poly A tail of 15 nucleotides (figure 2).   
  TCTP expression in Madurella mycetomatis 
 
 6  
5
 
4 
 
3  
2
 
 
 
 1  
 
Figure 2: Nucleotide sequence and deduced amino acid sequence of the TCTP gene of Madurella mycetomatis. 
In this sequence at least four exons can be found: exon 1 (amino acids 99-137), exon 2 (amino acids 200-337), 
exon 3 (amino acids 423-585) and exon 4 (amino acids 644-727). These exons are shown translated and are 
followed by three introns: intron 1 (amino acids 138-199), intron 2 (amino acids 338-422) and intron 3 (amino 
acids 586-643). The sequence preceding the first arrow (amino acids 1-8) and after the second arrow (amino 
acids 728-895) are mRNA. For only the sequence between those arrows (amino acids 9-727) the DNA sequence 
is known. Peptides are underlined and numbered. 
 
As seen in figure 3 the protein showed significant homology with the translationally 
controlled tumour protein (TCTP) gene of various organisms including fungi and yeasts.  The 
highest degree of homology was observed for the TCTP gene of the fungus Neurospora 
crassa (GenBankTM accession number XP_326319), with 61% aminoacid identity and 71% 
aminoacid similarity. At the protein level, M. mycetomatis TCTP was less closely related to 
mammalian TCTP, with only 39% identity and 56% similarity. 
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Figure 3: Phylogenetic tree analysis of TCTP protein sequences from different species. The tree distances were 
calculated using the Clustal V algorithm in the programm MegAlign (DNAstar). Both M. mycetomatis TCTP 
variants (I and II) (GenBankTM accession No. DQ218143-DQ218147),  were compared to TCTP sequences 
obtained from Brugia malayi (GenBankTM accession No. AAC47622), Candida albicans (EAK99010), Candida 
glabrata (XP_449328), Danio rerio (NP_937783),  Drosophila melanogaster (DmTCTP, NP_650048), Gallus 
gallus (NP_990729), Gibberella zeae (XP_382699), Homo sapiens (NP_003286), Hydra vulgaris (AAB18413), 
Kluyveromyces lactis (CAH01617), Magnaporthe grisea (EAA56278), Mus musculus (p63028), Neurospora 
crassa (XP_326319), Oryctolagus cuniculus (CAA12650), Oryza sativa (P35681), Pisum sativum (P50906), 
Plasmodium falciparum (NP_703454), Pseudotsuga menziesii (CAA10048), Saccharomyces cerevisiae 
(P35691), Triticum aestivum (AAM34280), Wuchereria bancrofti (AAK71499) and Yarrowia lipolytica 
(XP_504451). For each of the organisms the TCTP1 and TCTP2 signature sequences are given. In this sequence 
amino acids which do not correspond to the signature sequence (given in bold) and amino acids which do not 
belong in the signature sequence (-) are shown as well.  
 
In order to establish whether this gene was ubiquitously found in all M. mycetomatis strains 
we screened 38 isolates for its presence. After PCR screening of genomic DNA of these 
isolates it appeared that all strains possessed the TCTP gene homologue (data not shown). 
PCR RFLP exploring the genes from these isolates revealed that there was not one isoform of 
this gene but two. Subsequently sequencing of these genes confirmed this finding.  The 
isoforms as shown in figure 4 were named variant I and II.  Variant I was found in 53% of the 
isolates while variant II was found in 47% of the isolates. Further PCR analyses showed that 
both TCTP genes contained at least three introns of 64 bp (intron 1), 161 bp (intron 2) and 56 
bp (intron 3) and four exons (figure 2).  
According to the PROSITE pattern database (http://www.expasy.ch/prosite/entry, 
PDOC00768) two signature patterns can be identified for TCTP amino acid sequences, 
namely TCTP1 and TCTP2. After comparing the MmTCTP amino acid sequences with the 
database entries it was noticed that amino acid positions 49-54 in the MmTCTP variant I were 
identical to the typical TCTP1 signature sequence, [IFAE]-[GA]-[GAS]-N-[PAK]-S-[GTA]-E-
[GDEV]-[PAGEQV]-[DEQGAV]. In contrast, the TCTP2 sequence of this MmTCTP variant 
deviated from the known signature sequence, [FLIV]-x4-[FLVH]-[FY]-[MIVCT]-G-E-x(4,7)-
[DENP]-[GAST]-x-[LIVM]-[GAVI]-x3-[FYQW]. For the second variant this finding was 
reversed. This variant had a deviating TCTP1 signature sequence [IFAE]-[GA]-[GAS]-N-
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[PAK]-S-[GTA]-E-[GDEV]-[PAGEQV]-[DEQGAV] and a canonical TCTP2 signature sequence 
[FLIV]-x4-[FLVH]-[FY]-[MIVCT]-G-E-x(4,7)-[DENP]-[GAST]-x-[LIVM]-[GAVI]-x3-[FYQW]. 
Both deviating sequences each displayed only one amino-acid difference. In the TCTP2 
sequence of variant I, glutamate was replaced by serine and in the TCTP1 sequence of variant 
II, glutamine was found instead of either glycine, alanine or serine. 
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Figure 4: Comparison of the two TCTP variants. A. Alignment of the two TCTP variants of M. mycetomatis 
based on the BLOSUM 62 algorithm. Identical amino acid residues are shown as a dot. B. Banding patterns 
obtained for each variant after treatment with the endonuclease AluI. 
 
 
 
Since we obtained a complete cDNA 
sequence for variant I we used this to express 
and purify the recombinant TCTP variant I 
gene product as a histidine-tagged fusion 
protein. The yield of this recombinant protein 
was 50 mg per litre of E. coli culture. SDS-
PAGE gel analysis of the purified 
recombinant protein with the histidine tag 
revealed one clear band with a molecular 
weight of approximately 26 kDa (figure 5). 
This was slightly larger than the expected 
molecular weight but still in full accordance 
with the molecular weight of other cloned 
TCTPs (22). As seen in figure 5, the purified 
protein was essentially free of contaminating 
proteins. 
 
 
 
   
Figure 5: Twelve percent Coomassie stained SDS-PAGE
of the recombinant his-tagged M. mycetomatis protein.
Lane 1: SDS-Page broad range marker, lane 2: total E. coli
extract before inducement of the TCTP expression, lane 3:
total E. coli extract after inducement of the TCTP
expression, lane 4: protein extract after binding the his-
tagged recombinant TCTP protein to the HiTrap column,
lane 5: eluted his-tagged recombinant TCTP protein  83 
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TCTP is expressed in the developing grain  
To assess whether TCTP was expressed in vivo we isolated grains in their surrounding tissues 
from mice infected with M. mycetomatis. These grains were embedded in paraffin and antibodies 
raised against TCTP were used to demonstrate the presence of TCTP in these grains. The results 
obtained are shown in figure 6.  
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Figure 6: A. Stained histological section of a grain isolated from a mouse interaperitoneally inoculated with 120 
mg fungal mycelia and soil adjuvant (100x). Immunohistochemistry with anti-TCTP antibodies, counterstained 
with haematoxylin. The grain is surrounded by a type 1 host reaction. The grain is surrounded by three zones of 
host inflammation cells. The first zone, closest to the grain is composed of neutrophils, the second zone is 
composed of histiocytes. The outer layer is the vascular layer. The grain itself is divided into three 
developmental stages. The first stage is the early developing stage (1), the second stage is the intermediate stage 
(2) and the third stage is the developed stage (3).  B. TCTP is highly expressed in first stage of development. 
Immunohistochemistry performed with immune serum. C. First stage of development with pre-immune serum. 
D. TCTP expression in second stage of development, immune serum. E. Second stage of development, pre-
immune serum. F. No TCTP expression in third stage of development, immune serum. G. Third stage of 
expression, pre-immune serum. Figures B-G are photographed at 400x. TCTP expression is stained with the 
substrate NovaRed (orange). 
 
The grains in the intraperitoneal mouse tissues are typically filamentous and are 
surrounded by three zones of inflammatory cells, a type I tissue reaction as described by Fahal and 
El Hassan (16, 18, 19). The zone directly around the grain was composed mainly of neutrophils. 
This zone was followed by a region of histiocytes and an outer vascular zone. The fungal cells in 
the grain itself are mostly embedded in brown-pigmented cement material. It was clearly seen that 
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TCTP is not evenly expressed in the grain. In the grain itself, three stages of grain development 
are seen. The first stage (figure 6A, number 1) is the stage in which the grain is still forming. The 
brown-pigmented cement material in this part of the grain is not present yet (figures 6B and 6C) 
and the neutrophil zone surrounding the grain is not completely formed and only a few cell layers 
thick. This zone is invaded by the grain and fungal cells are in direct physical contact with the 
immune cells. The fungi are mostly seen as complete hyphae. In this part of the grain, TCTP was 
expressed abundantly (figure 6B). Most cells express the protein but some exceptions are noticed, 
even within hyphae where other cells do express the protein. In the second stage of the grain 
formation (figure 6A, number 2), the cement material is more developed but individual fungal 
cells are still seen (figures 6D and 6E). Some of the neutrophils are also still found between the 
fungal cells. The number of cells expressing TCTP was inversely related to the amount of cement 
material present. In the last stage (figure 6A, number 3) the grain is fully formed. The fungus is 
embedded into cement material and no neutrophils are seen within the grain (figures 6F and 6G). 
In this stage no visible TCTP expression was documented (figure 6F). 
 
Association between lesion size, duration of the disease and TCTP antibody levels 
The phage containing the TCTP insert was selected because of its reactivity with sera from 
infected mice. Mice infected with M. mycetomatis had antibodies against the protein while 
healthy control mice did not (results not shown). To test the antigenicity of MmTCTP in 
humans, an ELISA was developed. The IgA, IgM and IgG levels against the protein were 
measured. None of the patients or controls displayed an IgA level against this protein, but 
clear IgM and IgG responses were detected.  Since only comparative optical densities were 
measured, a prozone phenomenon could not be ruled out.  In figure 7 IgM and IgG levels 
against TCTP are summarised. Both in the patient group as well as in the Sudanese control 
group, significant IgM and IgG levels were measured against the protein, however in a lower 
percentage of controls than patients, and not all patients developed elevated levels. All 
individuals in the Dutch healthy control group had low anti-TCTP levels overall. For some of 
the patients it was known whether the fungus causing the infection produced TCTP variant I 
or II. Patients infected with a type II variant had detectable antibodies in an ELISA coated 
with the variant I protein. No significant difference in antibody binding was noticed when 
serum of variant II patients was used (data not shown). It was seen that the IgM level in the 
M. mycetomatis infected people was significantly higher compared to the Sudanese controls 
(Mann-Whitney, p=0.03) or to the Dutch control group (p=0.003). The IgG levels of the M. 
mycetomatis infected people were only significantly higher compared to the Dutch control 
group (p=0.002). It was also noted that the patients with massive eumycetoma lesions had the 
highest absorbances and that patients with the smaller or cured lesions had lower IgG levels 
(MH test for trend, p=0.030). No significant trend was documented for the IgM 
immuneresponse. Furthermore, it was seen that after a disease duration of 6-10 years anti-
TCTP levels were highest.  
Since some individuals in our healthy control group from Sudan had raised levels of 
antibodies against the recombinant TCTP-protein we analysed whether these elevated levels 
were due to the M. mycetomatis homologue of this antigen or due to cross-reactivity. Cross-
reactivity could occur with TCTPs from other infectious agents, such as Plasmodium 
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falciparum and Leishmania spp., which are locally endemic pathogens in the Sudan region as 
well. In order to test this, known TCTP sequences for various species were compared and we 
designed six M. mycetomatis specific peptides based upon non-conserved sequences of variant 
I of the TCTP sequence (see figure 2 for the position, code and sequence of the peptides). 
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Figure 7: IgG levels against the purified recombinant his-tagged TCTP protein measured at a wavelength of 450 
nm in an ELISA system. Each point represents the mean of three independent measurements per patient or a 
healthy control. A: IgM levels in correlation of the size of the lesion and the duration of the disease. B: IgG 
levels in correlation of the size of the lesion and the duration of the disease. The differences between the 
geometric means were tested for significance with the Mann-Whitney test. Furthermore it was tested if there was 
a significant trend or higher level in bigger lesions, by including size (small, moderate, massive) as independent 
variable, and log transformed level as dependent variable in a linear regression model. The p-values are stated as 
follows: p ≤ 0.0100 (**), p ≤ 0.05 (*), p = not significant (NS). 
 
As a precaution we also compared the peptides designed to variant II of the M. 
mycetomatis TCTP protein. Five of the six peptides were conserved in M. mycetomatis, with a 
maximum of 2 amino acids difference. Only one peptide, peptide 3, was not conserved. For 
this peptide, 6 out of the 13 amino acids were different between the two variants. With these 
peptides, ELISAs were performed and both the patient and the control sera were retested. In 
figure 8 the antibody levels against the six individual peptides are shown. Peptides 1, 2, 3, 4 
and 5 can clearly differentiate the patient population from the healthy Sudanese control 
population, but with peptide 6 the mean IgG levels of the patient population and the healthy 
Sudanese control population were not significantly different. When the patients were stratified 
according to massive lesions, moderate lesions, small lesions and cured patients the same 
picture was obtained for the peptides as with the whole TCTP protein (data not shown). 
Overall, the patients with the largest lesions had the highest antibody levels against the 
respective peptides, the level lowered with the decreasing size of the lesion. After 6-15 years 
of disease duration levels were the highest.  
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Figure 8: IgG level generated against the different TCTP peptides. In this graph the antibodies raised against the 
different peptides (numbers 1-6) in the M. mycetomatis infected patients (♦) are plotted next to antibodies found 
in the Sudanese healthy control group (◊). For reference the results obtained with the complete TCTP protein as 
shown in figure 7 are repeated in this figure as well (TCTP). The differences between the geometric means were 
tested for significance with the Mann-Whitney test. The p-values are stated as follows: p ≤ 0.0010 (***), p ≤ 
0.0100 (**), p ≤ 0.05 (*), p = not significant (NS). 
 
 
Discussion  
 
It has been demonstrated before that specific antibodies are raised against the agents of 
mycetoma. It was, however, never clear what the nature of the immunogenic epitopes was 
(23, 27, 29). In the present study we completely identify and characterise the first 
immunoreactive antigens from a M. mycetomatis isolate namely TCTP. Many functions have 
been recorded for TCTP. This protein appears to be involved in cell cycle control, stress 
responses, histamine release and interleukin production (12, 38). It is also known to bind the 
anti-malarial and anti-cancer drug artemisinin (7, 15). In our search for antigens, we 
constructed an expression library in phage λgt11, which was screened with sera obtained from 
M. mycetomatis infected mice. Screening the library resulted in 12 antigenic phages which all 
contained the same insert, namely the M. mycetomatis homologue of TCTP. This finding 
differs from results obtained for other pathogens such as Mycobacterium tuberculosis for 
which large numbers of independent and clearly different antigenic phages were found (9). 
The antigenicity of M. mycetomatis TCTP was confirmed by rabbit immunisation. Other 
parasites are also known to produce TCTP. Some examples are P. falciparum, Brugia malayi, 
Wuchereria bancrofti and Schistosoma mansoni (8, 22, 25, 32). These TCTPs have been 
documented to be antigenic as well (8, 22, 25, 32). 
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In the present study we found that the TCTP gene isolated from the expression library was 
one of two variants present in the species M. mycetomatis, which again further corroborates 
the genetic heterogeneity within this species (36). Although TCTPs have been found in a great 
variety of eukaryotic organisms no one has yet reported the presence of multiple variants of 
this gene within one species. In the mouse, rabbit and human genomes there are indeed 
pseudogenes of this protein known (21, 34, 35). But in the more ancient Hydra vulgaris and 
Labeo rohita no doublet TCTP mRNA is found (38, 41). This raises questions on the possibly 
different physiological findings of the TCTP variants. 
 
To test its antigenicity in humans an ELISA was developed with variant I of MmTCTP. A 
significant number of the patients seen in the Mycetoma Research Centre had raised 
antibodies against mmTCTP variant I, but, unfortunately, not all the patients. Reasons for this 
restriction are currently unknown but subject to further study. It also appeared that some 
individuals of the Sudanese healthy control population had an elevated antibody level against 
TCTP as well. The most simple an also likely explanation would be that these individuals 
raised antibodies after environmental exposure to the antigen. It could also be possible, since 
mycetoma has a long incubation time, that some of these individuals had sub-clinical or early 
M. mycetomatis infections. Another plausible explanation is cross-reactivity with TCTPs from 
other endemic infectious organisms. Although Rao demonstrated that antibodies raised 
against filarial TCTPs did not react against recombinant S. mansoni TCTP, Gnanasekar 
showed that antisera raised against B. malayi could detect recombinant W. bancrofti TCTP 
and visa versa (22, 32). These latter filarial TCTPs were closely related to each other, with 
98% sequence homology at the amino acid level (22). From the phylogenetic tree shown 
(figure 3), it can be easily seen that the closest homology was found with TCTP genes of other 
fungi. In order to determine whether cross reactivity with TCTPs from other species were 
causing the high levels in the healthy Sudanese control population, specific TCTP peptides 
which showed as little homology as possible with other TCTP sequences were developed. In 
the peptide ELISAs there was a clear difference between the mean IgG levels raised against 
the different peptides in the patient population and the healthy Sudanese control population. 
Only with peptide 6 no statistic significant difference in the mean IgG levels was detected.  
Apparently, peptides provide more specific ELISA targets than the full protein. This is 
biologically plausible and suggests that cross reactivity between TCTPs from various 
organisms is occurring in humans. Pathological effects of this cross-reactivity deserve 
additional research. 
Our experiments showed that the TCTP gene is present in all M. mycetomatis strains tested. 
Also, the immunogenic epitopes of variants I and II of the protein seems to be overlapping. 
This overlap was proven by comparing sera obtained from patients of whom it was known 
with which TCTP variant of M. mycetomatis they were infected. No statistically significant 
difference in antibody level was detected between the two variants. By developing peptides 
specific for conserved M. mycetomatis specific regions between the two variants, antibody 
responses could be compared. Since no difference in response between patients infected with 
variant I or variant II were found in the ELISAs, we could conclude that differences found in 
antibody level were not caused by the variability in the TCTP gene. This difference must be 
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due to other factors involved in TCTP expression.  For instance, it is possible that not all 
strains transcribe this protein in vivo (although they do so in vitro) and even if TCTP is 
transcribed it is likely that not all patients form antibodies against this protein to the same 
extent.  
 
In order to investigate TCTP expression in vivo, grains in surrounding tissues from infected 
mice were isolated. In these tissues TCTP expression could be demonstrated. TCTP 
expression was very high in the first stage of M. mycetomatis grain development, almost all 
fungal cells in this stage of development expressed TCTP. For other TCTPs it is known that 
the expression is also dependent on the developmental stage of the organism (22, 32, 35). 
TCTP is highly expressed in mitotically active stages while in postmitotic tissue it is hardly 
expressed at all (22, 32, 35). In the developing stage of the M. mycetomatis grain the fungal 
cells are probably mitotically active.  Expression was less in the second stage of grain 
development and almost non-existent when the grain was completely formed. In this latter 
stage the fungus is probably not mitotically active anymore and the fungal cells are 
completely embedded in cement material. This latter could also result in shielding of the 
antigen. In the first 15 years of infection, the antibody levels were elevated. This finding was 
seen both for the whole protein as for the individual peptides. Levels drop after prolonged 
infection (>15 yrs). Since eumycetoma is a chronic infection with a long incubation time and 
a slow progression, M. mycetomatis may well reside in the host for a prolonged period as a 
mitotically less active organism.  Combining the in vivo TCTP expression and the serological 
data this could indicate that after establishing the infection the organism becomes less 
reproductively active and less TCTP is expressed. The same can be said for the size of the 
lesion. It was demonstrated that the antibody response was associated with the size of the 
lesion since the patients with the largest lesions had the highest antibody levels. In patients 
with large massive mycetoma, many subcutaneous lesions exist in different stages of 
development, involving elevated high expression of TCTP. In the largest lesions probably 
most mitotically active cells are found. In these lesions the highest anti-IgG levels were found. 
Patients with only small lesions had similar antibody levels as the Sudanese controls. A 
correlation between the size of the lesion and the immune response was also reported for the 
crude antigens used in the double immunodiffusion method developed by Murray (30). 
Murray found a correlation with the number of precipitin bands and volume of the tissue 
involved in the disease (30). The TCTP antibody levels were also correlated with the duration 
of the disease. After 6-10 years anti-TCTP responses were the highest, whereas no correlation 
with duration of the disease was observed by Murray when using crude cell extracts of M. 
mycetomatis (30). 
 
Eukaryotic TCTPs are reported to respond to a wide range of extra-cellular signals and 
cellular conditions (11-13, 31). Growth factors, cytokines, starvation, heat shock, heavy metal 
stress, calcium stress but also viral infections: all have been reported to either induce or 
repress the formation of TCTP in various organisms (11-13, 31). Since TCTP is known to be 
expressed as part of a protective mechanism in many other eukaryotes, it could be involved in 
the pathogenesis of mycetoma caused by M. mycetomatis.  M. mycetomatis DNA has been 
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found in Sudanese soil and vegetation (1). When the fungus enters the body it will have to re-
adapt and TCTP expression might be part of the adaptation process. A similar phenomenon 
has been noted for the parasite B. malayi (22). In this parasite no TCTP is found in the pre-
infective stages but upon entering the host, TCTP becomes strongly upregulated. TCTP was 
also found to be upregulated by higher temperatures (28). It was hypothesised by Gnanasekar 
et al. that the entry of the parasite B. malayi from a cold-blooded insect vector to a warm-
blooded host could trigger higher expression of BmTCTP (22). However, for S. mansoni 
TCTP expression was significant in all developmental stages, including the pre-infective ones 
(32). In the developing stages of the M. mycetomatis grain, TCTP expression is high. This 
high TCTP expression is typical for mitotically active tissues and could be associated with 
stress conditions imposed by the host immune system or nutrient depletion during the invasive 
growth  (10, 35, 41).  
 
In conclusion, we discovered that M. mycetomatis TCTP is antigenic in mice, rabbits and 
humans. The TCTP protein was found mainly at the cell surface of the fungus and primarily 
in the developing part of the grain. TCTP has two variants in the species M. mycetomatis, and 
in an ELISA system, disease stage dependent immuneresponses were documented. Although 
TCTP may not be the best diagnostic tool, the ELISAs presented here could be useful in 
seroprevalence studies. In addition, studies into the influence of TCTP on mycetoma 
development or its use as a therapeutic vaccine or a vaccine in the prevention of infection are 
urgently warranted.  
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Abstract 
 
Madurella mycetomatis, one of the causative agents of mycetoma, secreted significant 
amounts of galactomannan-like compounds into the culture medium. These compounds were 
not detected in the patient serum. It could be that the nature of the sclerotia in patients 
(cementmaterial, melanin, tight package) prohibits diffusion of the galactomannan.  
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Introduction 
 
Madurella mycetomatis is a causative organism of eumycetoma, a disease characterized by 
tumourous masses, and formation of grains and purulent material (1). At present treatment of 
mycetoma is based on surgery and long-time antifungal therapy to prevent relapses. Ideally, 
continuous diagnostic monitoring of patients to determine the success or failure of antifungal 
therapy should be implemented. For the diagnosis of invasive aspergillosis, for instance, a 
sandwich enzyme-linked immunosorbent assay is widely used (5). Circulating galactomannan 
or galactomannan-containing proteins are detected by the assay through an antibody raised 
against the galactofuran epitopes present on these molecules (5). Immunological cross-
reactivity has been described for Paecilomyces variotii, Penicilllium spp, Geotrichum 
capitatum and Cryptococcus neoformans (3, 7). In the present study such galactomannan 
cross-reactivity was investigated for M. mycetomatis.  
 
 
Materials and Methods 
 
M. mycetomatis culture supernatant and patient sera 
Culture supernatant from 32 M. mycetomatis isolates was obtained by culturing a 70% 
transmission inoculum in RPMI-medium for 7 days at 37 oC (8). Serum was obtained from 
patients and healthy controls and frozen at –20 oC until further use.  
 
Galactomannan assay 
The platelia Aspergillus assay (Bio-Rad, Veenendaal, The Netherlands) was performed 
according to the manufacturer’s implications. The amount of galactomannan was determined 
with a concentration curve of pure galactomannan.  
 
 
Results  
 
Strain-dependent amounts of M. mycetomatis galactomannan-like compounds were secreted 
into the culture medium (figure 1). According to the cut-off value of 1 ng/ml, six isolates 
secreted no galactomannan-like compounds. The other 24 strains secreted these compounds in 
concentrations up to 12.9 ng/ml. In only 2 of the 16 patient sera galactomannan levels above 
the cut-off value of 1 ng/ml were found (Figure 1). There was no correlation with either extent 
or duration of the disease. In none of the healthy volunteer sera galactomannan levels above 1 
ng/ml were found.   
 
 
  95   
Chapter 6   
Concentration galactomannan in Madurella mycetomatis
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Figure 1: Galactomannan concentration in M. mycetomatis. Galactomannan concentrations were determined in 
the culture supernatant after culturing for 7 days in RPMI culture medium (■). Galactomannan concentrations 
were also determined in patient serum (▲) and serum from healthy Sudanese controls (▼). 
 
 
Discussion 
 
Significant amounts of galactomannan-like compounds were found to be secreted into the 
culture medium. Cross-reactivity in the galactomannan assay has already been described (3). 
The fact that galactomannan is secreted in the culture medium but not recovered from patient 
circulation can be caused by a variety of reasons. It could be that the structure of the sclerotia 
in patients (cementmaterial, melanin, tight package) prohibits diffusion of the galactomannan. 
For aspergillosis it has already been demonstrated that in some cases galactomannan could be 
detected in the bronchoalveolar lavage but not in the serum (2, 9). Furthermore, it could be 
that antifungal treatment of mycetoma hampers the performance of this test. All patients were 
treated with either high doses of itraconazole or ketoconazole. Marr et al. demonstrated that 
administration of antifungal agents on the day of test sampling decreased the sensitivity of the 
assay significantly (4).  It  could also be that the antigen is not secreted because of a lack of 
nutrients. It has already been shown for Aspergillus niger and Penicillium fellutanum that 
secreted antigens can be reused as carbon source when nutrients are deprived (5, 6). In 
nutrient-rich conditions, Aspergillus spp. release high amounts of galactomannan during 
growth, but these amounts can be reduced in a nutrient-poor environment such as serum. In 
conclusion, M. mycetomatis secreted compounds which are immunologically cross-reactive to 
Aspergillus galactomannan in vitro  but not in vivo .  
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Abstract 
 
Susceptibilities of Madurella mycetomatis against amphotericin B and itraconazole in vitro  
were determined by protocols based on NCCLS guidelines (visual reading) and a 2,3-bis (2-
methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium hydroxide (XTT) 
assay for fungal viability. The XTT assay was reproducible and sensitive for both antifungals. 
Itraconazole (MIC at which 50% of the isolates tested are inhibited [MIC50]) of 0.06 to 0.13 
mg/liter) was superior to amphotericin B (MIC50 of 0.5 to 1.0 mg/liter). 
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Introduction 
 
Little is known about the susceptibility of the fungus Madurella mycetomatis, the major cause 
of eumycetoma, to antifungal agents (6). In the past, ketoconazole was promoted as the drug 
of choice (4, 6, 8, 10, 15, 16), but clinical response to ketoconazole is often poor (5, 17, 18, 
25, 26). Other studies show that early treatment with itraconazole seems to be optimal (5, 10, 
17). Here we evaluate the in vitro  activities of itraconazole and amphotericin B against 36 
clinical isolates of M. mycetomatis.  
 
Materials and Methods 
 
MICs were determined visually by a method based on the NCCLS (approved standard M38-
A) (20). In addition, a quantitative colorimetric method using the dye 2,3-bis (2-methoxy-4-
nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium hydroxide (XTT) was used 
(12, 13, 24).  
 
M. mycetomatis strains 
Independent clinical isolates (n = 34) obtained from Sudanese mycetoma patients visiting the 
Mycetoma Research Clinic (University of Khartoum, Khartoum, Sudan) during the year 1999 
were included. Two additional clinical isolates were derived from patients from Mali (2). 
Strains were cultivated on Sabouraud dextrose agar with or without 80 mg of gentamicin 
(Centrafarm, Etten-Leur, The Netherlands) per liter or on malt extract agar (Difco 
Laboratories, Paris, France). Species were identified as described previously (1, 9).  
 
Antifungal agents 
Itraconazole was obtained from Janssen Pharmaceutica Products, Ghent, Belgium, and 
amphotericin B was obtained from Bristol-Myers Squibb, Woerden, The Netherlands.  
 
In vitro  antifungal susceptibility testing 
The protocol for susceptibility testing (broth macrodilution) was based on the NCCLS 
procedure for filamentous fungi (approved standard M38-A) [20]. To prepare inocula from 
cultures in RPMI 1640 with L-glutamine (0.3 g/liter) and 20 mM morpholinepropanesulfonic 
acid, mycelia were harvested by 5 min of centrifugation at 2,158 x g and washed once with 
sterile saline. After sonication (20 s at 28-µm maximum power; Soniprep, Beun de Ronde, 
The Netherlands) of the hyphal suspension, Tween 60 was added at 0.05% (vol/vol), and the 
transmissions were adjusted to 70 % at 660 nm (Novaspec II; Pharmacia Biotech). The 
inoculated tubes were incubated at 37°C for 7 days. Inoculum reading controls (hyphal 
suspension in saline without antifungals) were included, as were growth controls without 
antifungals.  
The viable fungal mass was determined colorimetrically with XTT as the substrate as 
described previously (19). Tubes containing final concentrations of 250 µg of XTT/ml and 
menadione (58 µM) were incubated for 2 h at 37°C and for another 3 h at room temperature. 
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The tubes were then centrifuged, and the extinction coefficient of the supernatant was 
measured at 450 nm in a microplate reader.  
 
Results 
 
Figure 1 shows the reproducibility of antifungal susceptibility testing of an M. mycetomatis 
strain (mm55) according to the XTT assay. For amphotericin B, a sudden switch to full 
reduction in viable fungal mass was observed. Exposure to itraconazole resulted in a 
concentration-dependent gradual decrease. 
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Figure 1: Reproducibility of susceptibility testing of M. mycetomatis strain mm-55 against amphotericin B and 
itraconazole by the XTT method. Curves represent the relative extinction at 450 nm for each drug concentration 
compared to the growth control (100%). Assays were repeated eight times. 
 
104 
                                                                                                           NCCLS based antifungal susceptibility testing 
In Figure 2, the results for the XTT assay and the modified NCCLS method were compared 
for M. mycetomatis strain mm55. A concentration-dependent pattern of antifungal activity, 
each being different for amphotericin B and itraconazole, was observed. The MICs of 
amphotericin and itraconazole for M. mycetomatis mm55 were 1 to 2 and 0.25 to 0.5 mg/liter, 
respectively. The MICs of the other isolates are shown in table 1. 
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Figure 2. Antifungal susceptibility testing of M. mycetomatis strain mm-55 against amphotericin B and 
itraconazole in duplicate. Curves represent the relative extinction at 450 nm for each drug concentration 
compared to the growth control (100%) obtained by the XTT assay. Bars represent the growth levels obtained by 
the modified NCCLS method as determined in a separate experiment. 
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MIC (mg/liter) 
Amphotericin B  Itraconazole Isolate XTT (>50 %) XTT (>80 %) NCCLS XTT (>50 %) XTT (>80 %) NCCLS 
Mm71 0.125 0.125 0.125 0.03 0.06 0.125 
P2 0.125 0.125 0.125 0.06 0.125 0.25 
Mm46 0.125 0.125 0.25 0.01 0.01 0.01 
Mm54 0.125 0.25 0.5 0.01 0.01 0.03 
Mm30 0.125 0.5 0.5 0.125 1 0.5 
Mm49 0.125 0.5 0.5 0.01 0.01 0.06 
Mm58 0.125 0.5 1 0.06 0.125 0.06 
Mm63 0.25 0.25 0.25 0.03 0.03 0.06 
Mm39 0.25 0.5 0.25 0.06 0.06 0.06 
Mm36 0.25 0.5 0.5 0.06 0.06 0.06 
Mm41 0.25 0.5 0.5 0.06 0.125 0.125 
Mm83 0.25 0.5 0.5 0.03 0.06 0.06 
Mm22 0.25 0.5 1 0.06 0.125 0.125 
Mm14 0.5 0.5 1 0.06 0.125 0.125 
Mm28 0.5 0.5 0.5 0.06 0.125 0.06 
Mm10 0.5 0.5 1 0.25 1 1 
Mm29 0.5 0.5 1 0.03 0.06 0.06 
Mm25 0.5 1 0.5 0.06 0.125 0.06 
Mm18 1 1 1 0.01 0.03 0.01 
Mm55 1 1 1 0.06 0.25 0.25 
Mm50 1 1 2 0.01 0.03 0.03 
Mm52 1 1 4 0.06 0.5 0.5 
Mm26 1 2 1 0.06 0.25 0.25 
Mm72 1 2 1 0.06 0.06 0.03 
Mm78 1 2 1 0.06 0.06 0.06 
Mm43 1 2 2 0.125 0.25 0.25 
Mm64 1 2 2 0.03 0.03 0.06 
Mm68 1 2 2 0.06 0.5 0.05 
P1 1 2 2 0.25 0.5 1 
Mm45 1 4 2 0.25 0.5 0.5 
Mm73 2 2 1 0.06 0.06 0.25 
Mm56 2 2 2 0.03 0.06 0.06 
Mm13 2 4 4 0.5 1 0.5 
Mm35 4 4 4 0.5 1 0.5 
Mm16 4 8 4 0.25 0.5 0.5 
Mm31 4 4 4 0.125 0.5 0.25 
Table 1: Antifungal susceptibilities of 36 M. mycetomatis clinical isolates. For the XTT assay, the 
concentrations resulting in more than 50 % or 80 % reduction in viable fungal mass are shown. For the NCCLS 
modified method, the concentrations resulting in complete inhibition of fungal growth (MIC) are shown. Data 
are median values for three determinations.  
 
 
Discussion 
 
The filamentous nature of M. mycetomatis frustrates the straightforward use of the 
standardized NCCLS protocols since a conidial suspension is usually used as an inoculum (7, 
11, 20). Preparing a standardized inoculum for the poorly differentiating and nonsporulating 
fungal species is problematic (9). To standardize the inoculum, the harvested hyphae were 
first homogenized. These inocula were found to be within the recommended range of 0.4 x 
104 to 5 x 104 CFU per ml (20).  
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As the initial hyphal suspension already shows significant turbidity, which complicates visual 
reading of the antifungal activity, the XTT assay was also used. It generated reproducible data 
and showed good agreement with the MIC data for amphotericin B. This overall agreement 
was also documented for various other fungal species (19).  
The antifungal effect of itraconazole is superior to that of amphotericin B. 
Approximately 45% of the 36 M. mycetomatis isolates showed susceptibility to itraconazole 
concentrations of less than 0.13 mg/liter, whereas amphotericin B was not effective at those 
concentrations. Prevention of growth of all isolates was obtained with itraconazole at 1 
mg/liter or less and with amphotericin B at 8 mg/liter or less; these results are in agreement 
with earlier findings for other filamentous ascomycetes (14, 18, 20). Activities of itraconazole 
against dermatophytes (11) and agents of hyalohyphomycosis, phaeohyphomycosis, 
chromoblastomycosis, and mycetoma were also demonstrated (18). Recently, itraconazole has 
been effectively used for the treatment of a case of fungal mycetoma due to Fusarium solani 
(27). Compared to itraconazole, voriconazole showed comparable or increased in vitro  
activity against a number of emerging and less common mold pathogens (21). The high in 
vitro  susceptibility of the M. mycetomatis isolates may nominate itraconazole as the drug of 
choice for treatment. About 33% of the M. mycetomatis isolates included in this study had an 
amphotericin B MIC that is higher than the average peak level in plasma of 1.5 mg/liter (22). 
In addition to the relatively low antifungal activity, the requirement for long-term treatment of 
mycetoma patients together with the potential toxic side effects of amphotericin B further 
limits its use as a first-line therapeutic agent.  
In conclusion, the XTT assay is optimal for antifungal susceptibility testing of M. 
mycetomatis since it avoids visual reading. It also provides additional insight into the 
dynamics of killing. The assessment of antifungal susceptibility may be particularly useful for 
patients not responding to initial medical treatment. 
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Abstract 
 
The in vitro  susceptibilities of 36 clinical isolates of Madurella mycetomatis, prime agent of 
eumycetoma in Africa, for ketoconazole, itraconazole, fluconazole, voriconazole, 
amphotericin B and 5-flucytosine were determined by the Sensititre system. This system 
appeared to be a rapid and easy test, and by using hyphal suspensions it generated results 
comparable to those of a modified NCCLS method. After 10 days of incubation the antifungal 
activity of ketoconazole (MIC90 of 0.125 µg/ml), itraconazole (MIC90 of 0.064 µg/ml) and 
voriconazole (MIC90 of 0.125 µg/ml) appeared superior to that of fluconazole (MIC90 of 128 
µg/ml) and amphotericin B (MIC90 of 1 µg/ml), MIC values being in the clinically relevant 
range. All isolates were resistant to 5-flucytosine (all MICs above 64 µg/ml). Based on the 
relatively broad range of MICs for the antifungal agents obtained, routine antifungal 
susceptibility testing for M. mycetomatis isolates seems to be relevant for adequate therapeutic 
management. 
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Introduction 
 
Eumycetoma is a chronic disease endemic in many tropical and subtropical countries and is 
characterized by tumefaction, draining sinuses and the presence of grains (8, 9, 15, 21 24). 
The lesion initiates in the subcutaneous tissue and spreads to destroy the surrounding skin, the 
muscles and the bones (8, 15). Eumycetoma can be caused by a variety of micro-organisms, 
but the causative organism most frequently encountered in Sudan is the fungus Madurella 
mycetomatis (9, 10, 15, 24).  Mycetoma caused by M. mycetomatis is usually treated with 
extensive surgery, combined with prolonged antifungal therapy (10, 15, 21). Surgery for 
mycetoma ranges from local excision of distinct lesions to amputation of the infected limb 
(8,10). In clinical trials a number of antifungals including itraconazole and ketoconazole are 
being used for the treatment of eumycetoma with various degrees of success (9, 16, 29). 
Limited data are available regarding the antifungal susceptibility of M. mycetomatis (2, 25, 
31). Determination of the in vitro  susceptibility of the non-sporulating M. mycetomatis is 
troublesome. In the method for susceptibility testing of spore-forming filamentous fungi 
according to the NCCLS guidelines (M38-A) a conidial suspension is used as an inoculum 
(28). For non-sporulating fungal species a hyphal suspension has to be used (2). In a recently 
published study by Ahmed et al. the hyphal inocula of M. mycetomatis were standardized by 
sonicating the fungus to get a homogeneous suspension (2). Using the modified NCCLS 
method the authors obtained reproducible amphotericin B data for 90% of the M. mycetomatis 
isolates tested (2). However, for itraconazole visual reading of the gradually decreasing 
antifungal activity was not always accurate. That is why Ahmed et al. used the XTT-assay to 
ease endpoint reading. In this assay the antifungal activity can be quantified by relating the 
viable fungal mass to levels of fungal mitochondrial dehydrogenase activity (18,26). The XTT 
assay appeared appropriate and accurate for determination of antifungal susceptibility of M. 
mycetomatis (2). Unfortunately, the modified NCCLS method combined with the viability 
based XTT assay are both time consuming and laborious and therefore not easily 
implemented to screen M. mycetomatis isolates routinely for their antifungal susceptibility 
against a large number of antifungals.  
A less laborious method, which became recently available, is the Sensititre system 
(Trek Diagnostic systems, Ltd., East Grinstead, England). This system is a commercial 
microdilution method that uses the oxidation-reduction indicator Alamar blue to determine the 
in vitro susceptibilities to amphotericin B, fluconazole, itraconazole, ketoconazole, 5-
flucytosine and voriconazole. The test has been successfully used to assess the susceptibilities 
of various yeasts and filamentous fungi including Aspergillus spp. (4, 7, 23, 27). In the 
present study we evaluated the in vitro  activities of a number of antifungal agents against 36 
clinical isolates of M. mycetomatis by using the Sensititre commercial system. In addition we 
compared this assay with the modified NCCLS method and the viability based XTT assay. 
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Materials and Methods 
 
M. mycetomatis strains 
A total of 36 clinical isolates of M. mycetomatis were included in this study. Thirty-four of 
these strains were obtained from patients seen in the Mycetoma Research Centre, University 
of Khartoum, Sudan. Two additional strains were obtained from patients originated in Mali. 
The strains were isolated from biopsies and maintained on Sabouraud Dextrose Agar  (Difco 
Laboratories, Paris, France). The strains were previously identified by morphology and PCR-
RFLP (2, 3, 5). 
 
Antifungal agents 
For the modified NCCLS method and the XTT assay, ketoconazole and itraconazole were 
obtained from Janssen Pharmaceutical Products, Belgium, fluconazole and voriconazole were 
obtained from Pfizer BV (Capelle aan de IJsel, The Netherlands) and amphotericin B from 
Bristol-Myers Squibb (Woerden, The Netherlands). 5-Flucytosine was obtained from ICN 
Pharmaceuticals Holland BV, Zoetermeer, The Netherlands.   
 
In vitro  antifungal susceptibility testing 
MICs were determined independent in duplicate with the colorimetric Sensititre® YeastOne® 
method (Trek Diagnostic Systems, Ltd, East Grinstead, England), the XTT assay and the 
modified NCCLS method (2).  M. mycetomatis was cultured for 10 days at 37oC in RPMI-
1640 medium supplemented with L-glutamine (0.3 g/L) and 20 mM MOPS.  The mycelia 
were harvested by 5 min centrifugation at 2158 g and washed with sterile saline. To 
homogenise the inoculum, the mycelia were sonicated for 20 sec at 28 micron (Soniprep, 
Beun de Ronde, The Netherlands). For performing the Sensititre test the final inoculum was 
prepared from the homogenised fungal suspension mixed with the YeastOne® broth (Trek 
Diagnostic systems) to obtain a transmission of 70 % at 660 nm (Novaspec II, Pharmacia 
Biotech).  Hundred microlitres of this suspension were applied to the Sensititre YeastOne® 
plate and the test was incubated for 7 days at 37 oC. MIC endpoints were determined visually 
at the first blue well for amphotericin B and the first purple well for the other antifungals. 
Drug concentrations used in this test ranged from 0.008 µg/ml to 16 µg/ml for itraconazole, 
ketoconazole, voriconazole and amphotericin B and from 0.125 µg/ml to 256 µg/ml for 
fluconazole and from 0.032 µg/ml to 64 µg/ml for 5-flucytosine. 
The XTT assay and the modified NCCLS method were performed according to 
Ahmed et al. (2). In short, MIC endpoints in the XTT assay were determined by adding the 
substrate 2,3-Bis {2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-
hydroxide} which is enzymatically converted to the coloured formazan in viable cells (18). 
The extinction of the supernatant was measured spectrophotometrically at 450 nm. The MIC 
endpoints were defined as the lowest concentration resulting in 80 % or more reduction in 
viable fungal mass (2).  The MIC endpoints using the modified NCCLS method are 
determined visually as the lowest concentration that prevented any discernable fungal growth 
(2,28). Drug concentrations used in both tests ranged from 0.016 µg/ml to 8 µg/ml for 
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itraconazole, ketoconazole, voriconazole and amphotericin B and from 0.25 µg/ml to 128 
µg/ml for fluconazole and from 0.125 µg/ml to 64 µg/ml for 5-flucytosine. 
 
Results 
 
For a total of 36 M. mycetomatis isolates the susceptibilities for ketoconazole, itraconazole, 
fluconazole, voriconazole, amphotericin B and 5-flucytosine were determined by using the 
Sensititre system, the NCCLS method and the XTT assay. For two strains MICs could not be 
determined using the Sensititre system because these strains did not grow in the presence of 
Alamar blue. The MIC distribution for the other 34 isolates is shown in figure 1. The MICs 
for the different antifungals appeared variable and dependent on the M. mycetomatis isolate.  
The majority of the M. mycetomatis strains showed high susceptibility to ketoconazole, 
itraconazole and voriconazole. For ketoconazole MICs ranged from <0.016-1 µg/ml and 
0.125 µg/ml ketoconazole was needed to inhibit 90 % of the isolates. The isolates were even 
more susceptible to itraconazole. For this antifungal an MIC-range of <0.016-0.5 µg/ml was 
found and only 0.064 µg/ml was needed to inhibit 90 % of the strains. The antifungal activity 
of voriconazole was similar to ketoconazole, with MICs ranging from <0.016-1 µg/ml, and a 
concentration of 0.125 µg/ml was needed for inhibition of 90 % of the isolates. The only azole 
for which a high range of MICs (0.25- >128 µg/ml) was found was fluconazole. A 
concentration of 16 µg/ml fluconazole was needed to inhibit 90 % of the isolates. For the non-
azoles the isolates were less susceptible. For amphotericin the MICs were between <0.016 
µg/ml and 4 µg/ml and a concentration of 2 µg/ml was required to inhibit 90 % of the strains.  
All M. mycetomatis isolates were resistant to 5-flucytosine.  
To determine the accuracy of the Sensititre test, all M. mycetomatis strains were 
investigated with three methods: the modified NCCLS method, the XTT assay and the 
Sensititre method. The percentage agreement in experimental outcome for each antifungal is 
shown in table 1. As is concluded from these data the reproduciblity of the Sensititre test was 
good. Reproducible results, differing no more than a 1 step dilution were obtained in more 
than 90% of the strains for all the antifungals except for ketoconazole (Table 1). For this 
antifungal only a reproducibility of 88.2% was found, which is still very high. When the 
Sensititre system was compared to the NCCLS method in 88.2% to 100% of the cases 
identical MICs or MICs differing a single dilution step difference were obtained. This was 
comparable to the agreement obtained between the NCCLS method and the XTT assay 
(85.3% to 100.0%). A somewhat lesser agreement was found between the Sensititre system 
and the XTT assay. In this case the agreements for the non-azole antifungals were still high 
(82.4 % for amphotericin B and 100.0% for 5-flucytosine) but marginally lower for the 
azoles. For fluconazole, the agreement was even as low as 67.6 %, while for the other azoles 
this varied between 70.6% and 91.2%. Overall, the XTT assay resulted in relatively higher 
MICs compared to the Sensititre method, being a two-step or three-step dilution difference.  
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Figure 1: Antifungal susceptibility (MIC) of 34 Madurella mycetomatis isolates for various antifungal agents 
according to the Sensititre system (black), the NCCLS method (dark grey) and the XTT assay (light grey) 
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Antifungal Reproducibility1 
of the Sensititre 
system (%) 
Sensititre system 
versus NCCLS 
method (%)2 
Sensititre system 
versus XTT 
assay 
(%)2 
NCCLS method 
versus XTT 
assay 
(%)2 
Ketoconazole 88.2 100 79.4 97.1 
Fluconazole 91.2 91.2 67.6 85.3 
Itraconazole 97.1 88.2 70.6 91.2 
Voriconazole 91.2 97.1 91.2 94.1 
Amphotericin B 91.2 100 82.4 94.2 
5-Flucytosine 97.1 100 100 100 
Table 1: Reproducibility and accuracy of the Sensititre method in comparison to the NCCLS method and the 
XTT assay.  
1 The reproducibility of the Sensititre system was determined by calculating the percentage agreement between 
tests. The sensititre system was considered reproducible for a certain isolate when the duplicate testresults 
differed not more than a single dilution in MIC value. 
2 The MICs obtained in each test were compared to MICs in the other tests. To validate the Sensititre system, 
data were compared with both those of the NCCLS method and those of the XTT assay. In order to compare the 
different MICs, percentage agreement was calculated. MICs were considered to be in agreement when not more 
than a single dilution difference in MIC was obtained. For comparison, the percentage agreement between the 
NCCLS method and the XTT assay is stated in the fifth column. 
Discussion 
 
Recently Ahmed et al. reported two reproducible assays to measure antifungal susceptibility of M. 
mycetomatis isolates to antifungal agents, being an adapted protocol based on the NCCLS (M38-
A) guidelines and a viability-based XTT assay for facilitating endpoint-reading (2).  Both test 
systems appeared reproducible and sensitive, but were also time-consuming. For routine use a test 
system for antifungal susceptibility should be cheap, fast and easy to interpret as well. Recently, 
the Sensititre system for determination of antifungal susceptibility of several yeast and fungal 
species like Candida spp., Crytococcus spp. and Aspergillus spp. has been introduced (4, 6, 20, 
23, 27, 30). In this system, the MIC endpoints can be determined visually because of the dye 
Alamar blue that is converted from blue to red when fungal growth occurs (4, 6, 20, 23, 27, 30). 
Various studies show that the MICs obtained for several yeasts in the Sensititre system were in 
good agreement with MICs obtained with the NCCLS method (4, 6, 20). However, for Aspergillus 
spp. there was less agreement between both methods (23, 27).  To investigate the value of the 
Sensititre system for M. mycetomatis isolates in the present study, this system was compared to 
the modified NCCLS method and the XTT assay (2). Good agreements were found between MICs 
obtained with the Sensititre method and modified NCCLS method. Overall, the MICs obtained 
with the Sensititre method were equal to or one-step lower than the MICs obtained with the 
modified NCCLS method. The fact that we found lower MICs with the Sensititre system was also 
reported for other fungal species like Cryptococcus neoformans and Aspergillus spp. (6, 27). 
Although we found lower MICs, the difference was not statistically significant. The discrepancies 
between the Sensititre system and the XTT-test were higher. This may be explained by the 
indicator systems being different in both test systems (17, 21). The discrepancies between the 
Sensititre system and the XTT-test were highest for the azoles. This suggests that the trailing 
endpoint effect, usually obtained with azoles, is measured more effectively with XTT than with 
Alamar blue. 
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In the present study the antifungal susceptibilities of 36 M. mycetomatis isolates against 
ketoconazole, itraconazole, fluconazole, voriconazole, amphotericin B and 5-flucytosine were 
determined using the Sensititre method. For two of the strains MICs could not be determined 
because these strains did not grow in the test medium in the presence of Alamar blue. Jahn et al. 
encountered the same problem when testing isolates of Aspergillus fumigatus. They found strain 
dependent differences which could not easily be explained (17). In the present study both 
ketoconazole and itraconazole appeared to be very effective in inhibiting the M. mycetomatis 
strains. For both antifungals only low concentrations were needed to inhibit 90 % of the clinical 
isolates, being 0.125 µg/ml and 0.064 µg/ml, respectively.  The MICs found for both antifungals 
correlate with attainable serum levels (5). Ketoconazole was one of the first antifungal agents 
used in the treatment of eumycetoma caused by M. mycetomatis, later itraconazole has been used 
as well (21, 22, 24). Although some clinical studies showed that ketoconazole and itraconazole 
resulted in complete cure, the clinical response to both agents is often poor (2, 21, 22, 24). This 
may partially be explained by the observed variation in MICs for the M. mycetomatis isolates. 
Fluconazole was less effective than ketoconazole and itraconazole in inhibiting the fungal growth. 
Two isolates had high MICs of >64 µg/ml fluconazole while the other isolates had MICs ranging 
from 0,125 µg/ml to 16 µg/ml. Although these MICs are high, they still correlate with 
physiologically attainable serum levels (5, 11).  Voriconazole, a relatively new azole which is 
highly effective against aspergillosis, showed similar high antifungal activity towards the M. 
mycetomatis strains compared with ketoconazole and itraconazole (13).  Amphotericin B appeared 
to be less effective than ketoconazole, itraconazole and voriconazole in inhibiting M. 
mycetomatis. This observation is in accordance with the study performed by Ahmed et al. (2). 
They also found that amphotericin B was less effective than itraconazole to inhibit M. 
mycetomatis, 33% of the isolates had MICs for amphotericin B, which exceeded the maximum 
plasma peak levels (2). Of all the antifungals tested in the present study 5-flucytosine was the 
least effective. Even at high concentrations no fungal inhibition was noticed. The M. mycetomatis 
isolates appeared to be resistant against 5-flucytosine, which is also the case for many other 
filamentous fungi (1, 12, 14, 19, 28). 
In conclusion, the Sensititre system is an appropriate system for the determination of the 
antifungal susceptibility of M. mycetomatis strains. The fungus was highly susceptible to 
ketoconazole, itraconazole and voriconazole, moderately susceptible to fluconazole and 
amphotericin B and resistant to 5-flucytosine. The variation in MICs observed for the different M. 
mycetomatis isolates suggests that the introduction of routine antifungal susceptibility testing for 
M. mycetomatis isolates is important for adequate therapeutic management. 
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Abstract 
 
Eumycetoma caused by Madurella mycetomatis is treated with surgery and high doses of 
itraconazole and ketoconazole. The latter agents are toxic and new therapies are required. 
MICs were determined for artemisinin and tea tree oil (TTO), two natural herbal compounds. 
M. mycetomatis was not susceptible to artemisinin but TTO did inhibit its growth. Since 
TTO’s prime component easily penetrates the skin, TTO could be a useful agent in the 
treatment of eumycetoma.  
 
  
  In vitro susceptibilities for TTO and artemisinin   
   121   
Introduction 
 
Eumycetoma is a subcutaneous disease caused by a variety of micro-organisms, both bacteria 
and fungi. The most common fungal causative agent is Madurella mycetomatis. Eumycetoma 
is usually treated for extended periods of time with high doses of either itraconazole or 
ketoconazole. Prolonged treatment with high doses of azoles can result in hepatic toxicity. In 
order to identify alternative antifungal therapies, the susceptibility of M. mycetomatis to other 
frequently used antifungal agents (amphotericin B, 5-flucytosine and voriconazole) have been 
determined before. M. mycetomatis remained most susceptible towards the azoles; no activity 
was seen with 5-flucytosine (27). In search of new antifungal agents, research is shifting to 
more traditional anti-infective folk medicines. An example of such a natural compound is, 
artemisinin, which is isolated from the plant Artemisia annua and used in traditional Chinese 
medicine (8, 16). In the early 1970s it was established that artemisinin was the compound in 
this plant extract with antiparasitic activities against Plasmodium falciparum (16). A. annua 
was also resistant to common plant pathogenic fungi (19). This resistance was due to 
substances produced by endophytes present on A. annua, however, artemisinin has antifungal 
activities too (19). Cryptococcus neoformans and Saccharamyces cerevisiae were inhibited by 
artemsinin, but Candia albicans was not (10, 18). Another example of a natural compound 
which appears to be successful in curing infections is tea tree oil (TTO), extracted from 
Melaleuca alternifolia. This oil was used by the Australian Bundjalung Aborigines of New 
South Wales for its anti-inflammatory and antimicrobial properties (6, 11).  
In vitro  MICs have been determined for a wide variety of micro-organisms and clinical 
studies indicated that treatment with TTO could improve the course of acne, dandruff, 
onychomycosis, oral candidiasis and tinea pedis (6). Since both artemisinin and TTO appear 
to be successful in clearing certain fungal infections, the in vitro  susceptibilities of a 
collection of strains of M. mycetomatis were compared to both agents and itraconazole, the 
agent most widely used in eumycetoma treatment. 
 
 
Materials and Methods 
 
M. mycetomatis strains 
In this study MICs, for a total of 34 clinical isolates of M. mycetomatis were determined (32 
obtained from the Mycetoma Research Centre, University of Khartoum, Sudan, 2 from Mali) 
for itraconazole (Janssen Pharmaceutical products, Berchem, Belgium), artemisinin (Sigma-
Aldrich, Zwijndrecht, The Netherlands) and TTO  (Novasel, Skarup, Denmark). The strains 
were isolated from biopsies and maintained on Sabouraud Dextrose Agar (Difco Laboratories, 
Paris, France). The strains were previously identified on basis of morphology and PCR-RFLP 
(1, 25). 
 
In vitro  antifungal susceptibility testing 
MICs were determined independently in triplicate using the previously reported 2,3-Bis(2-
Methoxy-4-Nitro-5-Sulfophenyl)-5-[(Phenylamino)Carbonyl]-2H-Tetrazolium-Hydroxide 
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(XTT) assay (2, 27). Drug concentrations used ranged from 0.016 µg/ml to 16 µg/ml for 
itraconazole (ITZ) and artemisinin (ART) and 0.016 % (v/v) to 1% (v/v) for TTO. All 
dilutions were prepared in DMSO, the final concentration DMSO per inoculum was as 
described by the CLSI criteria (20).  
 
 
Results 
 
In concordance with previously published MICs for M. mycetomatis, all strains were highly 
susceptible to itraconazole, the drug of choice to treat eumycetoma in Sudan (figure 1). MICs 
for itraconazole were evenly distributed in concentrations ranging from <0.002 µg/ml to 0.06 
µg/ml (figure 1). A concentration of 0.03 µg/ml was needed to inhibit the growth of 90% of 
the isolates (table 1).  
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Figure 1: Antifungal susceptibilities (expressed as MICs) of 34 M. mycetomatis isolates to itraconazole (ITZ), 
Tea Tree Oil (TTO) and artemisinin (ART) according to the XTT assay. Although in this graph M. mycetomatis 
seems to be the most susceptible to itraconazole, comparisons with TTO should be made with care. Itraconazole 
concentrations are shown in µg/ml while TTO concentrations are in % v/v. 
 
Isolates were less susceptible to artemisinin. Only two isolates were inhibited in growth by 
artemisinin, with MICs of 0.03 µg/ml and 0.5 µg/ml, respectively. The other 32 isolates were 
not inhibited, not even by 16 µg/ml artemisinin. In 19 of the 34 strains there was a marginal 
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inhibition in growth visible. Inhibition ranged from 20% to 50%. In the other 15 strains no 
inhibition and sometimes even stimulation of growth was noted.  
 
In contrast to artemisinin, TTO did inhibit M. mycetomatis growth. As seen in figure 1, MICs 
ranged from 0.008 % (v/v) to 0.25 % (v/v).  A concentration of 0.06 % (v/v) was needed to 
inhibit 50% of the isolates, a concentration of 0.25 % (v/v) was needed to inhibit 90% of the 
isolates (table 1).  
 
 
 
 
MIC Antifungal agent 
Range 50% 90% 
ITZ (µg/mL) <0.002 - 0.06 0.008 0.03 
ART (µg/mL) 0.03 - >16 >16 >16 
TTO (% v/v) 0.008 - 0.25 0.06 0.25 
Table 1: Susceptibility of M. mycetomatis to Itraconazole, Artemisinin and Tea Tree Oil. The in vitro  antifungal 
susceptibilities of M. mycetomatis to itraconazole (ITZ), artemisinin (ART) and tea tree oil (TTO). In this table 
the range of MICs found, the concentration at which 50 % op the isolates are inhibited and the concentration at 
which 90% of the isolates are inhibited are shown. 
 
 
Discussion  
 
The most common antifungal agents used in the treatment of mycetoma caused by M. 
mycetomatis are ketoconazole and itraconazole (3, 9). Success rates with these drugs are 
variable though and toxic side effects occur. Therefore, the antifungal susceptility of M. 
mycetomatis to a variety of other antifungal agents should be analysed. In vitro  antifungal 
susceptibilities to amphotericin B, itraconazole, ketoconazole, fluconazole, voriconazole and 
5-flucytosine have already been described (27). In the present study less common antifungal 
agents are explored, namely TTO and artemisinin, both representatives of traditional folk 
medicines. For artemisinin some antifungal effect against Cryptococcus neoformans and 
Saccharamyces cerevisiae but not against Candida albicans were noted previously (10, 18). 
M. mycetomatis was not inhibited by this drug. Interestingly very high MICs for S. cerevisiae 
were obtained when this species is cultured in medium with a fermentable carbon source such 
as glucose, while low MICs were found when nonfermentable carbon sources, such as 
glycerol or ethanol, were used (10, 18). In S. cerevisiae the inhibitory effect of artemisinin 
was shown to be caused by disrupting the depolarization of the mitochondrial membrane 
potential (10, 18). Another striking feature of artemisinin is its binding to the translationally 
controlled tumour protein (TCTP). Generally, the higher the TCTP expression, the more 
susceptible the cells were to artemisinin (4, 8). Although M. mycetomatis expresses TCTP 
both in vivo and in vitro, this did not result in growth inhibition by artemisinin (26).  
More interestingly, M. mycetomatis was found to be highly susceptible to TTO. 
Concentrations below 0.25 % (v/v) resulted in full inhibition of fungal growth.  This is 
comparable to the susceptibilities found for the yeasts Candida spp and Malassezia spp and 
the filamentous fungi Alternaria spp, Cladosporium spp, Fusarium spp and Penicillium spp 
(13-15, 28).  The susceptibilities of Aspergillus spp were variable, with Vazquez reporting 
high MICs exceeding 2% (v/v) while Hammer et al. reported MICs in the range 0.12 % (v/v). 
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A. niger required concentrations as high as 8% (v/v) to be inhibited (14, 28). In C. albicans, 
TTO alters the permeability of the cells and inhibits respiration in a dose-dependent manner 
(7, 12). TTO has also been used in clinical studies. It has been tested in the treatment of 
onychomycosis, refractory oral candidiasis and tinea pedis (5, 17, 22-24, 29). Success rates 
differ in each study. Some researchers reported improvement with TTO while others did not. 
For example, Tong et al. found that treatment with 10% (v/v) TTO in patients with tinea pedis 
did not give significant improvement while Satchell et al. did find significant improvement 
with 25% (v/v) TTO (22, 24). In order for a topical treatment with TTO to be effective in the 
treatment of subcutaneous mycetoma, the antifungal components of the agent must penetrate 
the skin. Nielsen and Nielsen, showed that the least lipophilic constituents of TTO could 
penetrate the skin (21). Among these less lipophilic agents were eucalyptol, α-terpineol and 
terpinene-4-ol (21). For some of the constituents of TTO the antifungal activity has been 
determined against a range of fungi, both yeast and filamentous fungi. Terpinene-4-ol, α-
terpineol, α-pinene, aromandendrene and β-pinene all had antifungal activities (11). The 
antifungal activities against C. albicans of the first four components were comparable to the 
antifungal activities found with TTO itself but much lower MICs for β-pinene were found 
(11). TTO consists of 40% terpinen-4-ol, which is an active antifungal agent and able to 
penetrate the skin. Considering that M. mycetomatis is in growth inhibited by TTO, would 
suggest that TTO might be useful as a topical agent in the treatment of eumycetoma. 
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Abstract 
 
One of the hallmarks of eumycetoma is the formation of fungal grains, which are secreted by 
multiple sinuses in infected tissues.  Madurella mycetomatis grains are black. This black 
colour was shown to be due to the presence of melanin. Melanin can be produced through 
various biochemical pathways. It appeared that M. mycetomatis melanisation could be 
blocked by inhibitors of the pyo- and dihydroxynaphthalene (DHN)-melanin pathways but not 
by inhibitors of the dihydroxyphenylalanine (L-DOPA)-melanin pathway. Melanin isolated 
from M. mycetomatis cells provides in vitro protection against the killing effects of the 
oxidant permanganate and several antifungals. When melanin was added to the culture 
medium, MICs were found to be 16-fold elevated in the case of itraconazole and 32-fold for 
ketoconazole. MICs for amphotericin B, fluconazole and voriconazole were not affected. 
Since itraconazole and ketoconazole are the main antifungal agents used to treat mycetoma, 
the clinical relevance of the in vitro rise in MIC should be studied further.  
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Introduction 
 
 One of the main characteristics of 
eumycetoma lesions is the formation of 
grains that are secreted through draining 
sinuses. Grains are encountered in different 
colours and textures which are all 
dependent on the nature of the causative 
agent (1). Grains can be green, yellow, red 
or pink but the most frequently encountered 
“colours” are white or black (1). The grains 
of the most common causal fungus, 
Madurella mycetomatis, are black (Figure 
1). M. mycetomatis grains consist of 
densely packed fungal mycelia embedded 
in a hard, brown matrix composed of extra-
cellular cement material (1, 31). The 
cement material seems to be composed of 
an extra-cellular pigment and host tissue 
debris (1, 31). It is  presumed that the 
black compound in the grain is melanin 
produced by M. mycetomatis.   
Melanins are negatively charged, hydrop
oxidative polymerization of phenolic or indolic
shown to protect micro-organisms against UV-ra
by alveolar macrophages (3, 14, 18). It has also b
as a physiological redox buffer, to provide struc
water and ions (18). Melanins may also play a r
(3). The ability of certain microbes to produce
pathogenicity in their respective animal or plant
Cryptococcus neoformans are less potent in esta
(17, 20, 24). Also, for the plant pathogens
lagenarium appresorial melanin is necessary fo
invasive power when infecting plant tissue (18).  
Fungi may biosynthesise melanin by 
extensively studied melanised fungal pathogen
diphenolic compounds such as 3,4-dihydroxyp
including Aspergillus fumigatus, Exophiala sp
melanin from polyketide compounds such as 1,3
(19). A third pathway has only recently been des
lipolytica, the human pathogen C. neoformans 
algae (2, 9, 26). Use of this pathway leads to me
not from L-DOPA (2, 26). The main difference Figure 1: An example of a mycetoma-foot. The
black grains within the lesions are shown in the
figure B.  129  
hobic, macromolecular pigments formed by 
 compounds (3, 14, 18). Melanin has been 
diation, enzymatic lysis, oxidants and killing 
een shown to chelate metal ions, to function 
tural rigidity to cell walls and to help store 
ole in protecting against antimicrobial drugs 
 melanin has been linked to virulence and 
 host species (19). Notably, albino strains of 
blishing an infection than melanised strains 
 Magnaporthe grisea and Colletotrichum 
r generating appropriate turgor and, hence, 
a variety of pathways. One of the most 
s, C. neoformans, forms its melanin from 
henylalanine (L-DOPA) (19). Other fungi 
p., and Alternaria alternata biosynthesize 
,6,8-tetrahydroxynaphthalene (1,3,6,8-THN) 
cribed in the cheese spoiling yeast Yarrowia 
and in bacterial species such as Shewanella 
lanin formation from tyrosine precursors but 
between this latter pyomelanin and the other 
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two melanins is that this pyomelanin is soluble. It is secreted by the fungus while DOPA – 
and 1,8-dihydroxynaphthalene (DHN-) melanin are solid, insoluble and usually bound to the 
cell wall.   
The aim of the present study was to identify the pathways used by M. mycetomatis to 
form its melanin and to investigate possible physiological roles of melanin during mycetoma 
infections. 
 
Material and methods 
 
Immunohistochemistry 
Deep tissue biopsies were taken from advanced mycetoma lesions from 3 different patients 
and embedded in paraffin. Slides were rehydrated and boiled for 1 hour in 6M HCl to detect 
possible melanisation of the grains. After boiling only the grain structures were left, whereas 
the surrounding tissue had dissolved. Non-boiled slides were used to determine if melanin 
was found outside the grains as well.  All slides were blocked by 2% BSA and 5% sucrose.  
Slides were incubated with melanin-specific antibody 6D2 (provided by Dr. Nosanchuk 
Albert Einstein College of Medicine, New York) for 1 hour at room temperature at a 
concentration of 5 µg/ml. Monoclonal antibody 6D2 (IgM) was generated against melanin 
derived from C. neoformans, this antibody was not specific for C. neoformans melanin since 
other types of melanin could also be detected. Non-melanised fungi were not bound by this 
antibody (21). Substitution of the primary antibody with buffer was used as a negative 
control.   Binding of the primary antibody was detected by a FITC-labelled goat-anti-mouse 
antibody  (CLB Biotechnology Services, Amsterdam, The Netherlands). The slides were 
mounted in DAPI-containing Vectashield (Vector Laboratories Inc., Burlingame, CA, USA) 
and examined with a Zeiss Axioplan 2 imaging fluorescence microscope (Zeiss, Göttingen, 
Germany). 
 
M. mycetomatis strains and culture conditions 
For this study 8 isolates of M. mycetomatis were used. These strains are part of a large culture 
collection from the Sudan Mycetoma Research Centre (Khartoum, Sudan). Cultures were 
maintained on Sabouraud dextrose agar (Difco Laboratories, Paris, France) by repeated 
subculture. For melanin isolation, strains were subcultured on minimal medium, which was 
composed of  2% agar (Difco Laboratories, Paris, France) 15 mM glucose (Baker, Deventer, 
The Netherlands), 10 mM MgSO4 (Merck, Haarlem, The Netherlands, 29.4 mM KH2PO4 
(VWR, Leuven, Belgium), 13 mM glycin (Sigma-Aldrich, Zwijndrecht, The Netherlands) and 
40 mg/ml gentamicin (Centrafarm, Etten-Leur, The Netherlands). To determine which 
precursors M. mycetomatis uses to form its melanin, the melanin-enhancers L-tyrosine and L-
DOPA were added to minimal medium in a concentration of 0.1 mM and 1 mM, respectively. 
Inhibition of melanin synthesis was tested by adding the following inhibitors to the minimal 
medium: sulcotrione (Riedel-deHaën, Seelze, Germany), niacin (Sigma-Aldrich, Zwijndrecht, 
The Netherlands), glyphosate (Luxan, Elst, The Netherlands), tricyclazole (Riedel-deHaën) 
and phthalide (Acros Organics, Geel, Belgium). Concentrations tested were: 0 mg/l, 5 mg/l, 
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25 mg/l, 50 mg/l, 75 mg/l, 100 mg/l and 200 mg/l.  Strains were incubated for two months at 
37 oC. After such an incubation period, all control cultures were clearly melanised.   
 
Melanin isolation 
Melanin for M. mycetomatis strain mm55, clinical isolate C. neoformans strain 106 and A. 
fumigatus  ATCC 204305 was isolated as described by Youngchim et al (33). In short, M. 
mycetomatis hyphae or C. neoformans yeast were first enzymatically lysed to form 
protoplasts. The protoplasts were incubated in the denaturant 4.0 M guanidine thiocyanate to 
generate dark particles, which were treated with proteinase K to remove residual proteins. 
Finally, the pellet was boiled in 6.0 M HCl for 1 hour to obtain pure melanin. Melanin 
concentration was measured by weighing dried mass. As a control, the dark particles were 
spotted onto glass slides and were probed with antibody 6D2 as described above. 
 
Anti-oxidant activity 
The anti-oxidant activity of the melanin was determined by a simple and rapid method (7).  
This method was based on the ability of a scavenger to inhibit the oxidation of 5-thio-2-
nitrobenzoic acid (TNB) to 5.5’dithio-2-nitrobenzoic acid (DTNB). To oxidize 60 µM TNB, 
6.4 mM permanganate was used. To scavenge this reaction, different amounts of melanin 
were added ranging from 80 µg/ml to 2.5 mg/ml melanin. As a control, oxidation was also 
spectrophotometrically assessed by the decrease of the permanganate concentration in 
solution at a wavelength of 525 nm. 
 
Antifungal susceptibility 
Antifungal susceptibilities were tested in duplicate using the Sensititre system (Trek 
Diagnostic Systems, Ltd.) as described by Van de Sande et al. (27). Since M. mycetomatis 
does not form melanin in RPMI medium, 250 µg/ml of purified melanin was added to each 
culture. Melanin was isolated from M. mycetomatis strain mm55. The experiments were 
repeated with 250 µg/ml melanin purified from C. neoformans, 250 µg/ml melanin purified 
from A. fumigatus and 250 µg/ml bovine serum albumin (BSA) (Sigma-Aldrich, Zwijndrecht, 
The Netherlands). MICs determined for isolates incubated without melanin were compared to 
those obtained in the presence of melanin. A difference in the MIC was deemed significant if 
there was at least a two-fold difference between MICs obtained in the presence or absence of 
melanin for the same strain. 
 
Binding of antifungal agents to melanin 
A volume of 200 microlitre of 800 µg/ml of amphotericin B (Bristol-Myers Squibb, Woerden, 
The Netherlands), itraconazole (Janssen Pharmaceutical Products, Beerse, Belgium), 
ketoconazole (Janssen Pharmaceutical Products, Beerse, Belgium), fluconazole (Pfizer BV, 
Capelle aan de Ijsel, The Netherlands) or voriconazole (Pfizer BV, Capelle aan de Ijsel, The 
Netherlands) was incubated with various concentrations of M. mycetomatis melanin (25 
mg/ml, 2.5 mg/ml, 250 µg/ml, 25 µg/ml, 2.5 µg/ml) for 3h at 37oC. Melanin particles were 
removed by centrifugation and the supernatant was used to determine the concentration of the 
antifungal compound as was left in solution. Concentrations of antifungal agents were 
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assessed with a standard large plate agar diffusion procedure with diagnostic sensitivity test 
agar (Oxoid, Basingstoke, UK) for amphotericin B, voriconazole and fluconazole and with 
yeast-peptone agar (7g/l yeast-nitrogen base, 7 g/l trypticase peptone, 15 g/l glucose and 15 
g/l agar) for itraconazole and ketoconazole. As test organism Candida albicans (amphotericin 
B) and Candida pseudotropicalis (itraconazole, ketoconazole, fluconazole and voriconazole) 
were used. Concentrations for the melanin-incubated samples were compared to a standard 
series for each antifungal agent ranging from  0.25 to 4 µg/ml.   
 
Results 
 
M. mycetomatis is melanised in the human host 
M. mycetomatis produces black grains in the human host (Figure 1). In order to determine 
whether the black colour of these grains is due to melanin, antibody 6D2 was used to detect 
melanin in tissue infected with M. mycetomatis. In figures 2A and 2B, a M. mycetomatis grain 
is seen, surrounded by neutrophils. When such a tissue section was stained with antibody 6D2 
it was seen that not the entire grain but essentially its rim and some individual hyphae within 
the grain were reactive and, consequently, considered melanised. Obviously, native human 
melanin was also found in the melanocytes present in the patient’s skin (results not shown). 
Surprisingly, melanin was also detected inside the neutrophils surrounding the fungal grain, 
which could suggests that fungal melanin, melanised fungal particles or non-polymerized 
precursors of melanin are phagocytosized. The precise role of this finding should be further 
studied. Melanisation of the grain itself was only seen when tissue sections were boiled in 6M 
HCl (Figures 2D and 2E). This implies that melanin exposure needs to be enhanced prior to 
immunodetection, as was also described for Coccidioides posadasii where the lipid-rich 
spherule outer wall blocked reactivity of antibody 6D2 (21). 
 
M. mycetomatis produces melanin via the pyo- and DHN-melanin pathways  
M. mycetomatis was cultured in the presence of either the melanin inducers L-tyrosine 
and L-DOPA or the different melanin-inhibitors. L-DOPA appeared to be toxic to M. 
mycetomatis, since no growth was noted when it was added to the medium, even at low 
concentrations. This  implied that L-DOPA was no useful precursor for M. mycetomatis 
melanin biosynthesis. This was confirmed by cultivation in the presence of both inhibitors of 
the L-DOPA-pathway (niacin and glyphosate). When either of these inhibitors was added to 
the culture media, melanisation was similar as for the non-inhibited controls (Figure 3). When 
examined by light-microscopy, the fungal cell walls showed clear melanisation. No inhibition 
of melanin synthesis was noted. These observations confirmed that M. mycetomatis does not 
use the L-DOPA-melanin biosynthesis pathway to form its melanin. In contrast, cultivation in 
the presence of additional L-tyrosine (precursor of both the L-DOPA- and the pyo-melanin 
pathway) resulted in a light-brown colony showing melanised particles and a secreted 
pigment. This secreted pigment turned black in the presence of ironsulfate.  
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Figure 2: Melanisation of M. mycetomatis grains in vivo . All figures represent grains found in human 
subcutaneous tissue of the foot. In figures A and B, grains are stained with HE and Grocott respectively. In 
figure C the same tissue is stained with melanin-specific antibody 6D2. In this figure melanin was shown to be 
present in individual cells in the neutrophil zone but the grain itself was hardly stained (magnification 630x).  To 
detect melanisation in the grain, slides were pre-treated by boiling 1 hour in 6M HCl to remove all other cellular 
compounds and afterwards stained with antibody 6D2. In figure D melanisation is seen within the grain itself. 
No melanisation is seen when the primary antibody was replaced by PBS only (figure E). Within the grain 
individual hyphae are melanised (F). Figure G represent a single hyphae within the grain (Grocott) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Melanin inhibition. In order to establish which pathway is used by M. mycetomatis inhibition 
experiments with 5 melanin-inhibitors are performed. In figure A the wildtype melanised isolate is shown. No 
difference between a non-inhibited isolated (figure A) and a niacin-inhibited or glyphosate inhibited isolates was 
noted (50 mg/l glyphosate, figure B). A non-melanised phenotype was obtained when 50 mg sulcotrione was 
added to the culture medium (figure D). When sulcotrione was added a brown pigment was secreted into the 
culture medium. No melanin was formed when either 50 mg/l phthalide or 5 mg/l tricylazole was added to the 
culture medium (5 mg/l tricyclazole, figure E). The melanised phenotype was microscopically also different 
from the non-melanised phenotype. On figure C a 400x magnification of the melanised phenotype is seen. The 
non-melanised phenotype is shown in figure F. This photo is made at a  400x magnification. The cells are longer, 
less branched and slimmer than the melanised phenotype.   
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Cultivation in the presence of an inhibitor of the pyo-pathway (sulcotrion) or with inhibitors 
of the DHN-pathway (phthalide and tricyclazole) resulted in non-melanised phenotypes 
(Figure 3). Melanisation of the cell wall vanished and the fungal hyphae appeared to be 
elongated (Figure 3). Inhibition of melanin synthesis was noted at concentrations of 25 mg/l 
sulcotrion or higher. Tricyclazole was an even more potent inhibitor of the DHN-melanin 
pathway than phthalide was. Only 5 mg/l tricyclazole was needed to completely block 
melanin synthesis while 50 mg/l phthalide was needed to establish the same effect. This 
shows that in case of M. mycetomatis tricyclazole is a stronger DHN pathway inhibitor than 
phthalide.  
  
M. mycetomatis melanin provides protection against oxidants 
The purified melanin particles of M. mycetomatis strain mm55 resembled the particles seen in 
culture. The amount of melanin was culture- and strain-dependent, meaning that some phase-
variation was noted in the amount of melanin production in each isolate. In order to establish 
whether melanin protects M. mycetomatis against reactive oxygen species produced by the 
host, we investigated whether it scavenged one of the strongest oxidants known, 
permanganate (Figure 4). When melanin was added to the permanganate it was noted that the 
more melanin was present, the less permanganate was left. If less permanganate was present 
the oxidation of TNB was less efficient since TNB was still measurable in the solution. From 
this experiment it appeared that 200-250 µg melanin could effectively scavenge the oxidation 
of TNB by permanganate.  
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Figure 4: Antioxidant activity of melanin. Fungal melanin in different concentrations was incubated with 6.4 
mM permanganate. After 10 minutes incubation TNB was added and measured.  TNB oxidation was calculated 
by the following formula: (OD412 of sample)/(OD412 of oxidized TNB)*100% (). The concentration 
permanganate reduced by melanin was stated as well (∆). Overall, the more permanganate was reduced by 
melanin the less TNB was oxidized.  
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M. mycetomatis melanin provides protection against itraconazole and ketoconazole 
Since M. mycetomatis melanin was shown to protect against permanganate, it might 
also protect against other agents that are detrimental to the fungus, including antifungal 
agents. MIC measurements, with or without addition of melanin extracted from M. 
mycetomatis, were performed for six antifungal agents, including the polyene amphotericin B, 
the antimetabolite 5-flucytosine and the azoles ketoconazole, itraconazole, voriconazole and 
fluconazole (see table 1). The same experiments were repeated with L-DOPA melanin 
extracted from C. neoformans (Figure 5), DHN melanin isolated from A. fumigatus (results 
not shown) and albumin (results not shown). No significant differences (meaning less than 
one two-fold dilution step) in MIC were noted for amphotericin B, 5-flucytosine, fluconazole 
and voriconazole upon preincubation with either type of melanin or albumin. However, a 
significant difference in the MICs for itraconazole and ketoconazole was documented in the 
presence of DHN-melanin isolated from either M. mycetomatis (Figure 5) or A. fumigatus 
(results not shown). This effect was not documented when assays were supplemented with L-
DOPA melanin or BSA. Due to the effect of M. mycetomatis melanin, itraconazole MICs 
were 16-fold increased, an even more significant increase was noted for ketoconazole (32-
fold). These elevations in MIC were comparable to the elevations found when A. fumigatus 
melanin was added. When taking into account that azole MICs of 2 µg/ml or higher may be 
associated with failure of therapy, this implies that upon melanin supplementation 6 out of 8 
and 5 out of 8 strains should be considered clinically resistant to ketoconazole and 
itraconazole, respectively (23). Without melanin supplementation, only a single strain should 
be considered resistant to ketoconazole. 
Table 1: MICs determined for 8 M. mycetomatis isolates for ketoconazole, itraconazole, voriconazole 
fluconazole, amphotericin B, 5-flucytosine. Alle MICs were determined with the Sensititre assay and MICs are 
shown without the addition of melanin (no mel) or with the addition of melanin (mel). 
Antifungal agents 
Ketoconazole Itraconazole Voriconazole Fluconazole Amphotericin B 5-Flucytosine  
 
No Mel Mel No Mel Mel No Mel Mel No Mel Mel No Mel Mel 
No 
Mel Mel 
Mm46 <0.008 (<0.008) 
0.25 
(0.125-
0.5) 
<0.008 
(<0.008) 
0.125 
(0.06-
0.25) 
<0.008 
(<0.008-
0.016) 
<0.008 
(<0.008-
0.016) 
1 (0.5-
2) 1 (1-2) 
0.25 
(0.125-
0.5) 
0.5 
(0.5-1) 
>64 
(>64) 
>64 
(>64) 
Mm30 
0.016 
(0.016-
0.03) 
1 (0.5-1) 
<0.008 
(<0.008-
0.016) 
0.25 
(0.25) 
0.06 
(0.06-
0.125) 
0.06 
(0.06) 
16 (8-
16) 16 (16) 
0.25 
(0.125-
0.5) 
0.25 
(0.25) 
>64 
(>64) 
>64 
(>64) 
Mm50 
0.03 
(0.03-
0.06) 
2 (1-2) 
0.016 
(<0.008-
0.032) 
1 (0.5-
1) 
0.06 
(0.06-
0.125) 
0.06 
(0.06) 4 (4-8) 8 (4-8) 1 (0.5-1) 
1 (0.5-
1) 
>64 
(>64) 
>64 
(>64) 
Mm68 0.06 (0.06) 2 (1-4) 
0.125 
(0.06-
0.25) 
4 (2-8) 0.06 (0.06) 
0.125 
(0.125) 8 (8) 
16 (8-
16) 1 (0.5-1) 2 (1-2) 
>64 
(>64) 
>64 
(>64) 
Mm14 
0.06 
(0.06-
0.125) 
2 (2-4) 
0.125 
(0.06-
0.125) 
2 (2-4) 
0.032 
(0.032-
0.064) 
0.064 
(0.032-
0.064) 
4 (4) 4 (4) 0.5 (0.5) 0.5 (0.5) 
>64 
(>64) 
>64 
(>64) 
Mm55 
0.125 
(0.06-
0.125) 
2 (2-4) 
0.125 
(0.06-
0.25) 
2 (1-4) 
0.06 
(0.03-
0.125) 
0.06 
(0.06-
0.125) 
8 (4-16) 8 (8) 1 (0.5-2) 2 (1-2) >64 (>64) 
>64 
(>64) 
Mm35 0.25 (0.25-0.5) 
16 (8-
16) 
0.25 
(0.125-
0.5) 
2 (2) 0.5 (0.25-0.5) 
0.25 
(0.125-
0.25) 
256 
(128-
>256) 
256 
(256-
>256) 
4 (2-4) 4 (2-4) >64 (>64) 
>64 
(>64) 
Mm13 2 (1-2) 16 (16) 0.5 (0.25-1) 
>16 
(>16) 2 (1-4) 2 (1-2) 
>256 
(>256) 
>256 
(>256) 
0.5 
(0.25-1) 
0.5 
(0.5) 
>64 
(>64) 
>64 
(>64) 
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Figure 5: MIC shift of DHN-melanin supplemented isolates (grey) and L-DOPA-melanin supplemented isolates 
(white) in comparison with non-melanin supplemented isolates. The absolute difference in MIC was calculated 
by extracting the MIC for a certain strain without melanin supplementation from the MIC of that same strain 
with melanin supplementation. Differences were stated as the number of two-fold dilutions in difference. The 
dashed line in this figure shows the difference allowed between tests for the same strain. Furthermore in this 
figure the structure of the different antifungal agents are shown.  
 
M. mycetomatis melanin binds amphotericin B, itraconazole and ketoconazole 
Since M. mycetomatis MICs for itraconazole and ketoconazole were increased with 
supplementation of melanin, it was investigated if DHN- and L-DOPA-melanin bound 
amphotericin B, itraconazole, ketoconazole, fluconazole and voriconazole. In figure 6 it is 
seen that amphotericin B is bound by both DHN-melanin and L-DOPA melanin. Binding 
occurred in a dose-dependent manner, the more melanin present, the lower the concentration 
of amphotericin B left in solution was after 3 h of incubation at 37oC. DHN-melanin was also 
able to bind ketoconazole in a dose-dependent manner, although binding was not as effective 
as seen for amphotericin B. After 3h of incubation with 25 mg of DHN-melanin still 46.8 % 
of ketoconazole was left in solution. Binding was only found for DHN-melanin, since still 
90.5 % of ketoconazole was present after incubation with 25 mg of L-DOPA melanin. The 
same effect was noticed for itraconazole although to a lesser extent. Fluconazole and 
voriconazole were not bound by either type of melanin. 
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Figure 6: Antifungal binding capacity of DHN-melanin isolated from M. mycetomatis (•) and L-DOPA-melanin 
isolated from C. neoformans (ο). Fungal melanin in different concentrations was incubated with 800 µg/ml of 
amphotericin B (A) ketoconazole (B), itraconazole (C), voriconazole (D) or fluconazole (E) for 3 h at 37oC. 
After incubation melanin was pelleted and the concentration of each antifungal agent left in solution was 
determined with agar diffusion. Curves represent the concentration antifungal agent left in solution after 
incubation with various concentrations of melanin compared to the same antifungal agent without melanin. 
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Discussion 
 
M. mycetomatis actively melanised in vivo. Melanin is found within the fungal grain as well 
as inside phagocytes surrounding the grains. In vitro melanisation of M. mycetomatis can be 
blocked with inhibitors of the pyo- and the DHN-pathways but not with inhibitors of the 
DOPA-pathway. The DHN-melanin inhibitor tricyclazole was a stronger inhibitor than 
phthalide. A similar difference has already been described for DHN-melanin-producers such 
as Aspergillus spp and Penicillium spp. (32).  
DHN-melanin and L-DOPA melanin are dark insoluble phenolic or indolic 
compounds, whereas pyomelanins are mostly brown, soluble pigments derived from 
homogentisic acid (HGA) (19). Since pyomelanins are brown soluble pigments it was 
expected that inhibition with sulcotrion would result in a phenotype lacking the secreted 
pigment in the culture medium, resembling sulcotrion-treated pyo-melanin producing micro-
organisms such as Mycosphaerella graminicola (15). The black melanin would not be 
affected by sulcotrione because this was probably synthesized through another melanin 
biosynthesis pathway. However, the phenotype obtained was opposite, suggesting that 
although sulcotrion inhibits melanin synthesis it does not inhibit synthesis of the secreted 
pigment, which, therefore, is probably not a classical pyomelanin. Since sulcotrione did 
inhibit synthesis of the cell wall-associated melanin, the pigments produced could be 
precursors of the solid melanin type. For instance, inhibition of DHN-melanin synthesis in 
certain fungal species (e.g. Pyricularia oryzae and Wangiella dermatitidis) resulted in a 
carmine red pigment in the culture media consisting of flaviolin and 2-hydroxyjuglone (10, 
16). Another option is that the pigment is pyo-melanin but the conversion of p-
hydroxyphenylacetaldehyde (HPAD) into hydroxyphenylacetic acid (HPAA) is catalysed by 
an enzyme not inhibited by sulcotrion. Interestingly, the pigment secreted by M. mycetomatis 
has some features, which have also been documented in pyomelanins. For instance, both 
pigments turn black in the presence of iron (11). Another option is that M. mycetomatis 
simply forms two types of melanin simultaneously. For C. neoformans it has recently been 
demonstrated both L-DOPA melanin and pyomelanin can be synthesized by the same 
organism, depending on the availability of the substrate (9).  
The DHN-melanin isolated from M. mycetomatis was able to scavenge permanganate, one of 
the strongest oxidants known to modern chemists. During a mycetoma infection, grains are 
usually in close contact with a layer of neutrophils which actually secrete reactive oxidant 
species such as hypochlorous acid, hydrogen peroxide and reactive oxygen (5, 8). The fact 
that permanganate was effectively melanin-scavenged implicates a strong protective function 
for the melanin produced by M. mycetomatis during infection.  
Supplementation of DHN-melanin in in vitro antifungal susceptibility assays rendered 
M. mycetomatis less susceptible to the antifungal agents itraconazole and ketoconazole, the 
prime agents used in clinical settings (1).  Not much has been published on the effect of 
melanin on antifungal agents. Most of these studies were performed with melanised yeast 
cells versus non-melanised ones (6, 29). The fungi were cultured in chemically defined media 
to acquire a melanised phenotype and were transferred afterwards into adjusted culture media 
to determine the MICs. Interestingly, the usually melanised isolates of C. neoformans and 
Histoplasma capsulatum were not able to produce melanin in these test media, not even when 
additional substrate was added (13, 28). During cultivation the melanised phenotype 
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disappeared and all resulting offspring was non-melanised (13). This could explain why no 
differences in MICs were found. Similar to other fungi used in melanin protection studies  
thus far, M. mycetomatis does not form melanin in RPMI culture media, the medium used in 
the M38A protocol from the Clinical and Laboratory Standards Institute (CLSI) during drug 
susceptibility testing (4). In order to establish the effect of melanin on the MIC we chose to 
add purified M. mycetomatis melanin to the culture medium as an in vitro simulation of the in 
vivo situation during infection. Furthermore, it was not feasible to determine MICs on 
minimal medium. Melanisation took at least one month and when melanised cells were 
inoculated on a fresh minimal medium agar plate, the resulting colony was not melanised. 
Only after a month of cultivation, melanised phenotypes were seen.    
Although for other fungi no MIC shift was described, it was shown that the time 
required for killing of melanised cells was much longer (13, 29, 30). This was thought to be 
the result of binding of antifungal agents to melanin (13, 28-30). We here demonstrate that co-
incubation of DHN-melanin with either itraconazole or ketoconazole during susceptibility 
testing results in an MIC shift. However, itraconazole and ketoconazole are two azoles with 
high protein binding capacity. In vivo serum protein binding is more than 90% for both 
azoles. In vitro protein binding has been described to affect MICs for ketoconazole, 
fluconazole and amphotericin B but not for itraconazole (25). When we performed our 
antifungal assay with  250 µg/ml albumin, no shift in MIC was observed and we therefore do 
not expect that the MIC shifts we observed with melanin are confounded by low protein 
amounts. The effect appeared melanin-specific since this increase was also noted when A. 
fumigatus DHN-melanin was added to the culture medium but no increase in MIC was noted 
when L-DOPA melanin was added. The fact that we did not document an amphotericin B 
MIC shift for L-DOPA melanin was unexpected since there is evidence that binding of 
amphotericin B or caspofungin to L-DOPA melanin significantly reduced its efficacy in time-
kill assays (28). In our own binding-assay we also found that amphotericin B is bound by both 
L-DOPA- and DHN-melanin. This binding did not result in a MIC shift when our antifungal 
susceptibility assay was supplemented with either type of melanin. In our assay the melanin 
remains in the solution during the whole experiment, in the time-kill assays performed by 
others melanin was removed after a period of incubation prior to MIC determination. 
Apparently, when leaving melanin in the solution, the amphotericin B bound by melanin 
might still be able to inhibit  M. mycetomatis growth. In previous studies no binding of the 
azoles voriconazole, fluconazole and itraconazole and the antimetabolite 5-flucytosine to L-
DOPA melanin was noted (28, 29). This was in agreement with the results we obtained in our 
binding-assay. Only DHN-melanin was able to bind the azoles itraconazole and ketoconazole, 
no evidence of binding to L-DOPA melanin was found in either the binding assay or the MIC 
assay. This suggests that binding of itraconazole and ketoconazole was specific for DHN-
melanin, which could explain that the only other MIC shift for itraconazole under influence of 
melanin was described in a DHN-melanin-producing fungus (Wangiella dermatitidis) (22). 
Since all azoles have a similar working mechanism, the differences in melanin binding should 
be traceable to the molecular structure of the azoles. Itraconazole and ketoconazole, which are 
structurally similar, differ considerably from fluconazole and its derivate voriconazole (12). 
All azoles possess an azole-ring, the active domain of the molecule. The azole-ring of the 
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imidazole ketoconazole is slightly different from the other three, harbouring only two nitrogen 
atoms instead of three. The difference in MIC effect is probably not functionally associated 
with the presence of an azole-ring. Interaction of melanin with itraconazole and ketoconazole 
is probably mediated by the dichlorobenzene ring or the long polyaromatic side chain or a 
combination of the two (see Figure 5). Binding of the azoles to melanin in vitro results in a 
decrease in MIC because of the lack of accessibility to the fungus. However, by binding the 
azole to the grain an artificial “slow release” capsule might be created, resulting in a constant 
local release of the antifungal agent. This implies that the effect of the binding of itraconazole 
and ketoconazole to DHN-melanin in vitro is not easily translated to its effect in vivo. Further 
studies are needed to establish the precise physiological role of melanin in the fungal grain.   
In conclusion, we demonstrated that M. mycetomatis is melanised in vivo and we 
identified the biochemical pathways leading to this melanisation. Melanisation of M. 
mycetomatis offers protection to strong oxidants and the antifungal agents itraconazole and 
ketoconazole in vitro. Its protective role in vivo still needs to be established.  
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Mycetoma is one of the less-studied infections occurring in the developing world. This 
infection, characterized by its deforming subcutaneous mass, its sinuses and the discharge of 
grains and purulent material still poses a hard-to-treat disease in many tropical and subtropical 
areas (7, 23, 24). The disease usually affects young men between 20 and 40 years of age and, 
therefore, it has a huge effect on local economy (7, 23, 24). One of the countries with the 
highest incidence is Sudan, with an estimated number of ~500 new cases seen in hospitals in 
1955 (1). The incidence that year was about 4.6 cases per 100.000 inhabitants (1, 57). Still, 
this is an estimation, the real incidence probably is higher, because patients tend to go to 
hospital only when the disease is in an advanced stadium and not all hospitals were invloved 
in the study of Abbott (1). Nevertheless, the incidence calculated is about the same as the one 
for meningococcal-C disease in The Netherlands before the vaccination campaign (15). 
Despite this relatively high though regional incidence and its deforming, debilitating nature, 
little attention has been paid to mycetoma so far. When searching PubMed for publications on 
this disease, 1631 hits can be found of which 723 are case reports and 148 are reviews. In 
total 88 of those articles are about mycetoma caused by Madurella mycetomatis. As seen in 
chapter 2 research has focused mainly on the epidemiology, the pathology, the diagnosis and 
the treatment of patients. In this thesis research was focused on the genetic variation in both 
pathogen and host, the antigenicity of M. mycetomatis and the antifungal susceptibility of M. 
mycetomatis. Topics which were only meagerly explored before. 
 
Genetic variation in Madurella mycetomatis and its human host 
 
Little is known about the risk factors associated with M. mycetomatis infections. M. 
mycetomatis is thought to reside in the soil in endemic areas. This was at least hypothesised 
because a large fraction of the patient population suffered from previous trauma, such as thorn 
pricks, before developing the infection (24). Although M. mycetomatis has never been 
successfully cultured from soil samples, Ahmed et al. were able to demonstrate that M. 
mycetomatis DNA can be found in the soil and vegetative material in the endemic areas in 
Sudan (3). When becoming infected with M. mycetomatis, the clinical presentation is quite 
similar in most patients, although there can be individual variations. For instance, the M. 
mycetomatis collection used in all the studies in this thesis, is derived from 40 myetoma 
patients. Some of the patients had large lesions, while others had only small lesions (chapter 
3, reference 61). These differences were associated with the duration of the disease, since 
some of the patients with large lesions were only infected for about a year and others with 
small lesions were infected for more than 10 years. The outcome of any infection is usually 
the result of both genetic predisposition of the patient and virulence factors of the pathogen. 
In order to establish if some of the isolates in our collection were genetically predisposed to 
forming large lesions, we typed our collection with AFLP (amplified fragment length 
polymorphism) as described in chapter 3. It appeared that strains originating from Central 
Sudan, which had formed moderate to large lesions, were genetically distinct from strains 
which had formed small lesions only, and which primarily originated from other parts of 
Sudan. Interestingly, strains originating from central Sudan had a marker homologous to a 
casein kinase I gene from Danio rerio, which was not found in strains originating from other 
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parts of Sudan. This same marker was also found to be associated with a higher MIC for 
amphotericin B. The study described in chapter 3 was the first to monitor genetic diversity in 
a large collection of M. mycetomatis. In a previous study, RAPD (random amplification of 
polymorphic DNA) was used to type this collection (4). Unfortunately RAPD proved not to 
be a good technique for subtyping M. mycetomatis because even after using 20 different 
primer species the authors had to conclude that the isolates were clonal (4). This clonality was 
confirmed by sequencing the ITS region of M. mycetomatis (5). This was contradicted by the 
AFLP technique used in chapter 3, implicating that AFLP is a more suitable technique for 
typing M. mycetomatis than RAPD is. Differences in M. mycetomatis genotypes have also 
been described by others (16, 18, 42). Lopes et al. used RAPD to type M. mycetomatis 
isolates originating from different countries (42), while Desnos-Ollivier et al. used ITS 
sequencing to show differences between isolates (18). The studies could not link genetic 
polymorphisms to fungal virulence traits in the way we did in chapter 3. 
 Showing that M. mycetomatis isolates may have a genetic make up for inflicting large 
lesions was a first step in understanding the pathogenesis of the disease. Usually the outcome 
of a disease is not only dependent on the pathogen itself, but also on the ability of the human 
host to clear the infection. In the past some studies have been done to determine why some 
develop mycetoma and others not. As is stated before, M. mycetomatis was shown to be 
present in the soil and vegetative material in the endemic area (3). The presumption that all 
inhabitants come into close contact with M. mycetomatis, was confirmed by various antibody 
and antigen tests (31, 53, 58, 62, 67). These serological diagnostic assays revealed that people 
living in the endemic areas all had certain amounts of antibodies against the causative agents. 
This implied that, although all people apparently contacted M. mycetomatis, only a small 
percentage developed this disease. It was therefore hypothesized that genetic impairment in 
the immune system was involved. This hypothesis was not new. In the past it had already 
been established that mycetoma patients probably had a deficiency in their cell-mediated 
immune response (46). This finding was never elaborated upon. Other genetic traits which 
could be of influence were investigated as well. For instance, a lack of differences in the ABO 
blood group types or Rhesus types between patients and the healthy Sudanese population was 
demonstrated (25). Since mycetoma lesions are usually characterized by a large zone of 
neutrophils surrounding them, we investigated if there was genetic impairment in one of the 
genes involved in neutrophil function (chapter 4). Out of eight genes investigated, different 
allele distributions were found for five of them. It appeared that mycetoma patients more 
often had a mutation in the complement receptor 1 gene (CR1). This receptor is not only 
found on neutrophils but also on many other cell types. The polymorphisms investigated here 
are responsible for the Knops blood group antigens Swain-Langley (Sl) and McCoy (McC). It 
appeared that the Sl2 and the McCa genotypes were more frequently encountered in the 
patient population than in the control group. Genetic differences were also found in the genes 
encoding CXCL8, CXCR2 and TSP4. All genotypes documented were correlated with a 
higher CXCL8 production. CXCL8 is the interleukin responsible for attracting neutrophils to 
the site of infection. Higher CXCL8 production in patients was also demonstrated 
phenotypically in the sera of these patients. Neutrophils participate in the acute inflammatory 
response and repair of damaged tissues (48). In wounds, neutrophils have the task of killing 
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invading microbes either by phagocytosis or excreting oxygen or nitrogen radicals (48). The 
latter effect has a downside, since the oxygen radicals not only kill invading microbes but can 
also cause serious tissue damage (19, 20). In neutrophil-depleted mice it was shown that 
wounds actually healed better than in control mice (19).  If depletion of neutrophils 
accelerates tissue repair, then a overdose of neutrophils at the site of infection could hamper 
wound healing. This was shown to be true for certain pulmonary diseases as well as for some 
autoimmune diseases as reviewed by Dovi (20). Delay in wound healing and extension of 
tissue damage in turn can be favorable for the pathogen, in deriving nutrients and in 
establishing infection. By producing too much CXCL8, and therefore attracting more 
neutrophils to the site of infection, the patient might unintentionally support the infection. The 
higher oxygen or nitrogen excretion caused by those neutrophils appear to be not harmful to 
M. mycetomatis. In chapter 4 we showed that the production of H2O2 by neutrophils can be 
counteracted by the production of catalases by M. mycetomatis. In chapter 10 we added that 
the melanin produced by M. mycetomatis is able to scavenge permanganate, one of the 
strongest oxidants known to modern chemists. The fact that permanganate was effectively 
scavenged implies a strong protective function for melanin during infection.  
  The nitric oxide synthase NOS2 was also differently distributed between patients and 
healthy controls. Most micro-organisms are susceptible to nitric oxide and are killed by it. In 
this case the mutation explored was more often found in the control population than in the 
patient population. The mutation, known as the NOS2lambaréné genotype, is associated with a 
higher nitric oxide production (38). This was phenotypically confirmed. Apparently, patients 
displayed lower nitric oxide production, which could impair killing of the micro-organisms. 
NOS2 has also been demonstrated to be prominently expressed and stimulatory during wound 
repair (47). Apparently, it is important that the wound heals slowly for establishing a 
mycetoma infection.  
  In summary, it appeared that genetic predisposition of the human host is involved in 
susceptibility to mycetoma infection. This could be a starting point for further research in this 
direction. Still, little is known on the genetic variability of the host or even the immune 
response triggered by a M. mycetomatis infection. Epidemiological, genetic, microbiological 
and demographic studies in endemic villages could be highly valuable in further establishing 
both the role of the human host and the pathogen in the development of mycetoma infections. 
By establishing why some people become infected and why others seem to be immune to the 
disease, could help develop future prevention campaigns and generate new opportunities in 
treatment. For instance, wounds in diabetic patients have been shown to heal better if 
neutrophils were repressed. By repressing or stimulating certain parts of the immune system, 
a M. mycetomatis infection might in the end be cleared by the host itself. The mouse infection 
model, developed by Ahmed et al could also be very helpful in developing this concept 
further (8). In the mouse model progression of the infection can be followed in both the 
fungus and the host. Upon entering the host, the fungus has to adapt itself. What genes will it 
activate? Why are some of the isolates more prone to give an extended infection, and why are 
“other genotypes” less likely to inflict an infection? What about additional host factors? What 
genes are essential to clearing this infection? How is the immune system responding to M. 
mycetomatis? These are all questions which still need to be answered.  
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Antigenicity of M. mycetomatis 
 
As recorded in chapter 2, many different options are available for diagnosing mycetoma. 
Establishing a correct diagnosis is important for the further treatment of this deforming 
disease. However, culture, pathology, serodiagnostic tools, molecular diagnosis, they all have 
their downsides. The ideal diagnostic assay would be an assay which would be cheap, easy to 
handle in the developing world and give a 100% conclusive positive or negative result. This is 
not easy if not impossible to establish, especially in case of serological assays. We therefore 
set out to gain insight in the antigenic make up of M. mycetomatis on which surprisingly little 
was known. The fact that mycetoma patients developed antibodies against M. mycetomatis 
was used in the past to develop serodiagnostic tests by using crude culture extracts as antigen 
(31, 50). The only attempt to characterize the nature of the epitopes present in these crude 
extracts was published in 1991 (68).  In that report cytoplasmic proteins were extracted from 
several eumycetoma agents and separated by SDS-PAGE. It appeared that the protein profiles 
were similar for all isolates tested (68). The precise nature of the most immunodominant 
proteins could not be determined in this study. No other attempts had been published. In 
chapters 5 and 6 we attempted to identify antigens expressed by M. mycetomatis in order to 
clarify pathogenesis of this disease and, if possible, to develop a new diagnostic test with 
these antigens. In chapter 5 we identified the translationally controlled tumour protein 
(TCTP) as the first major antigen of M. mycetomatis by developing a cDNA library. In 
chapter 6 it was demonstrated that M. mycetomatis also secretes galactomannan-like antigens 
in vitro, but not in vivo.  
TCTP is not unique to M. mycetomatis. TCTPs from other pathogens were already 
demonstrated to be antigenic (9, 28, 43, 56). The protein appeared to be present in two 
isoforms in M. mycetomatis, namely variant I (found in 53% of the isolates) and variant II 
(found in 47% of the isolates). M. mycetomatis TCTP (mmTCTP) antigenicity in humans was 
established by measuring the IgG and IgM responses by an ELISA developed with variant I 
of mmTCTP. Most patients had elevated antibody levels against mmTCTP variant I, but, 
unfortunately, not all. It also appeared that some individuals of the Sudanese healthy control 
population had an elevated antibody level against TCTP as well. Those individuals probably 
raised antibodies upon environmental exposure to the antigen which was confirmed by other 
serodiagnostic assays. Cross-reactivity with TCTPs from other endemic infectious organisms 
could also have occurred, as was already demonstrated for filarial TCTPs (28, 56). In order to 
determine whether cross reactivity with TCTPs from other species were the cause of the high 
antibody levels in the healthy Sudanese control population, six ELISAs with specific TCTP 
peptides were developed. In five of those ELISAs there was a clear difference between the 
mean IgG levels found in the patient population and those found in the healthy Sudanese 
control population. Only with “peptide 6” no statistically significant difference in the mean 
IgG levels was detected. IgG and IgM immune responses against the whole protein and 
selected M. mycetomatis-specific peptides were found to be correlated with lesion size and 
disease duration. Overall, the patients with the largest lesions had the highest antibody level. 
After 6-15 years of disease duration the antibody levels were highest. 
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During infection TCTP seemed to be expressed mainly in developing grains. TCTP 
expression in the developing grain could be high because of several reasons. Firstly, when the 
fungus grows in the human host, it will be mitotically active and will encouter stress 
conditions imposed by the host immune system or nutrient depletion during invasion which 
upregulate TCTP expression as was shown in infections with other microbes  (28, 56, 59). 
Also adaptation to new environmental conditions in general have been shown to upregulate 
TCTP. In the parasite Brugia malayi no TCTP expression in the parasite is found in the pre-
infective stages, but upon entering the host TCTP becomes strongly upregulated (28).  
The discovery of antigens expressed by M. mycetomatis during infection could give 
insight in the pathogenesis of this infection. Furthermore, it could eventually result in a 
vaccine candidate. In future experiments, cDNA libraries can be developed from strains 
grown in various culture media or in in vivo animal models. The first cDNA library we 
developed originated from a strain grown in standard culture medium, which results in a 
totally different phenotype of the fungus as seen during in vivo infection. By varying culture 
conditions, different proteins will be expressed, and the likelihood of finding different 
antigens increases. Developing an expression library from mRNA isolated from the grains 
present in infection is an interesting option. Although this might give practical difficulties in 
extracting mRNA, but when succeeding novel insights in disease progression might be 
expected. New antigens could not only be used as vaccine-candidates but also for the 
development of new diagnostic tools. The latter are still desperately needed, since the 
diagnostic tools available at the moment are either time-consuming (culturing) or prone to 
false positive or negative results (many of the serodiagnostic assays). Antigens can also be 
used to establish clinical cure. The galactomannan assay used in Aspergillosis is such an 
example. In that assay, galactomannan secreted by Aspergillus fumigatus can be detected in 
human serum. If galactomannan disappears this could indicate clinical cure. If such an antigen 
could be found for M. mycetomatis this could help in developing good criteria for determining 
clinical cure or improvement upon antifungal therapy. 
  
Antifungal susceptibility of Madurella mycetomatis 
 
At present, the treatment of eumycetoma caused by M. mycetomatis is usually based on local 
clinical experience rather than double blind placebo controlled clinical trials. In Sudan the 
most common treatment regime is 300-400 mg/day ketoconazole or 400 mg/day itraconazole 
for extended periods of time (23). Both treatment regimes alone can not cure mycetoma, but 
the lesions will become more localised and encapsulated which makes subsequent surgery 
much easier to perform (23). After surgery the patients are treated for several months or years 
with high doses of antimycotics. Still, recurrent infections are not uncommon. It was never 
shown that M. mycetomatis was actually susceptible to both agents in vitro. The reason for 
this is that M. mycetomatis does not sporulate, which makes it not suitable for classical 
NCCLS based in vitro antifungal susceptibility testing (13). In chapter 7 an alternative 
method for non-sporulating M. mycetomatis was developed on the basis of the NCCLS 
criteria. M. mycetomatis hyphae were disrupted by sonication to obtain a homogeneous 
suspension, which could be exposed to various concentrations of antifungal agents. For 
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endpoint-reading, XTT was added after 7 days of incubation. XTT can be used to quantify the 
antifungal activity by relating the viable fungal mass to levels of fungal mitochondrial 
dehydrogenase activity (37, 51). This method appeared to be reproducible (chapters 7 and 8, 
references 6 and 63) and it could also be used to determine the antifungal susceptibilities 
against less common antifungal agents, such as the natural compounds artemisinin and tea 
tree oil (chapter 9). Artemisinin is isolated from the plant Artemisia annua and it is used in 
traditional Chinese medicine (21, 33). It is also a well-known agent used in malaria treatment. 
Tea tree oil is extracted from the tree Melaleuca alternifolia and is still used by the Australian 
Bundjalung Aborigines of New South Wales for its anti-inflammatory and antimicrobial 
properties (11, 32).  
The down-sides of the NCCLS-based method were its time consumption and its 
laboriousness. In chapter 8 a less laborious method was therefore adapted for determining the 
antifungal susceptibility of M. mycetomatis. This method was the Sensititre system (Trek 
Diagnostic systems, Ltd., East Grinstead, England). In this assay, the in vitro susceptibilities 
to amphotericin B, fluconazole, itraconazole, ketoconazole, 5-flucytosine and voriconazole 
were determined. Endpoint reading was facilitated by the oxidation-reduction indicator 
Alamar Blue. In vitro susceptibilities of various yeasts and filamentous fungi were already 
successfully assessed by this system (14, 22, 52). For M. mycetomatis this system was shown 
to give reproducible results for 90% of the isolates. The Sensititre assay was in agreement 
with the visually based NCCLS assay and to a lesser extend with the XTT assay. The latter 
can be explained by the indicator systems being different in both test systems. Since the 
discrepancies between both assays were the highest for the azoles, this could suggest that the 
trailing endpoint obtained with azoles is measured more effectively with XTT than with 
Alamar Blue. Furthermore, XTT is measured spectrophotometrically and Alamar blue is read 
visually. The spectrophotometer is usually more sensitive and specific than the eye in 
measuring small differences in colour.  
By combining the data obtained with both assays used in chapters 7, 8 and 9 the first 
in vitro antifungal susceptibilities for M. mycetomatis were determined for a large collection 
of isolates. In vitro M. mycetomatis appeared to be most susceptible to the azoles 
ketoconazole, itraconazole and voriconazole with MIC90’s of 0.125 µg/ml, 0.064 µg/ml and 
0.125 µg/ml, respectively. These MICs correlate with attainable serum levels (17). 
Fluconazole was the least effective azole, inhibiting the fungal growth at a MIC90 of 16 
µg/ml. Although these MICs are high, they still meet physiologically attainable serum levels 
(17, 27).  Amphotericin B appeared to be less effective than ketoconazole, itraconazole and 
voriconazole in inhibiting M. mycetomatis (MIC90 2 µg/ml). Interestingly, M. mycetomatis 
was also very susceptible to tea tree oil, with a MIC90 of 0.25 % v/v. M. mycetomatis isolates 
appeared to be resistant to 5-flucytosine and artemisinin. Resistance to 5-flucytosine was 
already demonstrated for many other filamentous fungi (2, 13, 29, 30, 41). Resistance against 
artemisinin was noted for Candida albicans but not for Cryptococcus neoformans and 
Saccharomyces cerevisiae  (26, 36). 
These susceptibilities indicate that mycetoma is extremely susceptible to the azoles 
ketoconazole and itraconazole, which are currently used in the medical treatment of  
eumycetoma caused by M. mycetomatis (44, 45, 49). According to the low in vitro MICs 
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found in chapters 7 and 8, none of the isolates would be considered resistant. Surprisingly, 
although some clinical studies showed that ketoconazole and itraconazole treatment resulted 
in complete cure, the clinical response to both agents is often poor (6, 44, 45, 49).  Taken into 
account that the appearance of M. mycetomatis in vitro differs from the black grains produced 
in vivo there is probably a factor involved in the in vivo situation which offers M. mycetomatis 
some protection against the antifungal agents used. In chapter 10 our working hypothesis was 
that the black compound in the grain is melanin produced by M. mycetomatis and that this 
melanin may protect the fungus from the immune system and antifungal agents. Melanins are 
negatively charged, hydrophobic, macromolecular pigments formed by oxidative 
polymerization of phenolic or indolic compounds (12, 35, 40). Melanin has been shown to 
protect micro-organisms against UV-radiation, enzymatic lysis, oxidants, killing by alveolar 
macrophages, and antimicrobial drugs (12, 35, 40). Fungal melanin can be biosynthesised by 
three pathways. In the first pathway, melanin is formed from diphenolic compounds such as 
L-tyrosine and 3,4-dihydroxyphenylalanine (L-DOPA) (54). In a second pathway, melanin 
can only be derived from L-tyrosine, not from L-DOPA. This type of melanin, called 
pyomelanin differs from L-DOPA melanin by being a soluble brown pigment rather than an 
insoluble black pigment (10, 60). In the third pathway, melanin is biosynthesized from 
polyketide compounds such as 1,3,6,8-tetrahydroxynaphthalene (1,3,6,8-THN) (54).  
We demonstrated that M. mycetomatis was actively melanised in vivo. Melanin was 
found within the grain as well as inside phagocytes surrounding the grains. In vitro 
melanisation of M. mycetomatis could be blocked with inhibitors of the pyo- and the DHN-
pathways but not with inhibitors of the DOPA-pathway. Since pyo-melanins are soluble, the 
black pigment produced in the grain is probably DHN-melanin.  
To establish if melanin did protect M. mycetomatis against antifungal agents, the in 
vitro susceptibilities to ketoconazole, itraconazole, fluconazole, voriconazole, amphotericin B 
and 5-flucytosine, with or without adding isolated melanin to the culture medium, were 
determined by using the adapted Sensititre assay (chapter 8). It appeared that melanin did 
protect M. mycetomatis in vitro against the antifungal agents itraconazole and ketoconazole ( 
the prime agents used in clinical settings (7)) but not against the other antifungal agents. The 
spectacular 32-fold rise in MIC was unique for the melanin isolated from M. mycetomatis, 
since Cryptococcus neoformans melanin did not produce a rise in MIC. The limited number 
of experiments done in determining the effect of melanin on MICs of other melanised fungi 
did not show a MIC shift as was seen here. Melanin protected the fungi by extension of the 
killing-time (34, 65, 66). However, the problem with these time-kill experiments was that the 
fungi could not melanise in the culture medium used, and that, over time, isolates lost their 
melanised phenotype. Extension of the killing-time was thought to be the result of binding of 
amphotericin B and caspofungin to L-DOPA melanin (34, 64-66). In our assay no MIC shift 
for amphotericin B was noted when cryptococcal melanin was added. This suggests that, 
although amphotericin B is bound to cryptococcal melanin, its antifungal properties remain 
unaffected. No evidence was found that L-DOPA melanin bound azoles (64, 65). There was 
only one other publication in which the effect of DHN melanin on antifungal susceptibility 
was explored. A MIC shift for itraconazole was demonstrated, indicating that depletion of 
antifungal agents is dependent on the type of melanin formed (55). Surprisingly, the 
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spectacular MIC rises for M. mycetomatis was only documented for itraconazole and 
ketoconazole, not for voriconazole and fluconazole. Since all azoles possess the azole-ring, 
melanin probably does not bind to this ring. Instead, interaction of melanin with itraconazole 
and ketoconazole is probably mediated by the dichlorobenzene ring, the long side chain or a 
combination of the two, since those structures are not found in voriconazole and fluconazole.  
As was already mentioned, the present antifungal treatment for mycetoma caused by 
M. mycetomatis is based on usage of either itraconazole or ketoconazole. This seemed 
justified by the low MICs found in chapters 7, 8 and 9. Taken the spectacular 32-fold rise in 
MIC for these agents when tested in the presence of melanin in combination with their 
toxicity, thus could indicate that these agents might not be the most optimal choice in treating 
mycetoma. Interestingly, voriconazole with equally low MICs, did not give a rise in MIC 
when melanin was added. Furthermore, voriconazole has a higher safety profile, with low 
toxicity. Favourable results have been obtained with voriconazole in the management of M. 
mycetomatis eumycetoma without bone involvement (39).  
Through the development of assays for determining the in vitro susceptibility of M. 
mycetomatis against a variety of antifungal agents, the road has now been cleared for 
implementation of antifungal susceptibility testing in the clinical setting. By correlating in 
vitro antifungal susceptibility data with in vivo outcome of treatment, a standardised treatment 
regime must be developed. At the moment, each clinical institute applies its own regime. At 
the moment randomly trials in antifungal treatment are started.  Terbinafine and posaconazole 
have been used in mini-trials in order to establish their therapeutic potential of those agents in 
mycetoma treatment. In the future such trials, with other new agents including voriconazole 
and the echinocandins such as caspofungin and anidulafungin could improve antifungal 
therapy. Good clinical trials should include large numbers of patients, have standardized 
criteria for cure or improvement and should include adequate matched control groups.    
 
In conclusion 
 
The work described in this thesis was geared towards gaining insight in the genetic diversity 
of M. mycetomatis and its human host in relation to the antigenicity and the antifungal 
susceptibility of M. mycetomatis. We can conclude that both M. mycetomatis and its human 
host are “collaborately defining” the outcome of a mycetoma infection. Some M. mycetomatis 
isolates have the capacity cause larger lesions and patients do more often have a genotype 
encoding for a higher CXCL8 production and a lower nitric oxide excretion, both implicated 
in delay of wound healing. It was demonstrated that M. mycetomatis excretes galactomannan-
like antigens and a TCTP antigen in vitro. Only the latter is detectable in patient serum and 
could be used in serological studies. Three antifungal susceptibility assays (the NCCLS-based 
assay, the XTT assay and the Sensititre assay) were developed for determining the antifungal 
susceptibilities of M. mycetomatis against a great variety of antifungal agents. M. mycetomatis 
appeared to be susceptible to itraconazole, ketoconazole, voriconazole, fluconazole, 
amphotericin B and tea tree oil and resistant to 5-flucytosine and artemisinin. Furthermore, it 
was seen that the DHN-melanin produced by M. mycetomatis protects the fungus in vitro 
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against the azoles itraconazole and ketoconazole, resulting in 32-fold rises in MIC for those 
agents. This could suggest that the current therapy based on those agents might need revision. 
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Mycetoma is één van de “vergeten” infecties van de ontwikkelingslanden. Deze infectie wordt 
gekarakteriseerd door een misvormende subcutane massa, drainerende sinussen en 
uitscheiding van grains en purulent materiaal. In de endemische tropische en subtropische 
gebieden waar mycetoma hoofdzakelijk gevonden wordt, is de ziekte nog steeds erg moeilijk 
te behandelen (7, 23, 24). Over het algemeen worden vooral jonge mannen, in de leeftijd van 
20 tot 40 jaar, geïnfecteerd. Zij vormen vaak de werkende bevolking van het land en 
mycetoma kan daarom een groot effect hebben op de lokale economie (7, 23, 24). Soedan is 
één van de landen waar deze ziekte het meest voorkomt. In 1955, werden ~500 nieuwe 
mycetoma patiënten opgenomen in ziekenhuizen (1). De incidentie was dat jaar ongeveer 4.6 
gevallen per 100.000 inwoners (1, 57). Dit is echter slechts een schatting omdat de werkelijke 
incidentie waarschijnlijk hoger zal liggen. Patiënten in derdewereldlanden gaan over het 
algemeen pas laat naar een ziekenhuis, wanneer de ziekte al in een vergevorderd stadium is. 
Verder waren niet alle ziekenhuizen betrokken bij de studie van Abbott (1). De incidentie is 
echter relatief hoog, zelfs vergelijkbaar met de incidentie van het aantal meningococcen type 
C gevallen in Nederland voordat hiertegen gevaccineerd werd (15). Ondanks deze relatief 
hoge incidentie en de ernst van de infectie, was er slechts weinig aandacht voor mycetoma in 
de wetenschap. Als in Pubmed (een database voor medische literatuur) naar artikelen over 
mycetoma gezocht wordt, blijkt dat er slechts 1631 artikelen (van de 16 miljoen artikelen die 
in deze databank te vinden zijn) gevonden worden. Van deze 1631 artikelen zijn 723 artikelen 
zogenaamde case reports, waarin enkele patiënten besproken worden en 148 artikelen zijn 
reviews, samenvattingen van al eerder gepubliceerde bevindingen. In totaal zijn 88 artikelen 
verschenen over mycetoma veroorzaakt door de schimmel Madurella mycetomatis. Het 
onderzoek naar deze ziekte heeft zich tot nu toe geconcentreerd op de volgende onderwerpen: 
de epidemiologie van de ziekte, de pathologie, de diagnose en de behandeling van mycetoma 
patiënten (hoofdstuk 2).  
In dit proefschrift is het onderzoek verdeeld in drie thema’s. Het eerste thema betrof de 
genetische diversiteit van zowel de ziekteverwekker M. mycetomatis als de humane gastheer. 
Het tweede thema betrof de antigeniciteit van M. mycetomatis. De belangrijke 
onderzoeksvraag hier was welke factoren de schimmel bezit die een immuunrespons in de 
mens opwekken. Het derde en laatste thema betreft de antifungale gevoeligheid van M. 
mycetomatis. Een antifungaal middel is een antibioticum gericht tegen schimmels. Niet alle 
schimmels zijn even gevoelig voor deze middelen. In dit thema werd gekeken hoe gevoelig 
M. mycetomatis is voor de verschillende antifungale middelen die op dit moment beschikbaar 
zijn. Dit spectrum aan onderwerpen was tot nu toe maar weinig aan bod gekomen in de 
internationale wetenschappelijke literatuur.  
 
Genetische diversiteit in Madurella mycetomatis en z’n menselijke gastheer 
 
Er is slechts weinig bekend over de risicofactoren gerelateerd aan besmetting met de 
schimmel M. mycetomatis. Over het algemeen wordt gedacht dat M. mycetomatis zich in de 
bodem bevindt, en dan alleen in de endemische gebieden. Deze hypothese kwam tot stand 
doordat bij veel mycetoma patiënten ook bij gevorderde infecties nog stukjes Acacia doorn in 
de laesie aanwezig waren. Zij hadden vaak voordat ze een mycetoma-infectie opliepen een 
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wondje aan hun voet gehad waardoor de schimmel mogelijk binnen heeft kunnen komen (24). 
M. mycetomatis is echter nog nooit uit grondmonsters gekweekt maar het DNA van deze 
schimmel is wel in de grond en op planten in de endemische gebieden aangetroffen (3). Als 
men geïnfecteerd wordt door M. mycetomatis verloopt het ziektebeeld in de meeste patiënten 
vergelijkbaar. Er zijn echter wel individuele verschillen aantoonbaar. De M. mycetomatis 
collectie die in alle experimenten beschreven in dit proefschrift gebruikt werd, was afkomstig 
van 40 verschillende mycetoma patiënten. Zo hadden sommige patiënten erg grote laesies, 
terwijl anderen slechts kleine gelokaliseerde mycetoma-laesies hadden (hoofdstuk 2, 
referentie 61). Deze verschillen waren echter niet te wijten aan de duur van de ziekte, omdat 
sommige patiënten met grote laesies slechts één jaar geïnfecteerd waren met deze schimmel 
en anderen, die al meer dan 10 jaar geïnfecteerd waren, nog steeds kleine laesies hadden. Het 
verloop van infecties, wordt bepaald door zowel de genetische opbouw van de gastheer als 
door de virulentiecapaciteit van het pathogene micro-organisme. Virulentie factoren zijn vaak 
eiwitten of suikers die een schimmel in staat stellen infectie te veroorzaken of het 
immuunsysteem van de gastheer te omzeilen. De vraag of er genen in onze isolaten aanwezig 
waren die gerelateerd waren aan de ontwikkeling van grote of kleine laesies hebben we 
proberen te beantwoorden door de collectie te typeren. Dit werd gedaan met de zogenaamde 
AFLP (amplified fragment length polymorphism) typeer methode (hoofdstuk 3). Het bleek 
dat de isolaten die uit Centraal Soedan kwamen en die middelgrote tot grote laesies 
veroorzaakt hadden genetisch afweken van isolaten die slechts kleine laesies veroorzaakten. 
Deze laatste groep kwam ook niet speciaal uit één gebied in Soedan, maar bevatte isolaten uit 
zowel Centraal Soedan, West- en Noord-Soedan als ook uit de hoofdstad Khartoum. Wat 
opvallend was dat alle stammen die uit Centraal Soedan kwamen, een specifieke merker (een 
DNA-fragment) hadden die de andere stammen niet hadden. Deze merker vertoonde 
homologie met het caseine kinase I gen van de zebravis Danio rerio. Deze merker bleek ook 
nog eens geassocieerd te zijn met een hogere MIC voor amphotericine B.  De studie zoals 
beschreven in hoofdstuk 3 was de eerste die er ooit in slaagde om de genetische diversiteit 
van een grotere M. mycetomatis stammen-collectie vast te stellen. Het was echter niet de 
eerste studie waarbij genetische diversiteit werd onderzocht. Eerder was bijvoorbeeld RAPD 
(random amplification of polymorphic DNA) gebruikt (4). Het bleek echter dat RAPD een 
minder geschikte techniek was om M. mycetomatis te typeren. Zelfs na 20 verschillende 
primers gebruikt te hebben, konden de auteurs niets anders doen dan concluderen dat de 
Soedanese M. mycetomatis isolaten klonaal waren (4). De klonaliteit werd bevestigd door de 
constante DNA volgorde van de ITS regio (5). Dit duidt erop dat AFLP een hogere resolutie 
heeft dan RAPD. Dit geldt in ieder geval voor isolaten uit één geografische regio. 
Genotypische verschillen tussen M. mycetomatis stammen zijn ook door anderen beschreven 
(16, 18, 42). Zo vond Lopes bijvoorbeeld dat RAPD gebruikt kon worden om M. mycetomatis 
isolaten uit verschillende landen te typeren (42). Desnos-Ollivier liet zien dat er door de 
sequentie van de ITS regio te bepalen verschillen tussen de isolaten aangetoond konden 
worden (18). Geen van deze studies kon echter de genetische achtergrond van de schimmel in 
verband brengen met virulentie factoren. Dit hebben wij wel laten zien in hoofdstuk 3.  
 Sommige M. mycetomatis isolaten hebben blijkbaar een genetische blauwdruk die tot 
grote laesies leidt. Dit levert meer inzicht in de pathogenese van mycetoma. Maar zoals al 
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eerder gezegd, het ziekteverloop is niet alleen afhankelijk van de ziekteverwekker, maar ook 
van de gastheer. In het verleden zijn er een aantal studies uitgevoerd waarin werd onderzocht 
waarom sommige mensen wel myetoma krijgen, terwijl anderen dit niet krijgen. M. 
mycetomatis komt voor in de grond en op planten in het endemisch gebied en er is al 
aangetoond dat een groot gedeelte van de mensen die in dat gebied wonen in contact komen 
met de ziekteverwekker (3). Dit werd aangetoond toen verschillende antilichaam and antigeen 
testen ontwikkeld werden (31, 53, 58, 62, 67). Via die serologische testen kwamen 
onderzoekers erachter dat de meeste mensen die in het endemisch gebied leven, antilichamen 
gevormd hadden tegen de mycetoma veroorzakende micro-organismen. Dit duidde erop dat 
hoewel de meeste mensen blijkbaar in contact komen met M. mycetomatis, er slechts een klein 
percentage daadwerkelijk de ziekte ontwikkelde. Daarom werd de hypothese opgesteld dat de 
mensen die wel ziek werden een gebrek in hun immuunsysteem zouden hebben. Deze 
hypothese was niet nieuw, in het verleden was al aangetoond dat mycetomapatiënten een 
potentieel gebrek in de cel-gemedieerde immuunrespons hadden (46). Na dat eerste onderzoek 
is er echter nooit vervolgonderzoek uitgevoerd. Andere genetische karakteristieken die van 
invloed konden zijn op het ontwikkelen van de ziekte zijn ook onderzocht, ondermeer het 
ABO bloedgroepen systeem. Er werden echter geen verschillen tussen de ABO bloedgroepen 
of de Rhesus factoren gevonden tussen patiënten en een gezonde controlegroep (25). Omdat 
mycetoma lesies vaak gekarakteriseerd worden door een grote zone met neutrofielen 
(bepaalde cellen van het immuunsysteem) rondom de schimmel, hebben we gekeken of er een 
genetisch defect te vinden was in één of meerdere van de genen die betrokken zijn bij het 
functioneren van deze neutrofielen (hoofdstuk 4). Van de acht genen die onderzocht zijn 
werd er slechts in vijf verschil in allelverdeling tussen patiënten en controles gevonden. Het 
bleek dat mycetoma patiënten vaker een genetische mutatie in de zogenaamde complement 
receptor 1 (CR1) hadden. Deze receptor komt niet alleen voor op neutrofielen, maar ook op 
vele andere celtypen. De polymorfismen die wij bepaalden, zijn verantwoordelijk voor de 
Knops bloedgroep antigenen Swain-Langley (Sl) en McCoy (McC). Het bleek dat de Sl2 en 
McCa genotypen vaker gevonden werden in de patiëntenpopulatie dan in de Soedanese 
controle groep. Genetische verschillen werden ook gevonden in de genen CXCL8, CXCR2 en 
TSP4. De genotypes die bij patiënten gevonden werden, waren allemaal gecorreleerd aan een 
hogere CXCL8 productie. CXCL8 is het interleukine dat verantwoordelijk is voor de 
aantrekking van neutrofielen naar een infectiehaard. Hoge CXCL8 productie werd ook 
fenotypisch in het serum van de patiënten vastgesteld. Neutrofielen zijn onder andere 
betrokken bij de ontstekingsreactie en het genezen van beschadigde weefsels (48). In wondjes 
hebben neutrofielen vaak de taak om de binnendringende micro-organismen, zoals bacteriën, 
te doden. Dit doen zij door middel van fagocytose en uitscheiden van zuurstof- en stikstof 
radicalen (48). Deze radicalen doden niet alleen de micro-organismen maar kunnen ook voor 
additionele weefselschade zorgen (19, 20). In muizen, waarbij neutrofielactiviteit onderdrukt 
werd, bleken wondjes zelfs sneller en beter te genezen dan in normale, gezonde muizen (19). 
Als het onderdrukken van neutrofielen het genezen van wondjes versneld, kan het 
tegenovergestelde ook waar zijn. Als te veel neutrofielen in de infectiehaard aanwezig zijn, 
kan dit genezing remmen. Dit is al eerder aangetoond in bepaalde long- en 
autoimmuunziekten (20). Het vertragen van de wondgenezing, of het veroorzaken van extra 
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weefselschade kan voor de schimmel voordeel opleveren. Zo kan het pathogeen makkelijker 
aan voedingsstoffen komen en kan het zich in de infectiehaard beter ontwikkelen. Door te veel 
CXCL8 te produceren en daardoor te veel neutrofielen naar de infectiehaard te sturen, kan de 
patiënt zelf onbewust de infectie helpen handhaven. De productie van zuurstof- en stikstof 
radicalen die hiermee gepaard gaan lijken niet erg schadelijk te zijn voor M. mycetomatis. In 
hoofdstuk 4 bleek dat de productie van H2O2  door neutrofielen tegen gegaan kan worden 
door de productie van katalases door M. mycetomatis. In hoofdstuk 10 werd vervolgens 
gezien dat M. mycetomatis melanine vormt. M. mycetomatis melanine kon permanganaat 
onschadelijk maken. Permanganaat is een van de sterkste oxidatoren. Het feit dat 
permanganaat onschadelijk gemaakt kon worden laat zien dat melanine mogelijk een 
efficiënte beschermer is voor de schimmel. 
 Het laatste gen waarin verschillen tussen de patiënten- en de controlepopulatie 
gevonden werden was het gen NOS2. Dit gen codeert voor een stikstof synthase. Stikstof 
oxide is een van de stikstof radicalen die door neutrofielen uitgescheiden wordt om micro-
organismen te doden. De meeste micro-organismen zijn hier dan ook gevoelig voor en worden 
snel gedood. De NOS2 mutatie werd vaker in de controle populatie gevonden dan in de 
patiëntenpopulatie. De mutatie staat ook wel bekend als de NOS2lambaréné mutatie en wordt in 
verband gebracht met een hogere stikstof oxide productie (38). Dit werd fenotypisch 
bevestigd. Blijkbaar produceren patiënten een lagere hoeveelheid stikstof oxide, wat ervoor 
kon zorgen dat de M. mycetomatis minder effectief gedood werd. Ook NOS2 is betrokken bij 
de genezing van wondjes. Als NOS2 expressie onderdrukt wordt, geneest de wond veel 
minder snel (47). Blijkbaar is het belangrijk voor de schimmel dat de wond niet snel geneest. 
Mensen die een genotype hebben waarbij de wond snel geneest, hebben blijkbaar extra 
bescherming tegen een mycetoma-infectie.  
  Samenvattend blijkt dat genetische predispositie betrokken is bij het ontstaan van een 
mycetoma infectie. Ons werk vormt een goed startpunt voor meer onderzoek in deze richting. 
Van de immuunrespons die optreed nadat M. mycetomatis het lichaam binnen gedrongen is, is 
nog weinig bekend. Onderzoek in “endemische dorpjes” zou een goed startpunt zijn om de rol 
van zowel de schimmel als van de gastheer in het ontstaan en in de verdere ontwikkeling van 
een mycetoma-infectie te onderzoeken. De constatering dat sommige mensen wèl een infectie 
ontwikkelen en anderen ogenschijnlijk immuun zijn, kan helpen bij het voorkómen van deze 
ziekte. Meer inzicht in de rol van het immuunsysteem tijdens de ontwikkeling van een 
mycetoma-infectie kan ook nieuwe behandelingsmethoden opleveren. Bij mensen met 
diabetes bijvoorbeeld, blijkt dat als de neutrofielen onderdrukt worden, wondjes sneller 
genezen. Door bepaalde delen van het immuunsysteem te onderdrukken of door andere delen 
juist te stimuleren kan een M. mycetomatis infectie misschien door de gastheer zelf geklaard 
worden. Het muismodel, ontwikkeld door Ahmed, zou de basis voor zulke studies kunnen 
vormen (8). In een muismodel kan de infectie vanaf het begin gevolgd worden. Zowel de 
schimmel als de gastheer kunnen dan in detail bestudeerd worden. Als M. mycetomatis het 
gastheerlichaam binnendringt zal aanpassing plaats moeten vinden. Welke genen worden er 
aangezet? Zijn bepaalde M. mycetomatis isolaten beter in staat om een infectie te ontwikkelen 
dan andere isolaten? En wat voor een rol speelt fysiologie en de genetica van de gastheer? 
Welke routes zal die gebruiken om de infectie te klaren? Hoe reageert het immuunsysteem op 
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M. mycetomatis? Deze vragen zijn niet beantwoord. Met de studies beschreven in 
hoofdstukken 3 en 4 is slechts een begin gemaakt.  
  
Antigeniciteit van M. mycetomatis 
 
Zoals in hoofdstuk 2 al was beschreven, zijn er verschillende mogelijkheden om de diagnose 
mycetoma te stellen. Het stellen van de juiste diagnose is van belang voor de behandeling van 
deze ernstige ziekte. Microbiologisch kweken, pathologie, serodiagnostiek en moleculaire 
diagnostiek hebben allemaal hun gebreken. Een ideale diagnostische test moet makkelijk te 
gebruiken zijn in ontwikkelingslanden en een niet te weerleggen positieve of negatieve uitslag 
geven. Dit is niet gemakkelijk, zeker in het geval van serodiagnostische testen. Daarom 
hebben we geprobeerd om de antigeniciteit van M. mycetomatis in kaart te brengen. Het feit 
dat mycetoma patiënten antilichamen tegen M. mycetomatis opwekken, wordt gebruikt in het 
ontwikkelen van zulke serodiagnostische testen. In het verleden zijn er verschillende testen 
gemaakt met behulp van een ruwe antigeen suspensie, gemaakt uit cultuurextracten (31, 50). 
De enige poging om de epitopen in deze ruwe antigeen extracten te identificeren dateert uit 
1991 (68). In die publicatie werden cytoplasma-eiwitten uit verschillende mycetoma 
veroorzakers geïsoleerd en gescheiden door middel van SDS-PAGE. Het bleek dat de 
verschillende M. mycetomatis isolaten allemaal dezelfde antigenen tot expressie brachten (68). 
Wat deze antigenen nu precies waren, werd niet bepaald. Ook later zijn er geen pogingen 
meer gedaan om antigenen die door M. mycetomatis geproduceerd worden te karakteriseren. 
In hoofdstukken 5 en 6 hebben we gekeken welke antigenen door M. mycetomatis tot 
expressie gebracht worden in relatie tot de pathogenese van de ziekte en om een nieuwe 
serodiagnostische test met deze antigenen te ontwikkelen. In hoofdstuk 5 werd het 
translationally controlled tumour protein (TCTP) ontdekt met behulp van een cDNA 
expressiebank. In hoofdstuk 6 werd gedemonstreerd dat M. mycetomatis ook galactomannan-
achtige antigenen in vitro uitscheidt; echter dit gebeurt niet in vivo.  
TCTP is een eiwit dat niet uniek is voor M. mycetomatis. TCTPs van andere ziekteverwekkers 
bleken ook antigeen te zijn (9, 28, 43, 56). TCTP bleek echter in twee vormen in M. 
mycetomatis voor te komen: variant I komt in 53% van de isolaten voor en variant II komt in 
47% van de isolaten voor. De antigeniciteit van TCTP in mensen werd vastgesteld met IgG en 
IgM antilichaam bepaling met een ELISA. De meeste patiënten hadden antilichamen 
ontwikkeld tegen mmTCTP variant I, maar helaas niet allemaal.  Het bleek dat enkele 
gezonde Soedanese controles ook antilichamen tegen TCTP ontwikkeld hadden, mogelijk na 
blootstelling aan M. mycetomatis uit de omgeving. Kruisreactiviteit met TCTPs van andere 
endemische infectieveroorzakers kan ook opgetreden hebben. Dit was namelijk al bepaald 
voor filariële TCTPs (28, 56). Om te bepalen of kruisreactiviteit inderdaad het probleem was, 
werden zes peptiden ontworpen die zeer specifiek waren voor bepaalde delen van het M. 
mycetomatis TCTP eiwit. In vijf van de hier ontwikkelde ELISAs bleek er een duidelijk 
onderscheid te maken te zijn tussen patiënten en gezonde controles. IgG en IgM niveaus 
opgewekt tegen zowel het hele eiwit als de M. mycetomatis specifieke peptiden, bleken 
gerelateerd te zijn aan de grootte van de laesie en de duur van de ziekte. In het algemeen 
bleken de patiënten met de grootste laesies de hoogste antilichaam niveaus te hebben. Deze 
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niveaus werden lager naar mate de laesie kleiner werd. De hoogste antilichaamniveaus werden 
verder ook gevonden als patiënten al zo’n 6-15 jaar geïnfecteerd waren.  
Tijdens de mycetoma-infectie, bleek TCTP hoofdzakelijk in de zich ontwikkelende 
grain tot expressie te komen. Dit kan verschillende redenen hebben. Zo blijkt dat wanneer een 
schimmel zich in menselijk weefsel vermenigvuldigt, deze schimmel mitotisch actief is. 
Verder zal het dan fysiologische stress ervaren, voorbeelden hiervan zijn het immuunsysteem 
van de gastheer of een gebrek aan voedingsstoffen. Al deze factoren zijn betrokken bij hoge 
TCTP expressie in andere organismen (28, 56, 59). Ook het zich aanpassen aan nieuwe 
omstandigheden blijkt van invloed op de TCTP expressie. Zo blijkt dat er geen TCTP tot 
expressie gebracht wordt in de parasiet Brugia malayi wanneer deze zich in een pre-infectief 
stadium bevindt. Wanneer de parasiet echter z’n gastheer binnendringt wordt TCTP ineens 
sterk tot expressie gebracht (28).  
Zoals is hoofdstukken 5 en 6 te lezen was, zijn in dit proefschrift de eerste specifieke 
antigenen voor M. mycetomatis beschreven. Dit is een eerste stap naar verbeterd inzicht in de 
antigeniciteit van M. mycetomatis. Door M. mycetomatis antigenen te beschrijven, vooral die 
antigenen die tijdens infectie tot expressie gebracht worden, kan meer inzicht verkregen 
worden in de pathogenese van deze infectie. Verder kan de ontdekking van zulke antigenen, 
zelfs leiden tot het ontwikkelen van een vaccin tegen de ziekte. In toekomstige experimenten 
kunnen cDNA expressiebanken ontwikkeld worden vanuit verschillende kweek- en 
infectiecondities. De cDNA expressiebank beschreven in hoofdstuk 5, werd vanuit een 
standaard kweekmedium geproduceerd. Op standaard kweekmedium heeft de schimmel een 
totaal ander fenotype gedurende infectie. Onder verschillende kweekcondities zullen 
verschillende eiwitten tot expressie gebracht worden. De kans is dan groot dat verschillende 
antigenen gekarakteriseerd zullen worden. Nieuwe antigenen kunnen niet alleen als vaccin-
kandidaten beschouwd worden maar ook voor de ontwikkeling van goede serodiagnostische 
testen. Dit laatste is nog steeds nodig omdat de diagnostische testen die op dit moment 
gebruikt worden ofwel erg veel tijd kosten, ofwel te veel valspositieve en valsnegatieve 
resultaten geven. Verder zou het erg interesssant zijn als er een antigeen gevonden werd, wat 
uitgescheiden werd in de bloedstroom van de patiënten. Zo’n antigeen kan namelijk gebruikt 
worden om vast te stellen of iemand genezen is van de infectie. Op dit moment zijn er 
namelijk geen goede criteria om te bepalen of een patiënt genezen is of dat de patiënt goed 
reageert op therapie. Als een uitgescheiden antigeen verdwijnt uit het serum van een patiënt 
kan dit een indicatie zijn dat de patiënt klinisch genezen is.  
  
Antifungale gevoeligheid van Madurella mycetomatis 
 
De behandeling van eumycetoma veroorzaakt door M. mycetomatis is op dit moment vooral 
gebaseerd op de klinische ervaring van de behandelend arts. In Soedan worden patiënten 
meestal behandeld met ofwel 300-400 mg/dag ketoconazole ofwel 400 mg/dag itraconazole. 
Deze behandeling kan maanden tot zelfs jaren duren (23). Zelfs met dergelijke hoge doses 
antifungale middelen is de ziekte echter niet te genezen. De laesies zullen wel inkapselen en 
er zal geen verdere verspreiding plaats vinden waardoor de daaropvolgende operatie een stuk 
makkelijker uit te voeren is (23). Na de operatie worden de patiënten vaak nog maanden tot 
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jaren nabehandeld met antifungale middelen. Toch komt de infectie vaak terug, mogelijk 
omdat nog nooit wetenschappelijk bewijs is geleverd dat M. mycetomatis in vitro überhaupt 
gevoelig is voor deze antifungale middelen. De standaard antifungale gevoeligheidstesten 
zoals beschreven door de NCCLS maken gebruik van sporen waardoor deze testen niet voor 
de niet-sporulerende M. mycetomatis stammen gebruikt konden worden (13). In hoofdstuk 7 
werd een alternatieve methode, gebaseerd op de NCCLS criteria, voor M. mycetomatis 
ontwikkeld. In deze methode werden de hyfen van M. mycetomatis gehomogeniseerd door 
sonicatie. De homogene oplossing die dan ontstaat kan vervolgens aan verschillende 
concentraties antifungale middelen bloodgesteld worden. Om nauwkeuriger te kunnen 
bepalen wanneer de groei van de schimmel geremd wordt, werd XTT na 7 dagen kweken 
toegevoegd. XTT kan gebruikt worden om in de nog levende schimmelmassa de 
mitochondriale dehydrogenase activiteit te bepalen (37, 51). Deze methode bleek erg 
reproduceerbaar en nauwkeurig te zijn (hoofdstukken 7 en 8, referenties 6 en 63) en kon ook 
gebruikt worden om de antifungale gevoeligheid voor minder bekende antifungale middelen 
te bepalen. Voorbeelden hiervan zijn artemisinine en theeboom olie zoals beschreven in 
hoofdstuk 9. Artemisinine wordt geïsoleerd uit de plant Artemisia annua en wordt gebruikt in 
de traditionele Chinese geneeskunst (21, 33). Het is echter ook een bekend antimalaria 
middel. Theeboom olie wordt gewonnen uit de boom Melaleuca alternifolia en wordt gebruikt 
door de Australische Bundjalung Aboriginals van New South Wales omdat het 
ontstekingsremmende en antimicrobiële eigenschappen bezit (11, 32).  
Het grootste nadeel van deze methode gebaseerd op de NCCLS-criteria is dat het erg 
veel tijd en werk kost om de test uit te voeren. Dit zorgt ervoor dat de test niet snel in de 
routine gebruikt zal worden om de antifungale gevoeligheid van M. mycetomatis te bepalen, 
zeker niet in de “endemische laboratoria” die vaak minder goede apparatuur hebben. In 
hoofdstuk 8 werd dan ook een minder bewerkelijke methode ontwikkeld. Deze methode was 
de Sensititre methode (Trek Diagnostic systems, Ltd., East Grinstead, England). Met deze test 
kunnen de in vitro gevoeligheden voor amphotericine B, fluconazole, itraconazole, 
ketoconazole, 5-flucytosine en voriconazole bepaald worden. Om te bepalen of bij een 
bepaalde antifungale concentratie de schimmelgroei geremd wordt is de redox indicator 
Alamar blauw toegevoegd. Voor andere gisten en schimmels waren de in vitro gevoeligheden 
met dit systeem al eerder bepaald (14, 22, 52). Ook voor 90% van de M. mycetomatis isolaten 
bleek dit systeem reproduceerbare resultaten te geven. De gevoeligheden gevonden met de 
Sensititre test waren in overeenstemming met de klassieke NCCLS test en in iets mindere 
mate met de XTT test. Dit laatste kan verklaard worden doordat de indicators in beide testen 
verschillen in gevoeligheid en specificiteit. Een ander verschil was dat de XTT omzetting met 
de spectrofotometer gemeten werd, Alamar Blauw kleuring werd met het oog afgelezen. In 
het algemeen kan een spectrofotometer kleinere verschillen in kleur nauwkeuriger meten dan 
het oog.  
Door de antifungale data te combineren (hoofdstukken 7, 8 en 9) konden de eerste in 
vitro gevoeligheden voor M. mycetomatis bepaald worden. M. mycetomatis bleek in vitro het 
meest gevoelig te zijn voor de azolen ketoconazole, itraconazole en voriconazole met een 
MIC90 van respectievelijk 0.125 µg/ml, 0.064 µg/ml en  0.125 µg/ml. Deze MICs zijn 
vergelijkbaar met concentraties die in serum bereikt kunnen worden (17). Fluconazole was  de 
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minst effectieve azole, met een MIC90 van 16 µg/ml. Hoewel deze MICs erg hoog zijn, 
kunnen deze concentraties nog steeds effectief in serum bereikt worden (17, 27).  
Amphotericine B bleek minder effectief te zijn dan ketoconazole, itraconazole en 
voriconazole. Voor dit middel werd een MIC90 van 2 µg/ml gevonden. M. mycetomatis bleek 
ook erg gevoelig te zijn voor de theeboom olie. Hiervoor werd een MIC90 van 0.25 % v/v 
bepaald. M. mycetomatis was ongevoelig voor 5-flucytosine en artemisinine. Andere 
filamenteuze schimmels zijn ook resistent tegen 5-flucytosine (2, 13, 29, 30, 41). De gist 
Candida albicans bleek ook resistent te zijn tegen artemisinine, terwijl de gisten Cryptococcus 
neoformans en Saccharomyces cerevisiae wel gevoelig voor dit middel waren (26, 36). 
In vitro is M. mycetomatis erg gevoelig voor de azolen ketoconazole en itraconazole, 
de middelen die op dit moment gebruikt worden voor therapie (44, 45, 49). Aan de hand van 
de lage MICs die in hoofdstukken 7 en 8 gevonden werden voor deze middelen, zou geen 
van de isolaten resistent beschouwd worden. Toch is het opvallend dat in de klinische situatie 
veel patiënten terugkerende infecties krijgen (6, 44, 45, 49). Mogelijk zijn er in de in vivo 
situatie factoren die M. mycetomatis enige bescherming bieden tegen deze middelen. De 
schimmel groeit in vitro anders dan in vivo. In hoofdstuk 2 zijn een aantal voorbeelden van de 
in vitro koloniemorfologie van M. mycetomatis te zien. De kolonies zijn bruin van kleur en 
zacht. In de patiënt vormt de schimmel zogenaamde grains. Deze zijn zwart en erg hard. In 
hoofdstuk 10 was onze werkhypothese dan ook dat de zwarte component van deze grain 
melanine is dat door M. mycetomatis tijdens infectie gevormd wordt. Dit melanine zou de 
schimmel kunnen beschermen tegen het immuunsysteem van de gastheer en de antifungale 
middelen waar deze mee behandeld wordt. Melanines zijn negatief geladen, hydrofobe, 
macromoleculaire pigmenten die gevormd worden door middel van oxidatie van fenolische of 
indolische componenten (12, 35, 40). Het is al eerder aangetoond dat melanine micro-
organismen beschermt tegen UV-straling, enzymatische lysis, oxidanten, de dodende werking 
van macrofagen en antimicrobiële middelen (12, 35, 40). Schimmelmelanine kan gevormd 
worden via verschillende routes. Via de eerste route wordt melanine gevormd uit difenolische 
componenten zoals bijvoorbeeld L-tyrosine en 3,4-dihydroxyfenylalanine (L-DOPA) (54). 
Via de tweede route wordt melanine uitsluitend uit L-tyrosine gevormd worden. Dit type 
melanine wordt pyomelanine genoemd en verschilt van het L-DOPA melanine doordat het 
oplosbaar is en bruin van kleur (10, 60). Via de derde route wordt melanine gevormd uit 
polyketide componenten, zoals 1,3,6,8-tetrahydroxynafthalene (1,3,6,8-THN) (54).  
In hoofdstuk 10 lieten we zien dat M. mycetomatis in vivo gemelaniseerd is. Melanine 
werd zowel in de grain als in de fagocyten rondom de grain gevonden. In vitro kon de 
melanineproductie in M. mycetomatis geblokkeerd worden met remmers op de pyo- en de 
DHN-biosynthese, maar niet met remmers van de L-DOPA biosynthese. Omdat pyomelanines 
oplosbaar zijn, is het zwarte pigment wat door M. mycetomatis gevormd wordt waarschijnlijk 
DHN-melanine.  
Om te bepalen of dit melanine M. mycetomatis beschermt tegen de activiteit van 
antifungale middelen werden de in vitro gevoeligheden voor ketoconazole, itraconazole, 
fluconazole, voriconazole, amphotericine B en 5-flucytosine met de Sensititre test bepaald 
(zie hoofdstuk 8). De MIC werd bepaald in aan- of afwezigheid van zuiver melanine. Het 
bleek dat het melanine M. mycetomatis in vitro beschermt tegen de antifungale middelen 
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itraconazole en ketoconazole, de middelen die gebruikt worden in de kliniek (7). Melanine 
beschermde niet tegen de andere antifungale middelen. De spectaculaire 32-voudige stijging 
in MIC was uniek voor het melanine wat vanuit M. mycetomatis geïsoleerd was, omdat 
melanine geïsoleerd vanuit C. neoformans geen stijging in MIC te zien gaf. De beperkte 
aantallen experimenten die uitgevoerd zijn om het effect van melanine op de MICs van andere 
gemelaniseerde schimmels te bepalen hebben nooit eerder een zo duidelijke MIC 
verschuiving laten zien. Melanine beschermde de schimmels alleen door de tijd waarin een 
schimmel gedood wordt door een antifungaal middel te verlengen (34, 65, 66). In deze 
experimenten had men er echter geen rekening mee gehouden dat de schimmels geen 
melanine vormen in het kweekmedium waarin de test uitgevoerd werd. Tijdens het 
experiment verloren de gemelaniseerde isolaten hun melanine. De verlenging van de tijd 
waarin een schimmel gedood werd, werd toegeschreven aan het binden van amfotericine B en 
caspofungine aan L-DOPA melanine (34, 64-66). In onze test werd echter geen MIC shift 
voor amfotericine B waargenomen wanneer cryptococcenmelanine toegevoegd werd. Dit is te 
verklaren als cyptococcenmelanine wel amfotericine B bindt, maar ervoor zorgt dat de 
antifungale eigenschappen niet veranderen. In het verleden is geen bewijs  gevonden dat L-
DOPA melanine ook azolen kan binden (64, 65). Er is slechts één andere publicatie bekend 
waarin het effect van DHN melanine op de antifungale gevoeligheid onderzocht werd. In dat 
artikel werd wel een MIC verschuiving beschreven voor itraconazole. Dit kan dus betekenen 
dat de binding van antifungale middelen aan melanine afhankelijk is van het type melanine 
dat gevormd wordt (55). De MIC stijging werd voor M. mycetomatis alleen gevonden voor de 
azolen itraconazole en ketoconazole, maar niet voor de azolen voriconazole en fluconazole. 
Al deze azolen hebben een zogenaamde azole-ring. Hierdoor is het niet erg waarschijnlijk dat 
melanine aan deze ring bindt. De binding gebeurt waarschijnlijk via de dichlorobenzeenring 
of de lange zijketen, of door een combinatie van de twee. Deze structuren zijn uniek voor 
itraconazole en ketoconazole en zijn afwezig bij voriconazole en fluconazole.  
Zoals hierboven al een aantal keer genoemd is, is op dit moment de antifungale 
behandeling voor M. mycetomatis mycetoma gebaseerd op de middelen itraconazole en 
ketoconazole. Dit leek aanvaardbaar wanneer gekeken werd naar de lage MICs die gevonden 
werden (hoofdstukken 7, 8 en 9). Maar wanneer gekeken wordt naar de spectaculaire 32-
voudige stijging in MIC onder invloed van melanine en het feit dat zowel itraconazole als 
ketoconazole erg toxisch zijn, is het de vraag of deze middelen nog wel de juiste keuze zijn. 
M. mycetomatis was net zo gevoelig voor voriconazole en er werd geen MIC stijging voor dit 
middel gevonden in aanwezigheid van melanine. Een ander voordeel van dit middel is dat het 
veel minder toxisch is dan de oudere azolen. Ook in de klinische situatie is al gebleken dat dit 
middel goed in staat is M. mycetomatis eumycetoma te genezen met name wanneer de botten 
nog niet geïnfecteerd zijn (39).  
Door de ontwikkeling van testen waarmee de antifungale gevoeligheid voor M. 
mycetomatis bepaald kan worden ligt de weg nu open naar antifungale 
gevoeligheidsbepalingen in de routinediagnostiek. Door de in vitro gevoeligheidsdata te 
correleren aan de in vivo behandeling en de uitkomst hiervan, kan het huidige therapieschema 
verbeterd worden. Nu worden er nog willekeurige proeven met verschillende nieuwe 
antifungale middelen gedaan. Zo zijn de middelen terbinafine en posaconazole in mini-
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experimenten gebruikt om te kijken of ze enige therapeutische effectiviteit hebben in de 
behandeling van mycetoma. In de toekomst kunnen zulke experimenten met nieuwe middelen, 
waaronder voriconazole en de echinocandines caspofungine en anidulafungine de antifungale 
therapie wellicht verbeteren. In goede klinische studies zou een groot aantal patiënten 
geïncludeerd moeten worden. Verder zouden er gestandaardizeerde criteria voor totale 
genezing of verbetering opgesteld moeten worden en natuurlijk zouden er controlegroepen 
meegenomen moeten worden.  In de klinische studies die tot nu toe uitgevoerd zijn, bleken 
deze controles en criteria nogal eens te ontbreken. 
 
In conclusie 
 
Voor dit proefschrift hadden we als doel gesteld om meer inzicht te krijgen in de genetische 
diversiteit van zowel de schimmel M. mycetomatis als z’n humane gastheer. Tevens bepaalden 
we de antigeniciteit van M. mycetomatis en de antifungale gevoeligheid van M. mycetomatis. 
Uit hoofdstukken 3 en 4 blijkt dat zowel M. mycetomatis als z’n humane gastheer bepalend 
zijn bij het ontstaan en het verder ontwikkelen van de infectie. Sommige M. mycetomatis 
isolaten zijn genetisch voorgeprogrammeerd om grotere laesies te veroorzaken, patiënten 
hebben vaker een genotype waardoor ze meer CXCL8 produceren en minder stikstof oxide 
uitscheiden, factoren waardoor wondjes minder gemakkelijk genezen en infectie wordt 
vergemakkelijkt. In hoofdstukken 5 en 6 hebben we gezien dat M. mycetomatis in vitro 
TCTP en galactomannan-achtige antigenen uitscheidt. Slechts antilichamen tegen het TCTP 
antigeen zijn aantoonbaar in het serum van patiënten en kunnen daardoor gebruikt worden in 
serologische screenings. In hoofdstukken 7, 8 en 9 werden drie antifungale 
gevoeligheidstesten (de NCCLS-gebaseerde test, de XTT test en de Sensititre test) ontwikkeld 
en vergeleken in de bepaling van de antifungale gevoeligheid van M. mycetomatis tegen een 
groot aantal antifungale middelen. M. mycetomatis bleek gevoelig te zijn voor itraconazole, 
ketoconazole, voriconazole, fluconazole, amfotericine B en theeboom olie en resistent tegen 
5-flucytosine en artemisinine. Verder bleek in hoofdstuk 10 dat het DHN-melanine, wat door 
M. mycetomatis geproduceerd wordt de schimmel in vitro beschermt tegen de azolen 
itraconazole en ketoconazole. Dit resulteerde in een 32-voudige stijging in MIC voor beide 
middelen en kan betekenen dat de huidige therapie gebaseerd op deze middelen misschien niet 
de juiste is.  
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Bij het tot stand komen van dit proefschrift zijn vele mensen gedurende vele jaren betrokken 
geweest. Op de laatste pagina’s van dit proefschrift wil ik graag iedereen die in welke vorm 
dan ook een bijdrage aan dit proefschrift heeft geleverd, bedanken. Toch wil ik graag nog een 
aantal mensen bij naam noemen.  
 
Mijn promotor Prof. Dr. Dr. Alex van Belkum. Alex, je eigen unieke manier van begeleiden 
tijdens mijn promotie heb ik zeer gewaardeerd. Maar weinig promovendi zullen zoveel 
vrijheid gekregen hebben als ik tijdens mijn promotie. In hoge snelheid heb je mijn papers 
nagekeken en gecorrigeerd. Ik moest nog wel eens vragen wat je nu geschreven had, maar 
gelukkig was ik daar niet de enige in. Vaak moest je zelf ook drie keer kijken voordat je het 
ontcijferd had.  
 
Mijn co-promotor Dr. Irma Bakker-Woudenberg. Irma, bedankt voor al je hulp en adviezen 
bij het ontwikkelen van de in vitro antifungale gevoeligheidstest. Nu mijn promotie afgerond 
is, zal ik weer wat meer tijd krijgen om te werken aan het Aspergillus-onderzoek. De 
komende jaren zullen we vast nog leuke experimenten op dat gebied gaan doen. 
 
De paranimfen Jolanda en Astrid. Jolanda, we zijn samen begonnen als “die twee” op de 
HLO. Doordat we samen later aan de studie begonnen zijn, werden we “veroordeeld” om 
samen te werken. Dit beviel zo goed, dat we zelfs samen op één afdeling terecht gekomen zijn 
voor onze stage en later ook in ons werk. Astrid, ik heb je dit jaar in Papendal gemist. Ga je 
volgend jaar weer mee carnaval vieren?  
 
Mijn stagebegeleider Dr. Abdalla Ahmed en de stagiaires Dirk-Jan, Johan en Denise. 
Abdalla, you learned me the basic skills of working with M. mycetomatis. Hopefully we will 
work together once again in obtaining more knowledge about this disease and in establishing 
the Eumycetoma Working Group. I would also like to thank professor Dr. Ahmed Fahal for 
collecting samples in Sudan and taking the beautiful photographs I used in this thesis. Dirk-
Jan, Johan en Denise, ik heb het geluk gehad om drie ijverige stagiaires te begeleiden, 
zonder jullie hulp had het fagen- en melaninewerk heel wat langer geduurd.  
 
Collega’s van de Medische Microbiologie en Infectieziekten. Ten eerste natuurlijk Mehri, 
zonder jouw hulp zouden de Aspergillus-experimenten wel erg lang duren. Marian, vorig jaar 
heb je me ingewerkt in het tweedejaars vaardigheidsonderwijs. Ben benieuwd of we ook dit 
jaar weer memorabele studenten zullen krijgen. Deborah, Eeti, Gerjo, Hélène, John, 
Jurriaan, Kimberly, Mustaq, Nicole, Rogier, Susan, Susanne, Willem vL en Willem vW, 
ook jullie allemaal bedankt voor de gezellige tijd in het lab. Ik zal proberen weer wat vaker 
koffie mee te gaan drinken. Marja, ook jou wil ik bedanken. Als ik even genoeg van het 
schrijven had ging ik gewoon bij jou een spekje halen en een praatje maken. Daarna kon ik er 
vaak weer tegenaan.  
 
Collega’s van andere laboratoria. Vishal, bedankt voor je hulp bij het zuiveren van TCTP. 
Heidy, bedankt dat je me geholpen hebt met het optimaliseren van de immunokleuring voor 
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TCTP. Jojanneke, zo zie je maar wat “werkoverleg” in de trein kan opleveren. Bedankt voor 
de immunofluorescentie, zonder jouw hulp had ik nooit van die mooie plaatjes kunnen 
maken. Nu zelf nog promoveren hè.  
 
Kim A, ook jij bedankt. Na congressen in Parijs of in Kaapstad was het altijd leuk om samen 
met jouw de stad of het land nog even te verkennen. 
 
Treingenoten. Omdat de meeste Brabanders nu eenmaal in Brabant blijven wonen en vooral 
niet naar het “enge” Rotterdam verhuizen, wil ik ook mijn treingenoten bedanken. Danny, 
Jojanneke, Gido, Margaretha en Monique, jullie zorgden ervoor, dat de dagelijkse reis van 
en naar Rotterdam een stuk aangenamer werd (ik weet alleen niet of de andere treinreizigers 
het hier ook mee eens zullen zijn). Laten we hopen, dat het treinreizen voorlopig zo gezellig 
blijft, dat scheelt heel veel bij vertragingen en te korte treinstellen.  
 
Mijn familie. Er zijn niet genoeg pagina’s over om jullie te bedanken  voor alles wat jullie 
tijdens mijn leven voor mij gedaan hebben. Claudia, een lievere zus kan iemand zich niet 
wensen. Pap, nog bedankt voor alles wat je in mijn huis hebt gedaan. Zonder jouw hulp met 
het klussen, zou het waarschijnlijk nu nog niet bewoonbaar zijn. Ook nu nog kom je 
regelmatig langs om nog even iets te repareren of gewoon te nieuwsgierigen. Mam, bedankt 
voor het nakijken van mijn verslagen en ook de Nederlandse samenvatting van dit 
proefschrift. Mijn Nederlands is inmiddels sterk verbeterd sinds de basisschool, maar geheel 
foutloos zal het waarschijnlijk nooit worden.  
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